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ABSTRACT 
 
Fanconi Anaemia (FA) is a rare human genetic disease characterized by bone marrow 
failure, malformations, chromosomal instability and cancer susceptibility. Thirteen genes 
belonging to a common pathway have been identified, but their function is still unclear even 
if evidence indicates a role in DNA-repair. In the attempt to gain new insights on FA-BRCA 
pathway, this work aimed at finding and characterizing novel putative interactors of the FA 
proteins. Using the yeast two-hybrid system, we screened a cDNA library of human testis 
and rescued two clones. Clone 54, which encoded for a putative ubiquitin-conjugating 
enzyme E2 (UBE2U), was first found to interact with FANCD2 and then with FANCL (E3 
ubiquitin-ligase of the FA pathway), FANCC, FANCE and FANCF by direct interaction 
mating in yeast. Different assays indicated that the expression of this gene is limited to 
mouse and human testis (specifically in spermatocytes and spermatides). Interestingly, even 
mouse Fancd2 showed a high expression level in these two cell types, supporting the 
hypothesis of an interaction between the two proteins and a role of the FA-BRCA pathway 
during spermatogenesis. In order to confirm the binding between UBE2U and FANCD2, we 
transiently transfected cell lines with a tagged UBE2U. However, since we failed to detect 
the protein at any level, we tried to validate the interaction using mouse testis extract. Using 
the specific antibody we generated, we were however not able to confirm the binding, but, 
before excluding definitively the interaction, we should further investigate using more 
suitable antibodies. Clone 4, encoding for a novel putative exonuclease (ISG20L2), was 
instead found to interact with the C-terminus of FANCG. Though it was ubiquitously present 
at low levels in all the cells tested, it showed a stronger expression in mouse testis. In 
transiently transfected cells, ISG20L2 was detected primarily in nucleoli by 
immunofluorescence, but it was revealed also in the cytoplasmic fraction by western blot. 
Both nuclear and cytoplasmic distributions of the protein were confirmed at endogenous 
levels, after production of a specific antibody. Coimmunoprecipitation studies between 
ISG20L2 and FANCG did not confirm their interaction, but this might be in agreement with 
a recent report for ISG20L2 as a nucleolar exoribonuclease, not directly involved with DNA-
repair. 
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1.1 Fanconi anaemia: an historical perspective. 
 
Shortly after beginning his paediatric training at the Kinderspital in Zurich in 1920, 
Guido Fanconi encountered an unusual disorder that he described in a case report published 
in 1927 (Fanconi 1927). In a family with five children, three brothers had died of a severe 
condition that resembled pernicious anaemia, a special kind of anaemia characterized by 
macrocytic red blood cells, increased haemolysis and low levels of serum vitamin B12. In all 
three boys the disease had become manifest between the ages of five and seven, had had a 
fatal outcome and was associated with a congenitally small head (microcephaly), good 
intelligence, intensive brown skin pigmentation, cutaneous haemorrhage, hypoplasia of the 
testes, squint and very lively tendon reflexes. The blood picture was typical of pernicious 
anaemia, but with no signs of increased haemolysis. On the basis of a fourth case reported by 
Uehlinger (Uehlinger 1929), Fanconi realized in 1929 that the disorder affected not only 
erythropoiesis but all haematopoietic cell lines. Further cases made it clear to him that the 
haematological manifestations were merely the usually fatal late symptoms of a highly 
complex pathological process in a disorder often associated with various physical 
abnormalities. In 1931 the famous haematologist Otto Naegeli proposed that the syndrome 
should be called Fanconi anaemia (FA). Feat of Fanconi was to recognize that this strange 
collection of symptoms was a disease in its own right and this was made possible only by his 
precise observation and meticulous documentation. In the 23-page original paper of 1927, he 
filled 12 pages just with the symptoms of his three patients (Fanconi 1927). In the following 
decades there was much speculation about the aetiology of the disease and its pattern of 
inheritance. The topic occupied Fanconi for 40 years. He did not initially believe the widely 
held view that it was an autosomal recessive disorder. It seemed unlikely to him that the 
incredible multiplicity and variability of Fanconi anaemia could be explained by the 
mutation of a single gene. Moreover, the first epidemiological studies of Weicker and 
Fichsel showed a ratio of about 1:1 between diseased and healthy children in affected 
families, a far cry from the ratio of 1:4 typical for autosomal recessive inheritance (Fanconi 
1967; Fanconi 1970). As this is a rare disease, if there were an autosomal recessive 
inheritance pattern then parental consanguinity, that is, descent from the same ancestor, 
should be very common, which was not the case in experience of Fanconi. Also, Fanconi 
could not explain the phenomenon that had been described by Imerslund, O’Neill and 
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Varadi, who had reported two families in which mother and child suffered from Fanconi 
anaemia (Imerslund 1953). Therefore, in 1964 Fanconi published his hypothesis that Fanconi 
anaemia was caused by a chromosomal translocation (Fanconi 1964). This hypothesis was 
supported by the data he had so carefully collected, and also had the backing of geneticists, 
particularly as it was already known that patients with Fanconi anaemia had a normal 
number of chromosomes. At this time high-resolution technology for the examination of 
chromosomes was not widely available. Scientists all over the world began to search for this 
ominous translocation. They did not find it, but the additional thrust given to chromosome 
research bore fruit nevertheless. In 1964 and 1965 several research groups were able to show 
that Fanconi anaemia patients suffered from chromosomal instability that occurred 
spontaneously but that could also be induced, particularly by DNA cross-linking substances: 
for example, mitomycin C (MMC) or diepoxybutane (DEB) (Schroeder, Anschutz et al. 
1964; Schmid, Scharer et al. 1965; Schroeder 1966; Schroeder 1966; Swift and Hirschhorn 
1966; Auerbach and Wolman 1976). Therefore, endogenous and exogenous factors can lead 
to chromosome breaks and their consequences at any time during prenatal and postnatal 
development. In eyes of Guido Fanconi this, together with the assumption that there are 
probably many intermediate stages between maximum chromosome fragility and maximum 
stability, explained the incredible phenotypic variability between different patients with 
Fanconi anaemia and their susceptibility to cancer. He was particularly struck by the high 
incidence of acute myeloid leukaemia (AML) in patients with Fanconi anaemia, but various 
other cancers, particularly of epithelial origin, had also found unusually often in patients with 
the syndrome (Fanconi 1967).  
Fanconi anaemia is, despite doubts of Fanconi, a recessive disorder. Heterozygotes 
are not affected, but it seems that certain heterozygote mutations in individual Fanconi 
anaemia genes might occasionally also be associated with the development of certain cancers 
(Rischewski, Clausen et al. 2000; Condie, Powles et al. 2002; Liede, Karlan et al. 2004; 
Tischkowitz, Morgan et al. 2004). The best known example is BRCA2 (also known as 
FANCD1). On one hand, homozygote mutations in this gene are the molecular genetic 
correlate of the FA-D1 subtype of Fanconi anaemia. On the other hand, heterozygosity for 
certain mutations in this gene is found in patients with certain forms of hereditary breast, 
ovarian and pancreatic cancer (Wooster, Bignell et al. 1995; Lancaster, Wooster et al. 1996; 
Stratton and Wooster 1996; van der Heijden, Yeo et al. 2003; van der Heijden, Brody et al. 
2004). On the other hand, it is currently thought that the Fanconi anaemia pathway might 
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also be influenced by epigenetic factors (Dhillon, Shahid et al. 2004; Narayan, Arias-Pulido 
et al. 2004) and this was something Fanconi had already suspected.  
Since the identification of Fanconi anaemia as a distinct clinical entity, several 
milestones stand out in its subsequent characterization. The first is the discovery that 
cultured lymphocites from FA patients show spontaneous chromosomal instability 
(Schroeder, Anschutz et al. 1964). The second is the finding that FA cells are hyper-
responsive to the chromosome breaking and anti-proliferative effects of cross-linking agents 
such as mitomycin C (MMC) and diepoxybutane (DEB) (Sasaki and Tonomura 1973; 
Auerbach and Wolman 1976; Ishida and Buchwald 1982). This hallmark of FA cells allowed 
to develop a specific diagnostic test for the disease, overcoming most of the difficulties 
related to the extreme variability of the clinical features. The third milestone comes with the 
finding that a high degree of genetic heterogeneity underlies the disease, as shown by cell-
fusion and complementation studies (Strathdee 1992; H Joenje 1997; Joenje H 2000 ). The 
fourth milestone is the design of a complementation cloning method, directly derived from 
the complementation assay, that enabled the cloning of the first FA genes (Strathdee 1992). 
The last milestone in FA research field can be considered the purification of the ‘FA-core 
complex’ (Meetei, de Winter et al. 2003; Meetei, Sechi et al. 2003), that significantly 
contributed to discovery the current thirteen FA proteins interaction network. 
 
 
 
1.2 Fanconi anaemia: the disease. 
 
1.2.1: Inherited bone marrow failure syndromes, caretaker gene diseases and clinical 
features of Fanconi anaemia. 
 
Fanconi anaemia (FA) is a rare autosomal and X-linked human recessive disease. It is 
highly heterogeneous, caused by mutations in at least 13 genes (FANCA, FANCB, FANCC, 
FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ, FANCL, FANCM and 
FANCN) each of which associated to different ‘complementation groups’ (FA-A, FA-B, FA-
C, FA-D1, FA-D2, FA-E, FA-F, FA-G, FA-I, FA-J, FA-L, FA-M and FA-N). It is 
characterized by bone marrow failure, various developmental abnormalities, genomic 
instability and a high incidence of malignancies. Due to its clinical and cellular features, FA 
is considered a member of at least two classes of cancer predisposition syndromes: inherited 
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bone marrow failure syndromes (IBMFSs) and caretaker gene diseases (or DNA-repair 
diseases). IBMFSs are characterized by impaired haematopoiesis and aplastic anaemia that 
lead to bone marrow failure and cancer predisposition. Most inherited marrow failure 
syndromes are also associated with a range of congenital anomalies. Amegakaryocytic 
thrombocytopenia, Diamond-Blackfan anaemia, dyskeratosis congenita, severe congenital 
neutropenia, Shwachman-Diamond syndrome are some examples of IBMFS. Hereditary 
diseases that instead feature genomic instability in combination with a strong propensity to 
cancer are called caretaker gene diseases (or DNA-repair diseases). Xeroderma 
pigmentosum, hereditary non-polyposis colorectal cancer, Bloom syndrome, Werner 
syndrome, Nijmegen breakage syndrome, ataxia telangiectasia-like disorder and ataxia 
telangiectasia are examples of caretaker gene diseases. Their common feature is an impaired 
capacity to maintain genomic integrity, which results in the accelerated accumulation of key 
genetic changes that promote cellular transformation and neoplasia. Cancer predisposition in 
these two classes of diseases is an indirect result of the primary genetic defect.  
The prevalence of FA is estimated to be 1 to 5 per million, and heterozygous carrier 
frequency is estimated to be 1 in 300, although the true frequency is probably higher 
(Auerbach AD 2001; Joenje and Patel 2001). FA has been reported in many ethnic groups 
(Alter 1994) and founder mutations have been described in Afrikaaners (Rosendorff, 
Bernstein et al. 1987) and Ashkenazy Jews (Verlander, Kaporis et al. 1995) amongst others. 
Patients with FA show extreme clinical heterogeneity (Alter 1994; Auerbach AD 2001). The 
median age at diagnosis is 6.5 years for male patients and 8 years for female patients, 
although the age at diagnosis ranges from birth to 48 years. Survival was 19 years in cases 
reported between 1981 and 1990 and the median survival age has improved to 30 years in 
patients reported between 1991 and 2000 (Alter 2003).  
The most important clinical features of FA are haematological and these are 
responsible for the greatest morbidity and mortality in homozygotes. At birth, the blood 
count is usually normal and macrocytosis is often the first detected abnormality. This is 
followed by thrombocytopenia and anaemia, and pancytopenia typically presents between 
the ages of 5 and 10 years, with the median age of onset being 7 years (Auerbach and Allen 
1991; Butturini, Gale et al. 1994). Patients with FA develop bone marrow failure typically 
during the first decade of life. The actuarial risk of developing bone marrow failure is 90% 
by 40 years of age. A retrospective study of 145 FA cases published in 2004 showed that 
certain congenital abnormalities were potential risk indicators for the development of bone 
marrow failure. Patients with abnormal radii had a 5.5 times increased risk of developing 
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bone marrow failure compared with those cases with normal radii and the risk also increased 
with the number of heart, kidney, head, hearing and developmental abnormalities present 
(Rosenberg, Huang et al. 2004). In those children without congenital abnormalities the 
development of haematological abnormalities can be the first presenting feature of FA and 
can occasionally be the presenting feature in adulthood (Liu, Auerbach et al. 1991; 
Cavenagh, Richardson et al. 1996). 
The non-haematological clinical phenotype in FA is highly variable and individuals 
can have a wide multiplicity of clinical abnormalities (table 1) (Auerbach 1999; De Kerviler, 
Guermazi et al. 2000). Generalized skin hyperpigmentation, ‘cafe´ au lait’ spots and areas of 
hypopigmentation are often present and may sometimes be the only feature present. Skeletal 
abnormalities commonly include radial ray defects such as hypoplasia of the thumbs and 
radial hypoplasia; other skeletal defects that may occur include congenital hip dislocation, 
scoliosis and vertebral anomalies. Around one-third of FA patients have renal anomalies 
including unilateral renal aplasia, renal hypoplasia, horseshoe kidneys or double ureters. FA 
is associated with altered growth both in utero and postnatally; low-birth weight is common 
and the median height of FA individuals lies around the fifth percentile. This can sometimes 
be related to growth hormone deficiency or hypothyroidism (Wajnrajch, Gertner et al. 2001). 
Microphthalmia, microcephaly, conductive deafness and developmental delay are all often 
present. Males have a high incidence of genital abnormalities such as hypogenitalia, 
undescended testes and hypospadias with infertility being the norm, although there have 
been reports of males with FA fathering children (Liu, Auerbach et al. 1991). The FA 
phenotype can differ considerably within families; a report of four FA patients from two 
related consanguineous families who all had the same FANCA mutation demonstrated a 
wide variation in birth weight, skin pigmentation and the severity of skeletal, renal and 
genital abnormalities (Koc, Pronk et al. 1999). Moreover, up to one-third of FA cases do not 
have any obvious congenital abnormalities, and are only diagnosed when another sibling is 
affected or when they develop haematological problems (Giampietro, Verlander et al. 1997). 
 
 
Abnormality Frequency (%) 
Skeletal (radial ray, hip, vertebral scoliosis, etc..) 71 
Skin pigmentation (‘cafè au lait’, hyper- and hypopigmentation) 64 
Short stature 63 
Eyes (microphtalmia) 38 
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Renal and urinary tract 34 
Male genital 20 
Mental retardation 16 
Gastrointestinal 14 
Cardiac 13 
Hearing 11 
Central nervous system 8 
No abnormalities 30 
 
Table 1: Frequency of abnormalities in Fanconi anaemia  
 
 
1.2.2: Cancer in FA. 
 
FA patients have a high risk of leukaemia and solid tumours. A literature review of 
over 1300 reported cases from 1927 to 2001 found that 9% had leukaemia, mainly acute 
myeloid leukaemia (AML), 7% had myelodysplastic syndrome (MDS), 5% had solid 
tumours and 3% had liver tumours (Alter 2003). The distribution of the solid tumours was 
very unusual compared to the general population, since more than half were of the head and 
neck, oesophagus or vulva. The liver tumours were generally not malignant, and were 
thought likely to be related to prolonged androgen therapy used in FA patients treatment. A 
retrospective cohort study of 145 FA patients published in 2003 showed that nine had 
developed AML and 14 had solid tumours, most of which were of the head and neck, 
oesophagus, vulva or cervix (Rosenberg, Greene et al. 2003). The ratio of observed to 
expected cancers was 50 for all cancers, 48 for solid tumours and 785 for leukaemia. The 
cumulative incidence to age 48 was 10% for leukaemia and 29% for a solid tumour. A larger 
study of 754 patients in the International Fanconi Anemia Registry (IFAR) found neoplasms 
in 23%, with haematological neoplasms (mainly AML or MDS) in 15.9% and non-
haematological tumours in 10.5%, with about 3% of patients having more than one neoplasm 
during their lifetime (Kutler, Singh et al. 2003). The most common non-haematological 
tumours were squamous cell carcinomas (SCC) of the head and neck (HNSCC), vulva and 
cervix. The cumulative incidence of haematological and non-haematological neoplasms was 
33 and 28% respectively by age 40. The standardized incidence ratio for HNSCC in the 
IFAR registry was 500, with a median patient age of 31 years (Kutler, Auerbach et al. 2003). 
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These patients had poor tolerance for radiotherapy and chemotherapy, and the tumours were 
aggressive. Examples have been reported of young cases of apparently sporadic HNSCC 
with no known risk factors, who had a severe reaction to radiotherapy and who were later 
diagnosed as FA (Alter, Joenje et al. 2005). There is also evidence that conditioning for stem 
cell transplants in FA patients is associated with an increased risk of SCC of the head, neck 
and oesophagus (Rosenberg, Socie et al. 2005).  
Clinical and molecular characterizations of FA-D1 families with biallelic mutations 
in BRCA2 have revealed an even stronger cancer-prone phenotype in at least 16 confirmed 
D1 kindreds reported up to 2006 (Howlett, Taniguchi et al. 2002; Offit, Levran et al. 2003; 
Hirsch, Shimamura et al. 2004; Wagner, Tolar et al. 2004; Reid, Renwick et al. 2005). Early 
onset leukaemia was common, with a median onset at 2.2 years of age compared to 13.4 
years for all other FA patients in the IFAR registry (Wagner, Tolar et al. 2004); this was 
mainly AML, but there were also cases of T- and B-cell acute lymphoblastic leukaemia. 
There were nine cases with brain tumours (mainly medulloblastomas), and five with Wilms 
tumours (summarized in (Reid, Renwick et al. 2005)). It was proposed initially that FA-D1 
would occur in individuals who had at least one partially functional BRCA2 allele (Howlett, 
Taniguchi et al. 2002). This would be consistent with the fact that complete knockout of 
brca2 is an early embryonic lethal in the mouse (Ludwig, Chapman et al. 1997; Sharan, 
Morimatsu et al. 1997), whereas some mice homozygous for a C-terminal truncating brca2 
mutation are viable but succumb to lymphomas (Connor, Bertwistle et al. 1997; Friedman, 
Thistlethwaite et al. 1998). The frequency of BRCA2 mutation carriers in the general 
population is estimated to be around 1 in 1000 (Thompson D 2004), which corresponds to a 
mutant allele frequency of 0.0005 and a predicted homozygote frequency in the absence of 
selection of 1 in 4 million. Considered the incidence of FA in most populations as around 1 
in 250,000 and FA-D1 accounts for about 3.3% of all FA cases (Levitus, Rooimans et al. 
2004), this corresponds to an incidence of FA-D1 of 0.53 in 4 million, which is about half of 
the predicted incidence. Thus, it is possible that only a subset of mutant BRCA2 alleles is 
compatible with survival to term in humans. However, an assessment of the location of 
BRCA2 mutations in FA-D1 patients in comparison with BRCA2 carriers does not support a 
bias towards carboxy-terminal mutations in FA-D1 (Reid, Renwick et al. 2005). Also, the 
nature of the mutations in many of the reported FA-D1 cases would predict early truncation 
of the BRCA2 protein expressed from both alleles, and its absence has been confirmed in 
some cases by Western blot analysis (Hirsch, Shimamura et al. 2004).  
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Generally, the association of haematopoietic stem cell failure and a high risk of 
cancer with a chromosomal instability syndrome is not surprising. Excessive chromosome 
breakage might be expected to lead to unrepaired DNA-damage and apoptosis, or to 
mutations which could confer a selective growth advantage to a progenitor cell. Why cells of 
myeloid origin are particularly affected, leading to MDS or AML, is however not known; 
perhaps myeloid precursors are particularly susceptible to forms of DNA-damage that are 
recognized or repaired by the FA pathway. The unusual spectrum of solid tumours, with a 
preponderance of squamous cell carcinomas of the oral cavity and vulva or cervix is also 
unexplained. Evidence both for and against an involvement of human papilloma virus (HPV) 
in SCCs from FA patients has been presented (Kutler, Wreesmann et al. 2003; van Zeeburg, 
Snijders et al. 2004). A possible route to carcinogenesis is also an interaction of the 
environmental toxins to which the mucous membranes of the oral cavity and genital areas are 
exposed with a constitutional deficiency of the FA patient to detoxify such agents or to repair 
DNA-damage consequent to the exposure. Moreover, the highly cancer-prone phenotype of 
FA-D1 patients is not unexpected given the central role occupied by BRCA2 in homologous 
recombination repair. However, the high incidence of brain tumours in these patients is not 
characteristic of FA patients in general, or of BRCA2 mutation carriers, and remains to be 
explained, as does the association with familial Wilms tumour (Reid, Renwick et al. 2005). 
 
 
1.2.3: Diagnosis and assessment. 
 
Because FA has such a varied phenotype, it is difficult to diagnose solely on the basis 
of clinical features and if the diagnosis is suspected, it must be confirmed primarily by 
chromosome breakage studies and subsequently by molecular analysis. FA cells show 
increased spontaneous chromosome breakage, but this is highly variable and overlaps with 
the range for normal cells. Adding DNA cross-linking agents, such as mitomycin C (MMC) 
or diepoxybutane (DEB), increases the number of chromosome breaks with distinct ranges 
for normal and FA cells. This provides the basis for a widely used standard diagnostic test 
(Auerbach and Wolman 1976; Auerbach 1993). In this test, peripheral blood T-lymphocytes 
are stimulated to divide with a mitogen and then exposed to the DNA cross-linking agent 
such as DEB or MMC. Metaphase spreads of FA cells have increased numbers of 
chromosomal breaks per cell and an increased fraction of cells with breaks (Fig.1). 
Chromosome breakage studies can be carried out on amniotic cells, chorionic villus cells or 
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foetal blood and therefore it can be used also for prenatal diagnosis (Auerbach, Sagi et al. 
1985). Although MMC/DEB testing is highly specific for FA, interpretation is complicated 
in cases of somatic mosaicism (Dokal, Chase et al. 1996), where a haematopoietic stem cell 
has undergone gene correction and its progeny have repopulated the bone marrow. In these 
cases, there may be a normal chromosomal stability response in lymphocytes derived from 
the corrected stem cell so, if mosaicism is suspected, skin fibroblasts should be used for the 
breakage assay (Alter, Joenje et al. 2005). Another diagnostic technique with comparable 
accuracy to chromosome breakage studies is based on flow cytometric analysis of cells 
exposed to DNA cross-linking agents. It measures the prolonged progression through and 
arrest within the G2-phase, which is another characteristic of FA cells (Schindler, Kubbies et 
al. 1985; Berger, Le Coniat et al. 1993; Seyschab, Friedl et al. 1995). Such an approach has 
the advantage that it is less time-consuming, does not require cytogenetic expertise and it 
may also sometimes be helpful when there are discrepancies on DEB testing (Toraldo, 
Canino et al. 1998). However, it is not reliable in cases with concurrent myelodysplasia or 
leukaemia (Berger, Le Coniat et al. 1993; Seyschab, Friedl et al. 1995). Serum α-fetoprotein 
(AFP) levels are consistently elevated in FA patients irrespective of whether liver 
abnormalities are present and this could be used as a fast and cheap screening test in the 
sizeable group of individuals with early onset leukaemia or cancer, or other FA-like features, 
such as short stature, thumb abnormalities, skin pigmentation, or macrocytic anaemia 
(Cassinat, Guardiola et al. 2000). However, diagnostic precision varies with the type of AFP 
assay technique used so new AFP assays must first be carefully validated (Cassinat, Darsin 
et al. 2001). 
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Figure 1:Diepoxybutane-induced chromosomal breakage in a metaphase lymphocyte from a patient with 
Fanconi anaemia. Chromosomes with breaks and fusions are indicated with arrows 
 
 
 
 
1.2.4: Screening of FA complementation groups: methods and its importance. 
 
As described, one of the most striking features of FA is its high heterogeneity. To 
answer whether one or more genes caused FA, a complementation analysis method was 
developed in 1992 in the laboratory of M. Buchwald (Strathdee 1992), introducing also the 
designation of ‘complementation groups’ for FA patients. In particular, the methodology 
took advantage of cells hybridization techniques and MMC or DEB sensitivity of FA cells. 
In this approach, a hybrid cell line generated by fusing lymphoblasts from unrelated FA 
patients showed, after cross-linking treatment with MMC, either sensitive traits or resistance 
(complementation of the defect). In the first case, patients were classified to belong to the 
same ‘complementation group’, having defect in the same gene and consequently not being 
able to revert the phenotype in the hybrid cell line. In the second case, they belonged to 
different complementation groups, having defects in different genes and therefore being able 
to compensate (complement) each other in the hybrid cell line (Fig. 2). As mentioned, this 
discovery is one of the milestones in the FA research field since it shed light upon the 
genetic heterogeneity of the disease and it allowed the cloning of several FA genes, as we 
will discuss later. In addition, it enabled the determination of complementation groups for 
each patient, which has showed to be increasingly important (Shimamura and D'Andrea 
2003). In fact, some patients with other rare chromosome breakage syndrome, such as 
Nijmegen breakage syndrome, can have a positive DEB test. Additionally, some relation 
between genotype and phenotype has been reported (Nakanishi, Taniguchi et al. 2002); for 
example, patients in complementation group C (FA-C) had a significantly poorer survival 
than patients in group A (FA-A) and G (FA-G) (Kutler, Singh et al. 2003); FA-D1 subtype, 
as previously mentioned, is instead associated with increased predisposition to 
medulloblastoma, Wilms tumour, acute leukaemia in early childhood and is clinically 
different from other subtypes (Offit, Levran et al. 2003; Hirsch, Shimamura et al. 2004; 
Wagner, Tolar et al. 2004). Moreover, family members of patients with FA-D1 may be 
carriers of mutations in BRCA2 and may be predisposed to cancers (Wagner, Tolar et al. 
2004). Therefore, to confirm the diagnosis, to distinguish FA from other chromosome 
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breakage disorders and to manage each patient with FA and family better, FA subtyping is 
very important and should be performed routinely. However, complementation analysis is 
laborious and time consuming, therefore not suited for rapid screenings. As a valid 
alternative to this method, in 2002 was reported an assay based on the utilization of 
retroviruses (Hanenberg, Batish et al. 2002). In this approach, retroviruses expressing FA 
cDNAs were used to correct the phenotype of T-cells from FA patients, and this proved to be 
a rapid and accurate manner to determine complementation groups. Another important 
technique to subtype FA patients exploited nowadays is FANCD2 immunoblotting. It is 
based on the observation that, as we will discuss afterwards, the FA pathway can be divided 
in three levels and has a crucial point in the monoubiquitination of FANCD2 protein 
(Shimamura, Montes de Oca et al. 2002). This assay can be used in conjunction with 
retroviral techniques or direct gene sequencing to provide a rapid diagnostic and subtyping 
test (Shimamura and D'Andrea 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Complementation analysis revealed genetic heterogeneity among FA patients. MMC sensitive 
Epstein Barr virus immortalized B-lymphoblasts from different FA patients are fused to form a hybrid cell line. 
The resulting hybrid is either MMC sensitive or MMC resistant. Complementation of the MMC sensitive 
phenotype is only seen when the two cell lines have a defect in different genes (indicated with letters in lower 
case) and in that situation the patients are said to belong to different ‘complementation groups’ 
AAbb 
aaBB aaBB 
FA-n1 FA-n3 FA-n2 
aaaa 
BBBB 
aaAA 
bbBB 
MMC sensitive: no 
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MMC resistant: 
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1.2.5: Haematological management and haematopoietic stem cell transplantation. 
  
If there is no haematopoietic defect at time of diagnosis, haematological monitoring 
may be required once per year, but as the patient becomes older and develops haematological 
complications, haematologists play an increasingly central role. Many patients who develop 
bone marrow failure initially respond to treatment with androgens and haematopoietic 
growth factors (Rackoff 1999). Oral oxymetholone is the usual recommended androgen and 
trilineage responses can be seen in approximately 60% of cases. However, oxymetholone has 
side effects which include masculinization, acne, hyperactivity, growth spurt followed by 
premature closure of the epiphyses resulting in short stature, deranged liver enzymes, hepatic 
adenomas and potential risk of hepatic adenocarcinomas. Therefore, close monitoring, 
particularly of liver function (liver enzymes, bilirubin, AFP every 2–3 months and yearly 
liver ultrasound scans), is mandatory whilst on androgen therapy. Growth factors such as G-
CSF and GM-CSF can improve haematopoiesis either in conjunction with androgens 
(particularly if the patient is neutropenic) or if androgens have failed. They are usually 
avoided in patients with clonal cytogenetic abnormalities and are discontinued if such 
abnormalities develop while on therapy because of the potential risk of inducing or 
promoting leukaemia. 
Eventually, most patients become refractory to oxymetholone therapy and the natural 
history of FA ends in lethal bone marrow failure. The definitive treatment currently available 
to restore normal haematopoiesis when marrow failure or clonal haematopoietic abnormality 
occurs is haematopoietic stem cell transplantation (HSCT). As expected, HSCT is however 
unable to modify non-haematopoietic defects and abnormalities occurring in FA patients. 
Donor stem cells can be from bone marrow, peripheral blood or umbilical cord blood. The 
very high sensitivity to oxidative agents and DNA cross-linking agents of FA cells confers 
very peculiar tissue fragility. Then, when these patients undergo HSCT, they experience 
unusual and severe toxicities including cardiac myopathy, gastrointestinal haemorrhage, 
haemorrhagic ystitis and radiation skin burns. These toxicities mean that the classical 
myeloablative conditioning regimen must be avoided, as demonstrated by Gluckman and 
colleagues (Berger, Bernheim et al. 1980; Gluckman, Devergie et al. 1980; Gluckman, 
Devergie et al. 1983), on account of the toxicity induced by high-dose cyclophosphamide 
(CY) or high dose irradiation. In the same way, the occurrence of either severe acute or 
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chronic graft versus host disease (GVHD) leads to greater tissue damage than that occurs in 
non-FA patients. Thus, for decades, the development of adapted low-intensity conditioning 
regimen and selection of graft associated to the lowest GVHD risk were the main goals of 
physicians.  
In 1998, a group from St. Louis described the long-term follow-up of 50 FA patients 
transplanted from a sibling donor after low-dose CY (20 mg/kg total dose) and thoraco-
abdominal irradiation (500 cGy) as conditioning regimen (Socie, Devergie et al. 1998). With 
this treatment, 74 and 58 % of patients survived at 54 and 100 months, respectively, after 
transplantation. The occurrence of chronic GVHD and the use of more than 20 pre-transplant 
transfusions appeared to have significant adverse impact on survival by multivariate analysis. 
During the same period, a group from Seattle reported similar results using reduced intensity 
conditioning regimen without any irradiation. In addition, in this study the incidence of both 
acute and chronic GVHD appeared to be lower than in the French study (Flowers, Zanis et 
al. 1996). Then, a conditioning regimen avoiding any radiation and including anti-
thymoglobulins was developed. However, such a conditioning regimen could not prevent 
any solid tumor occurrence because of higher risk of squamous cell carcinoma in all FA 
patients, including non-transplanted ones. Essentially, as summarized by Gluckman and 
Wagner in a recent review (Gluckman and Wagner 2008), the best conditioning regimen 
must prevent rejection in population of patients who have received multiple transfusions, 
must limit early and late toxicities and must minimize the risk of GVHD. In addition, it 
seemed very important to plan transplantation before the appearance of abnormal clonality 
by at least a yearly bone marrow examination. Because of the strong side effects induced in 
vitro by alkylating agents such as CY on FA cell lines, it appeared interesting to develop a 
conditioning regimen without this type of chemotherapy. In 1997, a group from Israel 
published the first case report using a fludarabine-based conditioning regimen for an FA 
child in leukaemic transformation (Kapelushnik, Or et al. 1997). They were followed by 
many groups all over the world, and currently, fludarabine-based conditioning regimens are 
considered as the gold standard for FA patient transplantation. In 2007, Wagner and 
colleagues (Wagner, Eapen et al. 2007) reported the long-term results in 98 FA patients who 
underwent unrelated bone marrow transplant from 1990 to 2003 in centers collaborating with 
the National Marrow Donor Program. They showed higher probabilities of neutrophil and 
platelet recovery after fludarabine-containing regimens than non-fludarabine containing 
regimens did. Similarly, transplantation related mortality (TRM) and 3-year adjusted overall 
survival rates appeared better after fludarabine based conditioning regimens than non-
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fludarabine based regimens (65 vs 24% and 13 vs 52%, respectively). The other significant 
poor prognostic factors for mortality in this paper were patient age more than 10 years, 
cytomegalovirus (CMV) seropositivity and more than 20 blood product transfusions before 
transplantation. The authors emphasized practice changes including fludarabine-containing 
conditioning regimens to obtain strong T-cell depletion and early transplantation in FA 
patients exhibiting marrow failure. Recently, Yabe et al. (Yabe, Yabe et al. 2007) performed 
in vitro experiments that demonstrated the rationale for using fludarabine in these patients. 
The difference in breakage frequencies between FA and non-FA patient lymphocytes for 
cultures treated with fludarabine was not statistically significant.  
Nevertheless, some teams still remained satisfied by the results obtained with the 
‘old’ conditioning regimen based on CY, thoraco-abdominal radiation and antithymocyte 
globulin. For example, Cincinnati Children’s Hospital Medical Center reported 89% of 
actuarial survival at 10 years among 35 FA patients who received matched sibling donor 
HSCT in a single center experience (Farzin, Davies et al. 2007). In the same way, the 
experience reported in Saudi Arabia appeared interesting after conditioning containing CY, 
antithymocyte globulin and TBI at 450 cGy for FA patients with myelodysplasia (Ayas, Al-
Jefri et al. 2008). Finally, drugs associated with fludarabine and addition of ionizing 
irradiations still remain to be discussed, according to donor type (either related or unrelated) 
and/or according to marrow clonal abnormality occurrence before transplantation. In 2006, 
Bitan et al. (Bitan, Or et al. 2006) reported excellent results regarding seven patients who 
underwent HSCT from either matched sibling or matched unrelated donor after fludarabine-
based reduced-intensity conditioning regimen without radiation. In this short cohort, all 
seven patients were alive with 100% performance status. At the time of publication, no 
patient had developed secondary malignancy. Other groups still use the fludarabine-based 
conditioning regimen containing low-dose radiation (200–400 cGy) when patients are 
transplanted from unrelated donors (Locatelli, Zecca et al. 2007). For patients without 
matched sibling or unrelated donor, unrelated partially matched cord blood might represent 
an acceptable alternative.  
For those FA patients who survive the haematological complications, follow-up 
surveillance for solid malignancies is increasingly important (Alter 2003). A study of 
secondary cancers in 700 aplastic anaemia patients who received an allogeneic HSCT 
highlighted FA as an independent risk factor for developing malignancy, with a predicted 
risk of 42% at 20 years after transplant (Deeg, Socie et al. 1996). A retrospective study of 37 
FA patients who received an allogeneic HSCT reported a high risk of secondary 
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malignancies, notably head and neck carcinomas, which had a cumulative incidence of 53% 
10 years after SCT and occurred exclusively in FA patients who had developed acute or 
chronic GVHD (Guardiola, Socie et al. 2004). Surveillance for solid tumours has been 
advocated; in females this would be at an annual gynaecological follow-up to detect cervical 
and vulval tumours and both sexes should be kept under surveillance for oropharyngeal, 
oesophageal and hepatic tumours (Alter, Greene et al. 2003; Lowy and Gillison 2003). 
However, at present, it is unknown how effective such surveillance measures would be in FA 
patients. Cancer management based on the current evidence from FA patients tends to 
maximize surgical intervention whilst keeping chemotherapy and radiotherapy use to a 
minimum.  
 
 
1.2.6: Gene therapy. 
 
The serious haematological complications requiring HSCT mean that FA would be an 
ideal candidate disease for gene therapy, also because unaffected matched sibling donors are 
unavailable to the majority of the patients and the results of alternative donor transplantation 
remain unsatisfactory (Wagner, Eapen et al. 2007). Furthermore, the incidence of somatic 
mosaicism in FA patients suggests that FA cells corrected using gene therapy may have a 
selective advantage over defective cells. Gene therapy programmes were initiated in the 
1990s but very few patients were treated with this approach and in no case has been reported 
a long-term haematopoietic reconstitution. The major problem is the low efficiency of 
transfection of the target cells, which in turn depends on the scarcity of stem cells (Kelly, 
Radtke et al. 2007) and on the viral vectors. At present, γ-retroviral (Jacome, Navarro et al. 
2006) and lentiviral vectors (Yamada, Ramezani et al. 2003) seem to provide encouraging 
results in transfecting FA bone marrow cells, but a fully convincing strategy capable of 
expanding the cellular target still seems difficult to find. The newest approach based on the 
use of agents against proinflammatory cytokine TNF-α (Etanercept) is now currently under 
evaluation. The rationale of this strategy is that FA haematopoietic cells display excess 
apoptosis in response to TNF-α, which acts via increased production of reactive oxygen 
species, which in turn are harmful to FA marrow cells (Dufour and Svahn 2008). 
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1.3 Genetics and molecular aspects of Fanconi anaemia 
 
1.3.1: Cloning Fanconi anaemia genes: glimpses of a common functional pathway. 
 
The extreme rarity of the disease, together with its genetic heterogeneity, have long 
been obstacles to the cloning of FA genes until 1992. In that year, as anticipated, the 
laboratory of Manuel Buchwald developed a cloning method, directly derived from the 
complementation assay used to assign complementation groups to FA patients (Strathdee 
1992). The functional complementation cloning system relied on the capacity of a cDNA 
library plasmid, that expressed a normal copy of the defective FA gene, to correct the MMC-
sensitive phenotype of a FA lymphoblast cell line (Fig. 3). The success of this approach 
depended on several factors. Firstly, the cDNA library used to initially transfects the FA cells 
contained the relevant cDNA with its open reading frame intact. Secondly, the FA protein 
was not toxic when overexpressed. Thirdly, the cell line could be transfected (since human 
lymphoblasts are typically reluctant to take up exogenous DNA). Lastly, the transfected cell 
line did not spontaneously revert to MMC resistant at a significant rate. Despite these 
limitations, the method enabled the cloning of five FA genes: FANCC (Strathdee 1992), 
FANCA (Lo Ten Foe JR 1996), FANCG (de Winter JP 1998), FANCF (de Winter JP 2000) 
and FANCE (de Winter JP 2000). Additionally, FANCA was independently identified by 
positional cloning (Consortium 1996). A third method which combined features of both the 
complementation and positional cloning approaches led instead to the cloning of FANCD2 
(Timmers C 2001).  
The six genes identified up to 2001 resulted scattered throughout the genome and did 
not share any common feature. Database searches for all the predicted proteins revealed that 
significant conservation only occurred between vertebrate sequences, with the notable 
exception of FANCD2, that showed highly significant alignment scores with sequences 
found in lower organisms like Drosophila melanogaster, Caenorhabditis elegans and 
Arabidopsis thaliana. The relatively high degree of evolutionary conservation of FANCD2 
indicated that this protein might act in a conserved pathway and other FA genes had 
probably been superimposed later during the evolution. The lack of significant functional 
motifs in any of the FA proteins discovered precluded predictions about their molecular 
functions, but FANCD2 provided a first clue for a DNA-repair defect in FA cells. In fact, 
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upon DNA-damage, this protein co-localized in nuclear foci with the breast cancer 
susceptibility gene BRCA1 and the key protein for homologous recombination RAD51 
(Garcia-Higuera, Taniguchi et al. 2001; Taniguchi, Garcia-Higuera et al. 2002). Next, the 
discovery of FANCD1 gene in 2002 by direct sequencing of BRCA2, definitely stimulated 
the interest for FA. Bi-allelic mutations in BRCA2 were found in fact to cause FA while 
mono-allelic mutations in BRCA2 cause susceptibility to breast and ovarian cancers 
(Howlett, Taniguchi et al. 2002). BRCA2 was known to be functionally involved in 
homologous recombination repair (Moynahan, Pierce et al. 2001) and this finding 
highlighted the connections between FA, cancer and DNA-repair.  
The remaining FA genes have been cloned in recent years, mainly through proteins 
association studies, by using the biochemical technique of immunoprecipitation coupled with 
mass spectrometry (Fig. 4). In particular, in 2003, by immunoprecipitating FANCA in HeLa 
cells with a specific anti-FANCA antibody, the isolated immunocomplex was analyzed by 
mass spectrometry (Meetei, de Winter et al. 2003; Meetei, Sechi et al. 2003). Nine 
components were unambiguously identified into the protein complex, afterwards called ‘FA-
core complex’: the five expected proteins FANCA, FANCC, FANCG, FANCE, FANCF and 
four novel proteins named FAAP43, FAAP95, FAAP100 and FAAP250 (where ‘FAAP’ 
stands for FANCA-associated polypeptides and the numbers refer to their molecular 
weights). A tenth component, FAAP24, was found later in the immunoprecipitate of a 
FAAP250 antibody (Ciccia, Ling et al. 2007). Three FAAPs (FAAP 43, FAAP95 and 
FAAP250) were shown to be defective in FA patients. FAAP95 was the protein mutated in 
complementation group B patients (Meetei, Levitus et al. 2004), whereas FAAP43 was 
defective in the new isolated complementation group L (Meetei, de Winter et al. 2003) and 
FAAP250 was defective in patients of new complementation group M (Meetei, Medhurst et 
al. 2005). The proteins were named FANCB, FANCL and FANCM respectively and the 
discovery of three new FA genes validated the protein complex purification as a new 
approach for identification of disease genes. FANCN (or partner and localizer of BRCA2 
(PALB2))was later identified using the same strategy (Xia, Sheng et al. 2006; Reid, 
Schindler et al. 2007; Xia, Dorsman et al. 2007). The two components FAAP 24 and FAAP 
100, for which no corresponding mutations have been found in FA patients so far (Ciccia, 
Ling et al. 2007; Ling 2007), are likely to have pivotal roles nonetheless. In fact, normal cells 
that are inactivated by small interfering RNA (siRNA) depletion or gene knockout for these 
two genes show phenotypes that are characteristic of FA patients derived cells. FA patients 
carrying mutations in these two genes may well exist, but may be so rare that they are 
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currently absent from the available FA-patient repositories. Finally, the last two FA genes 
identified were FANCJ, encoding for the DNA helicase BRIP1 (BRCA1-interacting protein), 
also called BACH1 (BRCA1-associated C-terminal helicase 1), and FANCI, a paralogue of 
FANCD2. FANCJ was independently cloned by two groups in 2005: the first by using 
positional cloning (Levitus, Waisfisz et al. 2005) and the second by using genetic mapping, 
mutations identification and western blot data (Levran, Attwooll et al. 2005). Genome-wide 
search, databases analysis, biochemical studies and sequence analysis allowed instead to 
three groups the independent identification of FANCI (Dorsman, Levitus et al. 2007; Sims 
AE 2007; Smogorzewska, Matsuoka et al. 2007) as the thirteenth gene involved in FA and as 
the second FA protein to be monoubiquitinated. Relevant informations concerning all the 13 
gene so far identified are reported in table 2. 
 
 
Figure 3. Outline of the complementation cloning strategy.MMC-sensitive lymphoblasts froman FA patient 
are transfected with an episomal cDNA expression library containing a hygromycin selection marker. Cells are 
cultured in the presence of hygromycin to obtain cells that carry a cDNA construct. Selected cells are then 
cultured in medium with a MMC dose that kills the uncorrected FA cells and selects for the cells in which the 
FA defect is complemented by the cDNA construct. Subsequently, the episomal vector is extracted from the 
cells and the cDNA insert is sequenced. Finally, proof of identity for the insert representing the disease gene 
should come from the finding of pathogenic mutations in the patient cell line. 
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Figure 4. Identification of FA genes by protein association studies. An antibody against FANCA is added to 
a HeLa cell nuclear extract to precipitate FANCA and the proteins that bind to FANCA. The precipitated 
proteins are separated on an SDS-PAGE gel and the individual proteins are excised fromthe gel and analyzed 
bymass spectrometry. Subsequently, the genes encoding the novel proteins in the precipitate are analyzed for 
pathogenic mutations in FA patients with no mutations in any of the known FAgenes. 
 
 
In the late 1990s, after cloning the first FA genes, yeast two-hybrid assays and co-
immunoprecipitation studies revealed direct protein interactions between FANCA and 
FANCG, and between FANCC and FANCE (Kupfer, Naf et al. 1997) (Garcia-Higuera, 
Kuang et al. 1999) (Kruyt, Abou-Zahr et al. 1999) (Waisfisz, de Winter et al. 1999) 
(Medhurst, Huber et al. 2001). In particular, FANCA, FANCC, FANCF and FANCG all 
seemed to co-purify when recovered from nuclear extracts (Garcia-Higuera, Kuang et al. 
1999). These interactions were thought to have a functional basis, since the whole nuclear 
complex seemed to be disrupted in cell lines from complementation groups A, C, E, F and G. 
Expression of the complementing (wild-type) FA protein in these cell lines resulted in a 
reconstitution of the nuclear complex and correction of the cellular phenotype (Garcia-
Higuera, Kuang et al. 1999; Kruyt, Abou-Zahr et al. 1999; de Winter, van der Weel et al. 
2000). Cell lines from complementation group D seemed instead to have an intact nuclear 
complex (de Winter JP 2000; Garcia-Higuera, Taniguchi et al. 2001; Timmers C 2001), 
which suggested that FANCD2 and the putative FANCD1 proteins acted downstream of the 
other known FA proteins. FANCD2 protein was detected in two isoforms: FANCD2 short (-
S) and FANCD2 long (-L), where the long version consisted of the addition of a single 
molecule of Ubiquitin on lysine 561, a conserved amino-acid residue in FANCD2 
homologues from lower organisms. Mutation of this residue resulted in loss of ubiqutination 
and failure to complement sensitivity to cross-linkers in FA-D2 cell line (Garcia-Higuera, 
Taniguchi et al. 2001). This modification step was observed in HeLa cells upon exposure to 
various DNA-damaging agents and during genome replication. However, the link to the 
other FA proteins emerged from the crucial observation that FA cell lines from 
complementation groups A, C, E, F and G expressed only unmodified FANCD2, while the 
monoubiquitinated form of FANCD2 was restored upon complementation of these cell lines 
with their respective cDNAs. These results not only established a link between FA proteins 
and DNA-damage, but also functionally connected the FA proteins function in a linear DNA-
damage response pathway in which the first five FA proteins acted upstream of FANCD2. 
The discovery of FANCD2 monoubiquitination raised also the question of the identity of the 
E3 ubiquitin-ligase involved in the process. The obvious candidates were the five FA 
proteins required for FANCD2 monoubiquitination, but none of them contained E3 
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ubiquitin-ligase motifs. At cellular level, monoubiquitinated FANCD2 was observed to be 
targeted to discrete nuclear foci where it co-localized and co-purified with BRCA1 (Garcia-
Higuera, Taniguchi et al. 2001), a protein implicated in several DNA-damage response 
pathways (Scully, Chen et al. 1997). Nuclear foci appeared in cells after DNA-damage and 
in those cells undergoing DNA replication. Noteworthy, BRCA1 had an amino-terminal 
ring-finger motif, known to function as an E3 ubiquitin-ligase (Lorick, Jensen et al. 1999; 
Joazeiro and Weissman 2000), therefore this protein was initially speculated to have a 
potential role in FANCD2 monoubiquitination, until the putative E3 of the pathway was 
identified.  
As we will see in the next section, biochemical works carried on in recent years 
demonstrated that there actually is a ‘FA-core complex’ and that it purifies as part of a larger 
multiprotein complex with BLM (Meetei, Sechi et al. 2003; Ling 2007; Ciccia A 2007 ), the 
helicase mutated in Bloom syndrome (Yin, Sobeck et al. 2005), another genetic disease 
characterized by genomic instability and cancer predisposition.  
 
 
FA genes Prevalence in 
FA patients 
(estimated 
percentage) 
Chromosomal 
location 
Protein 
size 
(kDa) 
Requirement for 
FANCD2/FANCI 
ubiquitinations 
Conservation 
FANCA 66% 16q24.3 163 + Vertebrate 
FANCB ~2% Xp22.31 95 + Vertebrate 
FANCC 10% 9q22.3 63 + Vertebrate, 
FANCD1 ~2% 13q12-13 380 - Vertebrate, worm 
FANCD2 ~2% 3q25.3 155, 162 + Vertebrate, worm, insect, 
slime mould 
FANCE ~2% 6p21-22 60 + Vertebrate 
FANCF ~2% 11p15 42 + Vertebrate 
FANCG 9% 9p13 68 + Vertebrate 
FANCI ~2% 15q25-26 140, 147 + Vertebrate, worm, insect, 
slime mould 
FANCJ ~2% 17q22-24 140 - Vertebrate, invertebrate, 
yeast 
FANCL <0.2% 2p16.1 43 + Vertebrate, insect, slime 
mould 
FANCM <0.2% 14q21.3 250 + Vertebrate, invertebrate, 
yeast, archea 
FANCN ~2% 16p12.1 140 - Vertebrate 
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Table 2 Characteristics of the Fanconi anaemia genes (Adapted by permission from Macmillan Publishers 
Ltd: Nat Rev Genet(Wang 2007)). 
 
 
1.3.2: The FA-BRCA pathway. 
 
As reported, patients from different complementation groups display a diverse 
spectrum of clinical phenotypes (Levitus 2006), but cells from all subtypes of FA are 
hypersensitive to DNA interstrand cross-linking agents (DEB and MMC). In addition, 
biochemical evidences show that FA proteins directly interact. FA proteins are thus 
considered to cooperate in a common DNA-damage response or DNA-repair pathway called 
‘FA pathway’. Since the connection with BRCA proteins was elucidated, the pathway is also 
referred to as the ‘FA-BRCA’ pathway (D’Andrea AD 2003) or the ‘FA-BRCA network’ 
(Venkitaraman 2004). The progressive characterization of the thirteen proteins so far 
discovered has showed that they act at least at three stages in this pathway. If we consider the 
monoubiquitinations of FANCD2 and FANCI as an assay, the FA proteins can be 
functionally divided into three groups (Fig.5). Group I consisting of eight FA proteins 
(FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, FANCL and FANCM) plus FAAP 
24 and FAAP100, all of which are subunit of the ‘FA-core complex’. Cells that are deficient 
in any one of these proteins are defective in monoubiquitination of FANCD2 and FANCI. As 
a consequence, both FANCD2 and FANCI act downstream of the FA-core complex and 
form the group II proteins. It consists exactly of the two paralogues FANCD2 and FANCI 
which interact to form the FA ‘ID’ complex (Smogorzewska, Matsuoka et al. 2007). These 
two proteins are interdependent for their monoubuitination: FANCD2 deficient cells are 
defective in FANCI monoubiquitination whereas FANCI deficient cells are defective in 
FANCD2 monoubiquitination (Sims AE 2007; Smogorzewska, Matsuoka et al. 2007). The 
third group, group III, consists of FANCD1 (BRCA2), FANCN (also known as ‘partner and 
localizer of BRCA2’, PALB2) and FANCJ (also known as BRIP1 (BRCA1-interacting 
protein), or as BACH1 (BRCA1-associated C-terminal helicase 1)). Cells that are defective 
in any of the members of this last group have normal levels of FANCD2 monoubiquitination, 
indicating that the corresponding proteins function either downstream of the ID complex or 
in a parallel pathway. 
 
Group I: the FA core complex 
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The protein complex constituted by FANCA, FANCB, FANCC, FANCE, FANCF, 
FANCG, FANCL, FANCM, FAAP24 and FAAP100 is also known as ‘FA-core complex’. 
Several independent works revealed that all ten components of the FA-core complex are 
indispensable for FANCD2 monoubiquitination in response to DNA-damage or during DNA 
replication (Garcia-Higuera, Taniguchi et al. 2001; Meetei, de Winter et al. 2003; Meetei, 
Levitus et al. 2004; Ling 2007; Ciccia A 2007 ). Furthermore, the subsequently discovered 
FANCI protein (Dorsman, Levitus et al. 2007; Sims AE 2007; Smogorzewska, Matsuoka et 
al. 2007) was also shown to be monoubiquitinated and its monoubiquitination also depends 
on the other FA proteins of the core complex (Sims AE 2007; Smogorzewska, Matsuoka et 
al. 2007).  
The FA-core complex is necessary for monoubiquitination of FANCD2 and it is also 
required for monoubiquitination of FANCI, because monoubiquitination of FANCI depends 
on the monoubiquitination of FANCD2 (Sims AE 2007; Smogorzewska, Matsuoka et al. 
2007). Monoubiquitination consists in a covalent attachment of a single molecule of 
ubiquitin on a lysine residue of a target protein. This is a three steps reaction catalyzed by a 
ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin-
ligase (E3). Monoubiquitnation can change a subcellular localisation of a protein and/or its 
activity with biologically relevant consequences. The contributions of some subunits to 
monoubiquitination is probably indirect, through their participation in the correct assembly 
of the complex (Meetei, Levitus et al. 2004; Ling 2007), but one subunit, FANCL, is likely 
to be the catalytic subunit of the complex that monoubiquitinates FANCD2 and FANCI. 
FANCL contains a PHD finger or ring-finger-type ubiquitin-ligase motif and three WD40 
repeats (Meetei, de Winter et al. 2003). Recombinant proteins containing these motifs have 
E3 ubiquitin-ligase activity. Moreover, point mutations that inactivate the E3 ligase activity 
fail to rescue the defective FANCD2 monoubiquitination in cells that are deficient for 
FANCL (Meetei, de Winter et al. 2003; Gurtan, Stuckert et al. 2006). In addition, another 
subunit that might have a more direct role in FANCD2 monoubiquitination is probably 
FANCE, given that it can form a stable complex with FANCD2 in vitro (Pace P 2002). It is 
therefore plausible that the core complex works in a concerted manner in the ubiquitination 
reaction, with FANCL interacting with ubiquitin-conjugating enzyme E2 and FANCE 
recruiting FANCD2. 
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Figure 5: Classification and domain structures of Fanconi anaemia (FA) proteins. The FA proteins are 
classified into three groups on the basis of their roles in the monoubiquitination of FA proteins FANCD2 and 
FANCI. The brackets indicate that certain FA proteins can form complexes or subcomplexes (such as the FA 
core complex and the ID complex ) in which they work together as partners; inactivation of one such FA 
protein often affects the stability and nuclear localization of its partner proteins. ARM, armadillo repeat; BRC, 
the internal repeat domains of BRCA2; BRCA, breast cancer susceptibility; FAAP, FA-associated protein; P, 
phosphorylation; TPR, tetratricopeptide repeat motifs; Ub, ubiquitin; WD40, a repeat motif found in β-
transducin and other proteins. (Reprinted by permission from Macmillan Publishers Ltd: Nat Rev Genet (Wang 
2007)copyright (2007). 
 
 
In the core complex, there are also two components with DNA-interacting domains 
and activities: FANCM and FAAP24. The protein FANCM contains a DEAH-helicase 
domain and an ERCC4-like endonuclease domain (Meetei, Medhurst et al. 2005) whereas 
FAAP24 possesses a similar ERCC4-like endonuclease domain. The protein FAAP24 was 
shown to interact directly with FANCM and could target FANCM to single-stranded DNA 
(ssDNA) intermediates generated during repair (Ciccia A 2007 ). The heterodimer FANCM-
FAAP24 is similar to a family of structure specific endonucleases and they are considered as 
paralogues, since they are the only human proteins with a tandem helicase-endonuclease 
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domain structure. Their common ancestor might have resembled the archeal DNA-repair 
protein Hef, which contains the same two domains and show both helicase and endonuclease 
activities (Komori, Fujikane et al. 2002; Komori, Hidaka et al. 2004). Hef functions as a 
homodimer and can resolve stalled replication forks, however, so far, no endonuclease 
activity has been detected for either recombinant FANCM-FAAP24 proteins or for the 
purified FA-core complex. Careful examination of the FANCM sequence revealed that its 
endonuclease domain is degenerate at several residues that are supposed to be essential for 
the endonuclease activity (Meetei, Medhurst et al. 2005). Additionally, the endonuclease 
domain of FANCM is absent in orthologues from many lower eukaryotes such as Drosophila 
melanogaster, Caenorhabditis elegans and yeast (Meetei, Medhurst et al. 2005; Mosedale G 
2005 ). Notably, FAAP24 has no orthologues in these species. These results implied that the 
endonuclease function of FANCM might have been lost during the evolution. Furthermore, 
differently from its archeal and yeast orthologues (Hef and PH1) which do have helicase 
activity towards several DNA substrates (Komori, Fujikane et al. 2002; Komori, Hidaka et 
al. 2004; Prakash R 2005), FANCM does not seem to have helicase activity in vitro either 
(Meetei, Medhurst et al. 2005). Therefore, the mechanism of FANCM is probably different 
from its orthologues. Many proteins with helicase domains lack helicase activity but show a 
DNA translocase activity: examples of such proteins include ATP-dependent chromatin-
remodelling enzymes. FANCM does indeed have an ATP-dependent DNA translocase 
activity, possibly to work as an engine to translocate the core complex along DNA, an 
important step in DNA-repair. At this stage, FANCM might possess other ATP-dependent 
DNA-processing activities that remain to be revealed. Interestingly, certain structures that 
are generated during replication, such as ssDNA and Y-shaped DNA, do not activate 
FANCD2 monoubiquitination, although the affinity of these same DNAs for FANCM-
FAAP24 is higher than that of duplex DNA (Ciccia A 2007 ). 
The activation of the FA-BRCA network depends on ATR (Andreassen, D'Andrea et 
al. 2004; Pichierri and Rosselli 2004), a checkpoint kinase that is activated by replication 
stress. Several components of the FA-core complex are hyperphosphorylated in response to 
DNA damage, including FANCM, FANCA, FANCE and FANCG (Yamashita, Kupfer et al. 
1998; Qiao, Mi et al. 2004; Meetei, Medhurst et al. 2005; Matsuoka, Ballif et al. 2007; 
Wang, Kennedy et al. 2007). The phosphorilation of these proteins involves not only ATR, 
but also its downstream kinase checkpoint kinase 1 (CHK1) and possibly other kinases. 
These FA proteins might serve as signal transducers through which ATR regulates the 
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activity of the core complex, although this possibility remains to be demonstrated yet 
experimentally. 
 
Group II: the ID complex 
This group consists of the two paralogues FANCD2 and FANCI and several lines of 
evidence suggest that they are coordinately regulated and work together in an ‘ID’ complex. 
They co-immunoprecipitate with each other from cell lysates, both proteins are 
monoubiquitinated in response to DNA damage or replication cues, the monoubiquitination 
for both proteins depends on the FA core complex and their de-ubiquitination is catalysed by 
the same enzyme, ubiquitin-specific protease 1 (USP1) (Nijman, Huang et al. 2005; 
Smogorzewska, Matsuoka et al. 2007). Additionally, both can be phosphorylated by ATR or 
ataxia telangiectasia mutated (ATM) (Taniguchi, Garcia-Higuera et al. 2002; Andreassen, 
D'Andrea et al. 2004; Smogorzewska, Matsuoka et al. 2007) and when cells are exposed to 
DNA-damaging reagents, both proteins are redistributed to the chromatin and nuclei foci, 
which are believed to be the sites of DNA-repair (Garcia-Higuera, Taniguchi et al. 2001; 
Sims AE 2007; Smogorzewska, Matsuoka et al. 2007). Finally, each depends on the presence 
of its partner for stability and ubiquitination.  
A key question for this complex is therefore how it functions. Possible clues for this 
mechanism is that monoubiquitinated FANCD2 preferentially associates with chromatin 
while non ubiquitinated FANCD2 is enriched in soluble cell extracts (Meetei, Yan et al. 
2004; Wang, Andreassen et al. 2004). At this purpose, an elegant study using chicken DT40 
cells showed that monoubiquitination is crucial in targeting FANCD2 to chromatin 
(Matsushita, Kitao et al. 2005). In this work, a FANCD2 mutant with its ubiquitination site 
replaced by a non ubiquitinable residue (K563R; K563 in chicken is equivalent to K561 in 
human FANCD2) was fused to a single ubiquitin at its C terminus. When this FANCD2–
ubiquitin fusion protein was introduced to FANCD2-deficient cells, it associated with 
chromatin and corrected the cellular hypersensitivity to the DNA-crosslinking drug cisplatin. 
However, when the same FANCD2–K563R construct was fused to a ubiquitin point mutant 
(I44A) that was defective in interacting with ubiquitin-binding proteins, the fusion protein 
failed to localize to chromatin and also had a reduced ability to complement the drug 
sensitivity of the same cells. These results suggest that ubiquitin serves as a chromatin-
localization signal for FANCD2, and also implies the existence of a chromatin associated 
ubiquitin-binding protein that recognizes this signal and recruits monoubiquitinated 
FANCD2. When the FANCD2–K563R mutant was fused to histone H2B, the fusion protein 
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was constitutively associated with chromatin and could rescue the cisplatin sensitivity. 
Therefore, the chromatin association of FANCD2 can bypass the requirement of 
monoubiquitination, indicating that the sole function of monoubiquitination is to target 
FANCD2 to the chromatin. At the cellular level, monoubiquitinated FANCD2 and FANCI 
are concentrated at nuclear foci, which are believed to be the sites of DNA-repair. 
Interestingly, the formation of these foci depends not only on the FA-core complex, but also 
on BRCA1(Garcia-Higuera, Taniguchi et al. 2001). It was shown that FANCD2 is relocated 
to sites of stalled replication forks, and that this relocation depends on the FA-core complex, 
ATR and BRCA1, as well as a new player, γH2AX (Bogliolo, Lyakhovich et al. 2007). 
γH2AX is a phosphorylated form of a histone H2A variant, H2AX, which specifically 
associates with damaged DNA regions and is required for the subsequent recruitment of 
many DNA-repair molecules, including BRCA1. Cells that are deficient for γH2AX are 
hypersensitive to ICL drugs, but their FANCD2 monoubiquitination is normal (Bogliolo, 
Lyakhovich et al. 2007). γH2AX coimmunoprecipitates with monoubiquitinated FANCD2, 
suggesting that γH2AX has a role in recruitment or retention of the ID complex near 
damaged DNA (Bogliolo, Lyakhovich et al. 2007).  
At this point, one of the key questions is what does the ID complex do after it is 
recruited to DNA-damage sites. One study suggested that FANCD2 recruits BRCA2 to the 
damaged sites to promote homologous recombination repair (Wang, Andreassen et al. 2004). 
However, homologous recombination is only modestly affected in cells that are deficient for 
the FA-core complex or FANCD2 (Yamamoto, Ishiai et al. 2003; Niedzwiedz, Mosedale et 
al. 2004; Nakanishi, Yang et al. 2005), in contrast to BRCA2-deficient cells, in which 
homologous recombination is severely affected. These findings argue against a significant 
involvement of FANCD2 in BRCA2 recruitment during homologous recombination. Other 
evidence suggests that FA proteins also promote translesion synthesis (TLS) (Niedzwiedz, 
Mosedale et al. 2004; Nojima, Hochegger et al. 2005). For example, DT40 cells in which 
translesion polymerases REV1 (or REV1L) and REV3 (or POLZ) are inactive, are highly 
sensitive to DNA-crosslinking drugs; genetic analysis shows that these polymerases work in 
the same pathway as FA proteins to repair ICLs. The ID complex might have a similar role 
to proliferating cell nuclear antigen (PCNA) during polymerase switching in response to 
DNA-damage (McHugh and Sarkar 2006; Shen, Jun et al. 2006). Monoubiquitinated PCNA 
interacts with ubiquitin-binding domains of translesion polymerases and recruits them, 
allowing replicative polymerases to be replaced and the damaged sites to be bypassed 
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(Kannouche, Wing et al. 2004). By analogy, the monoubiquitinated ID complex might 
interact with and recruit translesion polymerases through a similar mechanism.  
Finally, results from several studies have pointed out that the FA ID complex is 
functionally more important than the FA-core complex. The clinical phenotypes of FA 
patients with FANCD2 mutations are in effect generally more severe than those of patients 
who are defective in FA-core complex proteins, including more frequent malformations and 
earlier manifestations of haematological malignancies (Kalb, Neveling et al. 2007). Also, all 
FANCD2 mutations identified so far are hypomorphic, and the patient-derived cells all 
express residual levels of both monoubiquitinated and non-ubiquitinated FANCD2 (Kalb, 
Neveling et al. 2007), indicating that FANCD2 is probably essential during human 
development and that its complete inactivation could be lethal. By contrast, patients who are 
defective in FA-core complex components frequently carry nullizygous mutations, indicating 
that they are non-essential. Additionally, FANCD2 knockout mice display certain 
phenotypes such as small eyes, perinatal lethality and epithelial cancers, which are not 
observed in mice in which genes encoding FA-core complex components are disrupted 
(Houghtaling, Timmers et al. 2003). Furthermore, the majority of FA-core complex genes 
are completely absent in many eukaryotic species that do contain orthologues of FANCD2 
(and FANCI). These differences suggest that ubiquitination of FANCD2 by the core 
complex is required for some but not all of the functions of FANCD2, and that the non-
ubiquitinated FANCD2 probably has indispensable roles in some developmental processes 
and tumour suppression. In addition to its participation in the FA pathway, FANCD2 has 
been suggested to participate in a separate signalling pathway that is activated by ATM in 
response to ionizing radiation (which causes double stranded breakages DSBs) (Taniguchi, 
Garcia-Higuera et al. 2002). In this pathway, ATM phosphorylates FANCD2 on serine 222, 
leading to activation of the S-phase checkpoint. Thus, the FA ID complex participates in at 
least two discrete pathways: one that responds to ATR and the FA-core complex, and the 
other one that is regulated by ATM.  
 
Group III: cancer and DNA repair 
This group consists of three proteins: FANCD1 (BRCA2), FANCJ and FANCN. In 
contrast to proteins from the other two groups, cells lacking group III proteins have normal 
levels of monoubiquitinated FANCD2 in response to DNA-damage, suggesting that these 
proteins function either downstream of the ID complex or in a separate pathway. 
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The first important feature of group III genes is their connection to breast cancer. 
Homozygous mutations at these loci cause FA while heterozygous mutations predispose 
female carriers to breast cancer. As previously mentioned, the first evidence for this came 
with the identification of the FANCD1 gene as BRCA2 (Howlett, Taniguchi et al. 2002). 
BRCA2 and BRCA1 are two major tumour-suppressor genes, mutations in which are linked 
to familial breast and ovarian cancers in women. Although BRCA1 is not mutated in FA 
patients, the BRCA1-interacting protein BRIP1, also known as BRCA1-associated C-
terminal helicase (BACH1), is identical to another member of group III, FANCJ (Levitus, 
Waisfisz et al. 2005; Litman, Peng et al. 2005; Godthelp, Wiegant et al. 2006). In addition, 
BRCA1 associates with BRCA2 to form a complex that is distinct from the BRCA1–BRIP1 
complex, and BRCA1 is required for both BRCA2 and BRIP1 to relocate to the sites of 
DNA-damage (Greenberg, Sobhian et al. 2006). Together, these data underscore an 
important connection between FA and breast cancer, and suggest that FA could be an 
attractive model to identify more breast cancer susceptibility genes and examine how they 
function. In this regard, BRCA1 was shown to form a new complex with receptor-associated 
protein 80 (RAP80, also known as UIMC1) (Kim, Chen et al. 2007; Sobhian, Shao et al. 
2007; Wang, Matsuoka et al. 2007) and abraxas. Both proteins are phosphorylation 
substrates of ATR or ATM, and are required for resistance to DNA-damage. Notably, 
RAP80 contains ubiquitin-interacting motifs, and is required for optimal accumulation of 
BRCA1 to the sites of DNA-damage.  
Group III proteins form stable complexes also with other DNA-repair proteins. 
BRCA2 and FANCN have been purified in a complex with the recombinase RAD51. FANCJ 
has been found in a separate complex with topoisomerase II binding protein 1 (TOPBP1) and 
the mismatch repair proteins mutL homologue 1 (MLH1) (Greenberg, Sobhian et al. 2006) 
and post-meiotic segregation increased 2 (PMS2) (Peng, Litman et al. 2007) (table 3). Both 
complexes also contain BRCA1 and its partner, breast cancer-associated ring domain 1 
(BARD1). Current evidence suggests that the FANCD1 (BRCA2)-FANCN complex 
participates in homologous recombination repair of DNA-damage. FANCD1 (BRCA2) 
interacts directly with RAD51, and this interaction might nucleate the formation of RAD51 
oligomers on ssDNA, a key step in homologous recombination repair (Sharan, Morimatsu et 
al. 1997; Pellegrini, Yu et al. 2002; Yang, Jeffrey et al. 2002). In BRCA2-deficient cells, the 
efficiency of homologous recombination repair is strongly reduced (Moynahan, Pierce et al. 
2001), and RAD51 fails to localize to nuclear foci in response to DNA-damage (Yuan, Lee 
et al. 1999). FANCN (or PALB2) is an essential component of the BRCA2–RAD51 
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complex, and inactivation of FANCN results in instability and mislocalization of BRCA2, as 
well as defective homologous recombination repair (Gurtan, Stuckert et al. 2006).  
The DNA-repair pathway that is mediated by the FANCJ-associated complex 
remains unclear. Knockdown experiments in mammalian cells suggest that FANCJ is a 
downstream effector of BRCA1 and mediates homologous recombination repair (Litman, 
Peng et al. 2005), but gene-knockout studies in chicken DT40 cells suggest that FANCJ acts 
independently of BRCA1 and is dispensable for homologous recombination (Bridge, 
Vandenberg et al. 2005). A complementation study using FANCJ patient derived cells 
showed that the interaction between FANCJ and BRCA1 is dispensable for the function of 
FANCJ in the FA pathway, whereas its interaction with MLH1 and PMS2 is essential (Peng, 
Litman et al. 2007). However, it is not obvious how MLH1 and PMS2 mediate the action of 
FANCJ, as cells that are deficient in these proteins do not display FA-like phenotypes such 
as MMC hypersensitivity. Notably, FANCJ contains a DEAH–box DNA helicase domain 
and a 5′-to-3′ helicase activity (Cantor, Drapkin et al. 2004). Considering that FA proteins 
function in the same pathway as translesion polymerases (Niedzwiedz, Mosedale et al. 
2004), it is possible that FANCJ promotes translesion bypass using a similar mechanism to 
what has been proposed for the human translesion polymerase POLQ (Seki, Marini et al. 
2003) and its D. melanogaster orthologue MUS308 (Shima, Munroe et al. 2004). Both of 
these proteins contain tandem helicase and polymerase domains. MUS308 mutant cells are 
highly sensitive to ICL drugs, and mice with mutations in POLQ also seem to have a 
potential defect in homologous recombination or ICL repair (Shima, Munroe et al. 2004). It 
has been proposed that the helicase domain removes the lagging strand at stalled replication 
forks and creates a loading zone for the polymerases (Guy and Bolt 2005). FANCJ might 
promote loading of a translesion synthesis polymerase to stalled replication forks by 
displacing unwanted DNA or proteins in a similar way. 
 
 
Proteins (disease) Properties or domain Function 
 Upstream of FA core complex  
ATR (Seckel syndrome) PI-3 kinase Phosphorilates FA core and ID 
complex 
ATRIP  A partner of ATR 
RPA OB-fold Bind ssDNA; activates ATR 
CHK1 Kinase A downstream kinase of ATR 
HCLK2  Associates with ATR; stabilizes 
CHK1 
NBS1 (Nijmegen FHA; BRCT Associates with MRE11 and 
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breakage syndrome) RAD50; required for ATR and 
ATM activation 
ATM (ataxia 
telangiectasia) 
PI-3 kinase Phosphorilates FANCD2 and 
possibly FANCI 
 FA core complex partners  
BLM (Bloom syndrome) Helicase Stabilizes and restarts replication 
forks 
Topoisomerase IIIα Type I topoisomerase An essential partner of BLM 
BLAP75/RMI1 OB-fold Binds DNA; an essential partner 
for topoisomerase IIIα 
RPA OB-fold Facilitates BLM helicase activity 
UBE2T E2 Ubiquitin-conjugating enzyme 
USP1 De-ubiquitination enzyme Removes ubiquitin from the ID 
complex; regulated by DNA 
damage and replication 
 Downstream FA protein partners  
γH2AX Histone H2A variant Phosphorilated following DNA 
damage; marks regions of DNA 
damage; recruits or retains 
DNA-repair molecules such as 
BRCA1 and FANCD2 
BRCA1 (breast cancer) E3 ring finger; BRCT Ubiquitin ligase; binds 
phosphorilated ATM or ATR 
sites; associates with BRCA2 
and FANCJ; recruits FANCD2, 
BRCA2 and FANCJ to damage 
sites 
BARD1 Ring finger Binds BRCA1; essential for the 
ubiquitin ligase activity of 
BRCA1 
RAD51  ATPase Required for homologous 
recombination; associates with 
BRCA2 and PALB2 
MLH1 (colorectal cancer) ATPase Associates with FANCJ, BRCA1 
and BLM; participates in 
mismatch repair 
PMS2 (colorectal cancer) ATPase Associates with FANCJ and 
BRCA1; a partner of MLH1, 
involved in mismatch repair 
TOPBP1 BRCT Associates with FANCJ and 
BRCA1; activates ATR 
 
Table 3: Proteins that crosstalk with FA-BRCA pathway 
ATM, ataxia telangiectasia mutated; ATR, ataxia telangiectasia and Rad3-related protein; ATRIP, ATR 
interacting protein; BARD1, BRCA1-associated RING domain 1; BLAP75, BLM-associated protein, 75 kDa; 
BLM, Bloom syndrome protein; BRCA, breast cancer susceptibility; CHK1, checkpoint kinase 1; FA, Fanconi 
anaemia; FANC, Fanconi anaemia complementation group; γH2AX, phosphorylated form of histone H2A 
variant H2AX; HCLK2, human homologue of the worm biological clock 2 protein; MLH1, mutL homologue 1, 
colon cancer, nonpolyposis type 2; MRE11, meiotic recombination 11 homologue A; NBS1, Nijmegen 
breakage syndrome protein; PMS2, post-meiotic segregation increased 2; RMI1, RecQ-mediated genome 
instability 1 homologue; RPA, replication protein A; TOPBP1, topoisomerase (DNA) II binding protein 1; 
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UBE2T; ubiquitin-conjugating enzyme E2T; USP1, ubiquitin-specific protease 1. (Adapted by permission from 
Macmillan Publishers Ltd: Nat Rev Genet(Wang 2007). 
 
 
1.3.3: Crosstalk of the FA-BRCA pathway with other DNA-repair proteins. 
 
The FA proteins interact with a range of proteins that are known to be involved in the 
DNA-damage response (table 3). Mutations in some of these proteins also cause diseases that 
are similar to FA, including genomic instability and cancer. One group includes ATR 
(Andreassen, D'Andrea et al. 2004; Pichierri and Rosselli 2004), its downstream kinase 
CHK1 (Wang, Kennedy et al. 2007) and molecules that participate in ATR activation such as 
RPA (Andreassen, D'Andrea et al. 2004), ATRIP (Sobeck, Stone et al. 2006), NBS1 (a 
component of the MRE11–RAD50–NBS1 complex) (Nakanishi, Taniguchi et al. 2002; 
Pichierri and Rosselli 2004; Stiff, Reis et al. 2005) and HCLK2 (Collis, Barber et al. 2007). 
These molecules activate the FA–BRCA network by facilitating phosphorylation of the FA 
core complex, the ID complex, BRCA1, BRCA2, PALB2 and γH2AX11, (Yamashita, 
Kupfer et al. 1998; Qiao, Mi et al. 2004; Ho, Margossian et al. 2006; Matsuoka, Ballif et al. 
2007; Wang, Kennedy et al. 2007). ATM can also be included in this group, however, it 
seems to be involved in activation of the intra-S phase checkpoint, but is not involved in 
FANCD2 monoubiquitylation or repair of ICLs (Taniguchi, Garcia-Higuera et al. 2002). 
Because ATR is usually activated by collapsed replication forks during DNA synthesis 
whereas ATM responds mainly to DSBs, the fact that the FA–BRCA network is activated by 
ATR but not ATM argues that the main function of this network is to recover stalled 
replication forks.  
A second group consists of proteins that work with the core complex, including BLM 
helicase and its DNA-processing partners, Topoisomerase IIIα, the BLM-associated 
polypeptide BLAP75 (or RMI1) and RPA. One important function of the BLM complex is to 
stabilize the stalled replication forks and allow a subsequent homologous recombination-
dependent process to restart replication (Cobb, Bjergbaek et al. 2003; Bjergbaek, Cobb et al. 
2005). The direct interaction between the BLM and the FA-core complex suggests that they 
work together to help restart arrested replication forks (Thompson, Hinz et al. 2005). Other 
proteins of this group include UBE2T, which has been reported as a possible E2 for 
FANCD2 monoubiquitination (Machida, Machida et al. 2006), and USP1, the de-
ubiquitination enzyme for FANCD2 and FANCI (Nijman, Huang et al. 2005). USP1 protein 
levels are regulated during cell-cycle progression and by DNA-damage signals, suggesting 
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that cells can modulate the amount of the monoubiquitylated ID complex, which reflects the 
status of the FA–BRCA network, through regulating USP1 (Huang, Nijman et al. 2006).  
A third group consists of proteins that work with downstream FA proteins. Among 
them are γH2AX and BRCA1, which seem to be essential for the recruitment of the ID 
complex, FANCJ and BRCA2 to damaged DNA regions. This group also includes proteins 
with DNA-processing activities, such as recombinase RAD51, which associates with 
BRCA2 and PALB2, and TOPBP1, MLH1 and PMS2, which interact with FANCJ. The 
translesion polymerases REV1 and REV3 can also be included in this group as they work in 
the same pathway as FA proteins, although so far they have not been shown to interact 
physically with any FA proteins. 
 
 
1.3.4: FA-BRCA network response following DNA damage: a current model. 
 
Several models have been proposed to describe how the FA-BRCA pathway 
promotes repair of ICLs. One of the simpler models, described in reference by (Kennedy and 
D'Andrea 2005), is reported in figure 6. In this model, FA proteins work with nucleotide 
excision repair, translesion synthesis and homologous recombination proteins to remove an 
ICL at a stalled replication fork. Briefly, FANCM and FAAP24 might target the core 
complex to the stalled replication fork, where it can be activated by ATR through 
phosphorylation. The BLM complex is also recruited and prevents the stalled fork from 
collapse. The phosphorylated FA core complex then activates the ubiquitin-ligase activity of 
FANCL, which monoubiquitinates the ID complex (which can possibly also be 
phosphorylated by ATR before its ubiquitination). The ICL is unhooked by MUS81–EME1 
and XPF–ERCC1 endonucleases, creating a DSB in the DNA (Kuraoka, Kobertz et al. 2000; 
Hanada, Budzowska et al. 2006). ATR also phosphorylates γH2AX, which is incorporated 
into the chromatin that surrounds the damaged DNA region. The monoubiquitinated ID 
complex is then recruited to and retained at the site of DNA-damage by γH2AX and BRCA1. 
This allows subsequent entry of the BRCA2–PALB2–RAD51 complex to the damaged site, 
thereby promoting a homologous recombination-dependent restart of the stalled fork. The ID 
complex might also recruit REV1 and REV3 translesion polymerases in a similar mechanism 
to that by which monoubiquitinated PCNA allows damaged DNA to be bypassed. FANCJ 
might use its helicase activity to clear the DNA template and promote the loading of 
translesion polymerase. 
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Figure 6: Signalling through the Fanconi anaemia (FA)–breast cancersusceptibility (BRCA) network in 
response to DNA damage. a | A model for the upstream FA–BRCA network. Briefly, a stalled replication fork 
activates ataxia telangiectasia and Rad3-related protein (ATR) and its downstream kinase checkpoint kinase 1 
(CHK1). They activate the FA core (composed of FA proteins A, B, C, E, F, G and L)and ID complex 
(composed of FA proteins D2 and I) by phosphorylation. The core complex translocates and is recruited to sites 
of DNA damage by FA proteins FANCM(M in the figure) and FAAP24 (FA24 in the figure), where it 
monoubiquitylates the FA–ID complex, and might also help to recruit the ID complex to the chromatin. 
FANCM and FAAP24 might also directly process the DNA as part of a DNA-repair reaction. The ubiquitin-
activating enzyme (E1) and a conjugating enzyme (UBE2T)work together with the FA core complex (E3) to 
monoubiquitylate the ID complex. A de-ubiquitylation eyzyme, USP1, removes the monoubiquitin from the ID 
complex to‘switch off’ the network after the damage is repaired. b: A model for the downstream FA–BRCA 
network. ATR phosphorylates the histone H2A variant H2AX (makingH2AX), along with BRCA1 and 
BRCA2, which might allow various repair complexes to be recruited to the damaged loci through protein–
protein interactions. The BRCT domains in BRCA1 recognize phosphorylated ATR or ataxia telangiectasia 
mutated(ATM) sites, and might be involved in the recruitment of the repair proteins. A complex of BRCA2 and 
partner and localizer of BRCA2 (PALB2) can promote a homologous recombination-dependent restart of the 
replication fork, whereas FANCJ(also called BRCA1-interacting protein 1 (BRIP1)) probably promotes 
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translesion bypass. The BLM helicase complex could work together with the FA core complex to stabilize and 
re-start the stalled replication forks. P, phosphorylation; Ub ubiquitylation. . (Reprinted by permission from 
Macmillan Publishers Ltd:: Nat Rev Genet(Wang 2007)copyright (2007). 
 
 
1.3.5: Other branches of the FA-BRCA pathway. 
 
In addition to defective DNA--repair, a number of other possible causes of the 
cellular and clinical abnormalities found in FA have been also recognized and these are 
summarized in this section.  
 
Oxygen sensitivity. 
Several works have shown that FA cells exhibit increased oxygen sensitivity, and 
chromosome breakage is reduced in the presence of low ambient oxygen concentrations 
(Joenje, Arwert et al. 1981; Joenje 1989). Many DNA cross-linking agents produce reactive 
oxygen species (ROS) and it is possible that the sensitivity of FA cells to cross-linkers is due 
to an impaired ability to counteract ROS (Pagano and Youssoufian 2003). Studying 
apoptosis in FA-C cells, Clarke and Philpott showed that they behaved like normal cells 
when exposed to MMC at 5% oxygen concentration and were hypersensitive to MMC at 
20% oxygen, implying that it is the ROS generated by MMC, rather than the DNA cross-link 
formation, that causes toxicity in FA cells (Clarke, Philpott et al. 1997). Other lines of 
evidence come from yeast-two hybrid studies, which have shown that the FANCC protein 
interacts with NADPH cytochrome p450 reductase (Kruyt, Hoshino et al. 1998) and FANCG 
with cytochrome p450 2E1 (CYP2E1) (Futaki, Igarashi et al. 2002), both enzymes that 
produce ROS.  
 
Apoptosis and telomere maintenance.  
Apoptosis is abnormally regulated in FA cells, although the exact nature of the 
abnormality remains unclear. In one study, the treatment of four FA lymphoblastoid cell 
lines with MMC led to a higher level of apoptosis (Kruyt, Dijkmans et al. 1996), but other 
studies have shown higher levels of spontaneous apoptosis, lower levels after c-irradiation, 
and no difference after MMC exposure (Rey, Scott et al. 1994; Rosselli, Ridet et al. 1995; 
Ridet, Guillouf et al. 1997). Increased apoptosis may be related to the inability of FA cells to 
repair damage or to defective FA protein interactions with other proteins in the apoptosis 
pathways (Cumming, Lightfoot et al. 2001; Pang, Keeble et al. 2001). Accelerated telomere 
shortening has been detected in FA as well (Leteurtre, Li et al. 1999; Hanson, Mathew et al. 
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2001; Li, Leteurtre et al. 2003), but this is also found in other forms of aplastic anaemia 
(Ball, Gibson et al. 1998) and in MDS (Boultwood, Fidler et al. 1997). This could be 
explained by haematopoietic stem cells undergoing a higher than normal number of cell 
divisions to generate mature end cells. However, there is evidence that, in addition to 
replicative shortening, there is also a higher rate of breakage at telomeric sequences in FA 
cells, suggesting a defect in telomere maintenance (Callen, Samper et al. 2002). 
 
Haematopoiesis. 
Defective haematopoiesis in FA has been demonstrated using in vitro bone marrow 
culture assays (Stark, Thierry et al. 1993) and FA cells show altered levels of certain growth 
factors, such as reduced interleukin (IL)-6 (Rosselli, Sanceau et al. 1992), granulocyte-
macrophage colony-stimulating factor (GM-CSF) (Stark, Andre et al. 1993), IL-1b (de 
Cremoux, Gluckman et al. 1996) and increased tumour necrosis factor-a (TNF-α) (Schultz 
and Shahidi 1993; Rosselli, Sanceau et al. 1994). These may affect haematopoiesis by 
altering the bone marrow microenvironment, leading to deregulation of cellular homeostasis, 
differentiation and response to stress (Lensch, Rathbun et al. 1999). Compared with other 
tissues, haematopoietic tissue is particularly sensitive to DNA-damage caused by radiation or 
cytotoxic therapy. However, while other DNA-repair disorders such as Xeroderma 
Pigmentosum or Ataxia telangiectasia have an increased risk of certain malignancies, they do 
not have the striking incidence of bone marrow failure seen in FA. This suggests that the FA 
proteins play a specific critical role in the maintenance of haematopoietic stem cells and it is 
likely that a combination of different functions of the FA-BRCA pathway are implicated. 
The initial decline in haematopoietic stem cells leading to bone marrow failure could be the 
result of defective telomere maintenance and high rates of apoptosis whereupon selective 
pressures. As a result of an altered signalling environment against a background of genome 
instability, this could lead to the emergence of apoptosis-resistant mutant clones, which in 
turn may ultimately lead to the development of AML (Lensch, Rathbun et al. 1999). It is 
clear that as well as interacting in a complex, at least some of the individual FA proteins 
interact with proteins in other pathways, and are responsible for the cellular characteristics 
described above (Reuter, Medhurst et al. 2003). For example, FANCC interacts 
independently with a number of other proteins including hsp70 leading to suppression of the 
kinase activity of PKR and thereby modulating apoptotic signalling (Pang, Christianson et al. 
2002). FANCC also interacts with STAT1, which is involved in the response signals to 
interferons (Pang, Christianson et al. 2002).  
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1.3.6: Disease models. 
 
Generation of various knockout murine models for Fanca (Cheng, van de Vrugt et al. 
2000; Wong, Alon et al. 2003), Fancc (Chen, Tomkins et al. 1996; Whitney, Royle et al. 
1996), Fancg (Yang, Kuang et al. 2001; Koomen, Cheng et al. 2002), Fancd2 (Houghtaling, 
Timmers et al. 2003), Fanca-Fancc double (Noll, Battaile et al. 2002), Fancl/Pog(Agoulnik, 
Lu et al. 2002) and Fancd1/Brca2 (Navarro, Meza et al. 2006) have been reported. These FA 
mice display chromosome instability, defective germ cell development, reduced fertility and 
sensitivity to DNA cross-linking agents. However, they do not develop spontaneous bone 
marrow failure, except for mouse models of the FA-D1 group harboring homozygous 
hypomorphic mutations in Fancd1/Brca2 (Navarro, Meza et al. 2006). Treatment with MMC 
causes bone marrow failure in Fancc knockout mice (Carreau, Gan et al. 1998). The reason 
for the absence of spontaneous bone marrow failure in FA mice is still unknown. Fancd2, 
Fanca and Fancc mice are reported to develop tumours including adenocarcinoma, 
lymphoma, sarcoma and ovarian granulosa cell tumour. In addition, many Brca1- and Brca2- 
deficient mouse models with cancer susceptibility have been generated (reviewed in 
reference (Moynahan 2002)). However, despite the lacking of spontaneous bone marrow 
failure, FA mice are still regarded as useful tools to test the applicability of new FA 
treatment modalities. They are in fact essential for gene therapy development (Gush, Fu et al. 
2000; Noll, Bateman et al. 2001; Yamada, Olsen et al. 2001; Galimi, Noll et al. 2002; Rio, 
Segovia et al. 2002; Haneline, Li et al. 2003; Yamada, Ramezani et al. 2003), ex vivo 
manipulation of hematopoietic stem/progenitor cells (Li, Le Beau et al. 2005) and cytokine 
treatment (Carreau, Liu et al. 2002). 
Drosophila, Caenorhabditis elegans, Xenopus and zebrafish homologs of FA genes 
have been recently identified. The FA gene network is conserved from zebrafish (Titus, 
Selvig et al. 2006) and Xenopus (Sobeck, Stone et al. 2006) to human, while only FANCD2, 
FANCL and FANCM have Drosophila homologs (Marek and Bale 2006), and 
FANCD1/BRCA2, FANCD2, FANCJ and FANCM have homologs in C. elegans (Collis, 
Barber et al. 2006). Drosophila and C. elegans models can therefore be useful for testing the 
functions of key proteins in the FA-BRCA pathway. As only FANCD2, FANCL and 
FANCM are present in Drosophila, these proteins may constitute the minimal FA-BRCA 
pathway machinery. In turn, C. elegans may enable a better understanding of the roles of 
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FANCD1 (BRCA2) and FANCJ in the context of the minimal machinery constituted by 
FANCD2 and FANCM. As with vertebrate mutants, Drosophila fancd2 and fancl mutants, 
as well as C. elegans fancd2 mutants, show hypersensitivity to DNA cross-linking agents 
(Collis, Barber et al. 2006; Marek and Bale 2006). Drosophila and C. elegans models may, 
therefore, be useful to dissect the roles and regulations of the FA-BRCA pathway in a less 
complex network. The zebrafish model may prove a valuable tool with which to investigate 
the impact of FA-BRCA pathway failure on development, as fancd2-deficient zebrafish 
embryos develop similar defects to those found in children with FA, including shortened 
body length, microcephaly and microphthalmia (Liu, Howlett et al. 2003). The Xenopus 
model mostly constitutes a powerful tool with which to investigate the regulation of the FA 
pathway in vitro through cell-free assay systems using replicating egg extracts (Sobeck, 
Stone et al. 2006). Such assays could also be exploited for screening drugs that modulate the 
FA-BRCA pathway. 
 
 
1.3.7: Disease targets and ligands. 
 
As described, the FA-BRCA pathway is required for cellular resistance to DNA 
cross-linking agents, including widely used anti-cancer drugs such as cisplatin, MMC and 
melphalan. As such, inhibition of this pathway will lead to sensitization of tumour cells to 
these drugs, therefore the FA-BRCA pathway is an attractive target for developing small 
molecule inhibitors that may be clinically useful as chemo-sensitizers in the treatment of 
cancer. The FA-BRCA pathway involves formation of a multi-subunit protein complex 
bearing E3 ligase activity, several enzymes (ubiquitin ligase and conjugating enzyme, de-
ubiquitinating enzyme, kinase, ATPase/DNA translocase and ATPase/helicase) and many 
protein–protein or protein–DNA interactions. All of these components are potential targets 
for small molecule inhibitors of the pathway. Drug development is still in the early stages, 
and therefore not many informations are available. A high-throughput cell-based screening 
assay for small molecule inhibitors of the FA-BRCA pathway has, however, been developed 
in the laboratories of Alan D’Andrea (Chirnomas, Taniguchi et al. 2006). In this screen, 
FANCD2 nuclear foci formation was utilized as readout of the inhibition of DNA-damage 
induction. A partial result focusing on one inhibitor, curcumin (diferuloylmethane), has been 
published (Chirnomas, Taniguchi et al. 2006). Curcumin inhibits FANCD2 
monoubiquitination and nuclear foci formation, although its exact target in the pathway has 
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not been yet identified (Chirnomas, Taniguchi et al. 2006). However, curcumin sensitizes an 
ovarian cancer cell line to cisplatin in an FA-BRCA pathway-dependent manner, suggesting 
that curcumin sensitization of cisplatin mostly occurs through FA-BRCA pathway inhibition 
(Chirnomas, Taniguchi et al. 2006). In order to establish curcumin as a useful cisplatin 
chemo-sensitizer, a detailed analysis of combinations of curcumin with cisplatin, in vivo 
studies using mouse models and identification of the target of curcumin in the pathway are 
still required.  
More recently, a work published in 2008 shows instead how phenylbutyrate may 
potentially have therapeutic utility as a cisplatin sensitizer in head and neck cancer (Burkitt 
and Ljungman 2008). In this study, the authors report that phenylbutyrate inhibits the FA-
BRCA pathway through the down regulation of BRCA1 as well as through an FA-BRCA-
independent mechanism. This potentially relevant finding could help overcome one of the 
clinical limitations of cisplatin treatment, since these tumours, initially responsive to this 
treatment, later acquire resistance (Taniguchi, Tischkowitz et al. 2003). 
Elucidating the mechanisms of action of candidate inhibitors identified in the above-
mentioned screens seems to be crucial for development of specific and effective inhibitors of 
the FA-BRCA pathway and for further understanding the regulation of the pathway itself. 
Precise analyses of the effects of each drug on individual steps in the FA-BRCA pathway 
will be required to identify their specific targets. These analyses will include in vitro ATR 
kinase assay, in vitro UBE2T and FANCL autoubiquitination assays, assessment of FA-core 
complex formation and evaluation of nuclear foci formation of DNA-repair proteins 
including BRCA1. A better understanding of the regulatory mechanisms, as well as the 
identification of new partners of the FA-BRCA pathway, is also crucial for the identification 
and development of inhibitors. Finally, although multiple groups have been working on 
structural analysis of FA proteins, so far few FA protein crystal structures have been reported 
(BRCA2/FANCD1 (Yang, Jeffrey et al. 2002)and FANCF (Kowal, Gurtan et al. 2007)), but 
also such studies could provide useful information for drug design as well as for elucidation 
of the targets of the candidate inhibitors. 
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1.4 Protein-protein interactions and yeast two-hybrid systems. 
 
1.4.1: Signalling networks and how to dissect them. 
 
Signalling networks are key elements in all major aspects of cellular life, playing a 
major role in inter- and intra- cellular communications. They are involved in diverse 
processes such as cell-cycle progression, cellular metabolism, cell-cell communication and 
appropriate response to the cellular environment. The latter comprises a whole range of 
networks that are involved in regulation of cell development, differentiation, proliferation, 
apoptosis, and immunological responses. The key mechanism involves the transductions of 
extra-cellular signal across the cell surface to different effectors in the cytosol and the 
nucleus (Kolch 2000). Deregulation of these pathways is often associated with malignant 
diseases (Hahn and Weinberg 2002). Due to the multitude of signalling cascades, it is of 
utmost importance to decipher the proteins playing key parts in these networks, and the 
means by which signals are transmitted by these molecules. The means of analysing 
signalling networks have undergone dramatic changes over the last decade. There has been a 
general shift in paradigm from dedicating a work of a lifetime to the analysis of a single 
protein to the analysis of cellular and biochemical processes and networks. This step has 
been enabled by a dramatic improvement in technologies and experimental strategies mainly 
in the fields of genomics and proteomics. Fifteen years ago, biochemical and cell-biological 
approaches, together with genetic screens in model organisms (mainly the fruit fly 
Drosophila melanogaster and the nematode worm Caenorhabditis elegans) have dominated 
the scene to map the function of cellular signalling pathways. The elucidation of signalling 
networks was traditionally done by identifying the different protein components one by one. 
The genetic approaches usually designed as variations of epistasis or rescue experiments 
provided information on the hierarchical relationship of the gene under study to the newly 
identified genes by showing that one is dependent on (or independent of) the other for 
particular biological functions. While powerful in mapping interdependencies, molecular 
mechanisms remained open. In contrast, the biochemical approaches could reveal 
mechanisms, but unfortunately they were largely confined to known interactions. Pathway 
mapping was much of a trial and error process driven by educated guesses. Many of the best 
guesses were based on a synthesis of the genetic and biochemical information showing that 
in principle such a combination could be very powerful. However, since the participating 
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genes or proteins were identified and characterized one at a time, either approach could take 
many years of work with slow progress. The sequencing of the human genome, as well as the 
genome of important model organisms such as mouse (Mus musculus), D. melanogaster, C. 
elegans, and the budding yeast Saccharomyces cerevisiae has tremendously increased the 
possibilities of network mapping. DNA microarray analysis of mRNA expression for the 
first time permitted global genome wide analysis and quickly became a routine platform that 
is in widespread use today. Proteomics had a slower start due to the increased complexity 
and widely different physicochemical properties of proteins as compared to nucleic acids, 
which make analysis much more demanding. Nevertheless, the pace of progress has 
accelerated enormously in the last few years and proteomic approaches have gained a high 
popularity especially for the analysis of protein-protein interactions and signalling pathways 
(Zhu and Snyder 2002; Zhu, Bilgin et al. 2003). A variety of proteomic techniques has been 
implemented in the search for understanding the molecular mechanisms of signalling and the 
underlying rationale is simple. The transduction of a signal occurs by binding of ligands to 
receptors, recruitment of adaptor proteins, enzymatic reactions such as phosphorylation and 
ubiquitination, subcellular redistribution and assembly (or disassembly) of molecular 
machines that cooperate in functional pathways. These processes have in common that they 
invariably involve protein-protein interactions, and it seems logical to presume that by 
tracking the protein interactions, one can track the flux of the signal and hence reconstruct 
the pathways. As protein-protein interactions are so important, there are a multitude of 
genetics and biochemical methods to detect them: yeast two-hybrid system, two-dimensional 
gel electrophoresis, mass spectrometry, in vitro pull-down assays, immunoprecipitation, 
protein microarray, fluorescence resonance energy transfer (FRET), RNA interference 
(RNAi) knock-down, cDNA library screening. Each of the mentioned approaches has its 
own strengths and weaknesses, especially with regard to the sensitivity and specificity of the 
method. However, the first systematic approach used for searching for potential interaction 
partners for a selected protein was the yeast two-hybrid system (Fields and Song 1989), and 
a large amount of our current knowledge of protein-protein interactions involved in 
signalling events has been derived from experiments exploiting this technique. 
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1.4.2: Yeast two-hybrid system. 
 
The yeast two-hybrid system was originally developed by Fields and Song in the 
1989. Protein-protein interactions between two proteins had generally been studied using 
biochemical techniques such as cross-linking, co-immunoprecipitation and co-fractionation 
by chromatography. Fields and Song generated a novel genetic system to study these 
interactions, exploiting the yeast Saccharomyces cerevisiae and the properties of its 
transcriptional factor GAL4. The GAL4 protein is composed of two separable and 
functionally distinct domains: an N-terminal domain which binds to specific DNA sequences 
(binding domain/BD), and a C-terminal domain containing acidic regions, necessary to 
activate transcription (activator domain/AD). A system with two hybrid proteins, where the 
GAL4 DNA-binding domain (BD) was fused to a protein “X” (bait) and a GAL4 activating 
region (AD) to a protein “Y” (prey), was set up. The principle was that, if proteins X and Y 
can form a protein– protein complex so that the complex brings the two domains of GAL4 
into proximity, transcription of a reporter gene regulated by GAL4 is initiated (Fig. 7). They 
tested the system constructing separate plasmids carrying the sequences coding for (a) the 
GAL4 BD and (b) the GAL4 AD, fused in frame to DNA sequences coding for the protein 
products of the yeast genes SNF1 and SNF4 respectively. SNF1 and SNF4 proteins were 
known to interact (personal communication to the authors)(Fields and Song 1989). They 
introduced these two plasmids into a yeast strain containing a reporter gene, the LacZ gene 
from E.Coli, fused to the GAL1 promoter. The resulting β-galactosidase activity was detected 
by the formation of blue yeast colonies on medium supplemented with the chromogenic 
substrate 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) (Fields and Song 
1989). The two-hybrid system immediately appeared to have the potential to identify ideally 
any two interacting proteins. Further development of the system allowed investigators to use 
a protein of interest as bait, to identify cellular proteins that interact (Chien, Bartel et al. 
1991), especially since cDNA libraries become largely available. Generally, the DNA 
sequence coding for the product of a gene of interest (X) can be fused to GAL4BD and 
introduced on a selectable plasmid into an appropriate yeast strain. There it will bind to the 
GAL1 promoter and function as the bait. The yeast cells are transformed with a cDNA library 
constructed in a GAL4AD vector encoding for prey proteins (Y). The transformed cells are 
plated onto medium that selects for the presence of both plasmids and are then screened for 
β-galactosidase activity. Interaction between the GAL4AD-Y fusion protein (prey) and the 
bait provided by the GAL4BD-X fusion protein activates transcription of GAL1-lacZ and 
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results in a blue yeast colony. The gene coding for the interacting protein can be recovered 
from the blue yeast colony.  
Several versions of the basic two-hybrid system have been described in literature 
(Chien, Bartel et al. 1991; Durfee, Becherer et al. 1993; Vojtek, Hollenberg et al. 1993). One 
of the most used versions employs the selectable reporter gene GAL1-HIS3. In this system, 
the binding domain plasmid carries the yeast TRP1 gene and a sequence derived from X 
fused to GAL4BD. The activating domain plasmid carries the yeast LEU2 gene and a 
sequence from a cDNA library fused to GAL4AD. These plasmids are transformed into a 
yeast strain which requires tryptophan, leucine, and histidine (trp1, leu2, his3) and contains a 
functional copy of HIS3 controlled by the GAL1 promoter (GAL1-HIS3). If the binding 
domain and activating domain fusion proteins interact, the GAL1-HIS3 reporter gene will be 
activated and the yeast cell will grow on Synthetic Dropout (SD) medium lacking the amino 
acids Trp, Leu, and His. Thus there is positive selection for the presence of activating 
domain plasmids encoding proteins that interact with the BD-X fusion protein. When 
compared with biochemical methods, the major distinction of two-hybrid method is that the 
readout is essentially generated by phenotypes that can be easily scored (cell growth, colour, 
fluorescence). Furthermore, two-hybrid interactors can be unambiguously identified by DNA 
sequencing of the plasmid encoding the prey protein, taking advantage of well-established 
tools for DNA analysis. It is this ability, to identify both an interacting protein and the gene 
which encodes for it, that makes the two-hybrid system so powerful.  
 
Requirements of the two-hybrid system 
The steps involved in accomplishing a two-hybrid screen with a specific protein gene 
(X) are as follows: (1) Construction of the BD-X fusion plasmid. (2) Transformation of the 
BD-X fusion plasmid into yeast. (3) Testing the BD-X fusion plasmid in yeast for auto-
activation of reporter genes. (4) Testing the BD-X fusion plasmid for expression of X 
protein. (5) Construction of the AD-cDNA fusion plasmid library. (6) Transformation of the 
AD-cDNA fusion plasmid library into the yeast strain carrying the BD-X fusion plasmid and 
selection for the activation of GAL1-HIS3. (7) Screening putative positives for the activation 
of other reporter genes. (8) Identification of false positives. (9) Analysis of true positives. 
(10) DNA sequence analysis of AD-cDNA fusions. (11) Deletion mapping of interacting 
domains. These procedures require some expertise in DNA manipulation and yeasts 
handling. All of the following operations are necessary to ensure that the outcome is a 
collection of clones with the desired properties. 
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Figure 7. The two-hybrid principle. Two proteins are expressed separately, one (a bait protein) fused to the 
GAL4 DNA-binding domain (BD) and the other (a prey protein) fused to the GAL4 transciptional activation 
domain (AD). 
 
Strong and weak points of yeast two-hybrid system  
The two-hybrid system is a proven, invaluable tool of cell biology. It has a high 
sensitivity, enabling detection of weak and transient interactions. The experimental setup is 
relatively straightforward even if time consuming. It enables simultaneous detection and 
characterization of protein–protein interaction using a single protocol. It can be used to 
identify novel proteins interacting with the bait protein, without the need of any a priori 
knowledge. Since the experiment is undertaken in an in vivo system (e.g. yeast), proteins of 
interest are likely to fold appropriately and thus the screen is more likely to detect genuine 
interacting proteins. However, the two-hybrid system also has its specific limitations. Both 
false positives and false negatives can occur and are considered to be the most serious 
technical problems. False positivity can arise for a variety of reasons: proteins interacting 
with the DNA upstream of the reporter gene or with proteins that interact with the promoter 
sequence are prone to detection as false-positive in the two-hybrid system. For example, the 
original two-hybrid system was designed to activate transcription through RNA polymerase 
II. Therefore, it is problematic to identify novel proteins which interact with the RNA 
polymerase II activators (as bait). False-negativity can also be caused by a range of reasons: 
some proteins fused with BD or AD cannot localize in the yeast nucleus, cannot fold 
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properly, are not functional when expressed as a fusion protein, are toxic to the host, 
sometimes the appropriate posttranslational modification does not take place, or the potential 
interacting protein is not sufficiently represented in the library. Therefore, other independent 
methods (e.g. techniques based on biological function) must be used in parallel to confirm 
and verify the hits detected by the two-hybrid system 
 
 
1.4.3: Evolution of two-hybrid system. 
 
Over the years, scientists modified the traditional two-hybrid system technique. 
Whilst these derivatives all use similar principles, the various modifications enabled ‘fine-
tuning’ of the approach for specific purposes. 
1) A one-hybrid system was developed to study protein–DNA interaction, where the 
protein binds to AD and the DNA fragment of interest is cloned upstream of the reporter 
gene. If the protein binds to the specific DNA (promoter) of interest, transcription of the 
reporter gene is initiated (Meng and Wolfe 2006). 
2) In order to characterize protein function, sometimes it is desirable to select for 
disruption of a particular interaction by introduction of point mutations, deletions or through 
the use of protein or pharmacological inhibitors. Thus, reverse and counter-selection two-
hybrid systems were developed. In these systems, the wild-type protein which can interact 
with the bait, causes sensitivity to selection reagents (e.g. cytotoxic compounds) and the cells 
die. Only cells expressing proteins harboring the mutations disrupting the interaction will 
survive (Shih, Goldman et al. 1996; Vidal, Brachmann et al. 1996). Therefore, this approach 
can be used to identify novel mutants of the prey that no longer bind to the other protein of 
interest (the bait). Similarly, chemical compound libraries can also be screened for entities 
with the ability to block particular protein–protein interactions. 
3) One of the major limitations of the traditional two-hybrid system has always been 
that some proteins, especially components of signal transduction pathways in higher 
eukaryotes, need post-translational modification for their ability to interact with others and 
thus they require modifying enzymes which are not present in yeast. The three-hybrid system 
was developed and applied to facilitate the post-translational modification of the prey 
proteins, by co-transfecting the necessary enzyme into the system, to ensure that prey 
proteins are functional in the host. This technique enables rapid mapping of modifications 
required for a certain inter-protein interaction. The most common such modification is 
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protein phosphorylation, which is most often induced by specific stimuli and requires the 
expression of particular kinases. An example of the application of the Y3H strategy was 
published by Osborne and colleagues. in their library screening study to identify proteins 
which specifically interact with an immunoreceptor tyrosine-based activation motif 
(ITAMs)-containing IgE receptor-derived, phosphorylated bait (Osborne, Dalton et al. 1995). 
In the bait, the gamma subunit of the high-affinity IgE receptor, FcεRI, was used to isolate a 
novel SH2-containing family member (interactions between FcεRI cytoplasmic tail and the 
Syk or Lyn SH2 domains), which requires the phosphorylationof the ITAMs by tyrosine 
kinases. A plasmid encoding the tyrosine kinase was introduced together with the bait and 
the prey. This method was initially used for characterizing interactions that are mediated by 
tyrosine phosphorylation, but can be adapted to other post-translational modifications. 
Another use of the three-hybrid system is detection of weak interactions between multiple 
proteins. In most cases, proteins bind to a number of other proteins and form large, multi-
component complexes containing both weak and strong interactions. In order to identify 
novel proteins that weakly interact with a protein of interest, a known interacting protein can 
be co-expressed and this may supply a bridge and thus strengthen the interaction for the 
novel proteins with lower affinity interaction (Tomashek, Sonnenburg et al. 1996; Tirode, 
Malaguti et al. 1997). 
4) In addition to the classical Saccharomyces cerevisiae system, other hosts, such as 
E. coli, have also been used. This was proposed to have multiple advantages over the yeast 
system, such as fast growth, higher transformation efficiency, nuclear localization not 
required, domains with eukaryotic activation domains do not activate E. coli transcription, 
and fewer indirect interactions involving bridging by endogenous proteins (review (Hu 
2001)). A recent study exploiting the E. coli two-hybrid system was based on the twin-
arginine translocation (Tat) pathway to identify interacting proteins in this pathway. Two 
reporter systems via the Tat pathway were used, one based on growth on selective media 
(maltose based) and the other enzymatic assay using a chromogenic substrate. Compared to 
other studies, the development of this E. coli two-hybrid system improved the accuracy of 
proteome-wide two-hybrid analyses (Strauch and Georgiou 2007). 
5) In the original two-hybrid system, interacting fusion proteins (both prey and bait) 
need to be transported into the nucleus in order to activate the transcription of the reporter. 
This limits the interactions detected by the system. For instance, using full-length trans-
membrane proteins as baits is problematic, due to misfolding or lack of localization in the 
nucleus. Some strategies to allow the two-hybrid system to take place in the cytoplasm and 
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membrane were developed to circumvent this pitfall. Instead of using nuclear transcription 
factors to construct two fusion proteins, β-galactosidase was split into two fragments and re-
constituted through a bait/prey interaction, and the β-galactosidase activity served as a 
measurement of the strength of the interaction of the bait and the prey. Thus the protein–
protein interaction could be studied in the cytoplasmic milieu (Rossi, Blakely et al. 2000). In 
another approach, the Ras-controlled signalling cascade on the Saccharomyces cerevisiae 
plasma membrane, which harbors temperature-sensitive Ras Guanine Exchange factors 
(GEF) Cdc25-2, was used. GEFs stimulate the transition of Ras between an inactive 
GDPbound form and an active GTP-bound form. Sos protein is one of the mammalian GEFs. 
If the Sos is recruited to the membrane, it will stimulate the transition of the Ras, hence the 
initiation of the signaling cascade, and allow growth at the non-permissive temperature (37 
◦C). Therefore, a bait (X) fused with Sos can identify membrane proteins (Y, prey) which 
interact with the bait. The readout of this system is based on the survival of Saccharomyces 
cerevisiae and the ability to grow when the temperature is increased from 25 ◦C to 37 ◦C 
(Aronheim, Engelberg et al. 1994; Aronheim, Zandi et al. 1997). 
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AIMS OF THE STUDY 
 
The FA-BRCA pathway consists of at least 13 proteins, playing a role not yet elucidated in 
DNA-damage response. Additionally, FA proteins could also be involved in other 
mechanisms as oxidative stress, haematopoiesis and apoptosis. During the last few years, an 
intricate network of interacting proteins has been emerging, suggesting that many members 
potentially involved in this pathway are still missing. Consequently, identification of the FA 
interactors is regarded as essential achievement for the understanding of molecular 
mechanisms responsible for the disease.  
In this perspective, the main goals of this PhD project were the identification and the 
characterization of novel genes involved in the FA-BRCA pathway. For this purpose, the 
work of this thesis was subdivided in two parts.  
First, we have exploited the systematic approach of the yeast two-hybrid system to 
isolate potential interactors of FA proteins, focusing our attention on two novel proteins, one 
(UBE2U) binding FANCD2 and the other one (ISG20L2) binding FANCG. Then, we have 
characterized these two genes using different approaches, such as bioinformatics, 
biochemistry, molecular biology and cellular biology. Our attempts to functionally link these 
two proteins to the FA-BRCA pathway have so far failed. However, their function should be 
further investigated to exclude any potential connection with the FA proteins, at least during 
spermatogenesis, where the role of FA-BRCA pathway has never been studied, despite the 
high expression levels of its components in testis.  
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Chapter 2 
MATERIALS AND METHODS 
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Plasmids 
The coding sequences of FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG full-
length and their fragments were amplified by polymerase chain reaction (PCR) with Pfu 
DNA-polymerase (Promega) from the pREP4 expression plasmids in which they were 
originally cloned (IMAGE consortium). The FANCL cDNA was obtained by reverse 
transcription (RT)-PCR on CaCo2 mRNA (primers) and cloned into TOPO TA cloning 
(Invitrogen). Full length cDNAs and partially overlapping cDNA fragments of FA genes 
were subcloned in frame with the GAL4 DNA-Binding Domain into the yeast two-hybrid 
vector pGBKT7 (Clontech) and in frame with the GAL4 DNA-Activating Domain into the 
vector pGADT7 (Clontech)(Table 4). All constructs were verified by direct DNA sequence 
analysis by using T7 Sequencing Primer (5'–TAATACGACTCACTATAGGGC–3'), 3' 
DNA-BD Sequencing Primer (5'–ATCATAAATCATAAGAAATTCGCC–3') and 3' AD 
Sequencing Primer (5'–AGATGGTGCACGATGCACAG–3') The full-length cDNAs of 
clone 54 (short and long) were obtained by (RT)-PCR on human testis mRNA and subcloned 
into yeast vectors pGBKT7 and pGADT7 (Clontech). Clone 54 was subcloned into 
mammalian expression vector pcDNA 3.1 (Invitrogen) in fusion with either FLAG, or HA, 
or Myc tag Coding sequence of ISG20L2 was obtained by (RT)–PCR from HEK293 cell 
lines mRNA and it was cloned into TOPO TA cloning. Plasmid constructs were generated by 
subcloning cDNA from TOPO TA cloning by proper enzymatic digestion of the plasmid. 
 
Bacterial strains and plasmids transformation 
Escherichia Coli strains DH5α (Invitrogen) and Top10F (Invitrogen) were used in the 
construction and propagation of all plasmid constructs. For each transformation, 1-50 µg of 
DNA was added to 25-50 µl of chemically competent cells. Incubated on ice for 30 min, the 
cells were next subjected to heat shock at 37 or 42 °C for 1 min and next incubated on ice for 
2 min. The cells were recovered in 1 ml Luria-Bertani (LB: 1% bacto-tryptone, 1% NaCl and 
0.5% Bacto-yeast extract) or SOC (2% bacto-tryptone, 0.5% bacto-yeast extract, 10mM 
NaCl, 2.5mM KCl, 10mM MgCl2, 20mM glucose) broth and then incubated for 40 min at 
37°C with shaking (200-250 rpm). Cells were plated on LB-agar (18g/L) containing 
appropriate antibiotics (ampicillin or kanamycin 100µg/ml) with an incubation at 37°C 
overnight. 
 
 
 60 
cDNA Forward (5’-3’) Riverse (5’-3’) 
FANCA CCGGAATTTAAGGCCATGTCCGACTCG GCGTGTCGACCCGTCAGAAGAGATGAGG 
FANCA1 CCGGAATTCAAGGCCATGTCCGACTCG GCGTGTCGACCCACTCTCTCTGCATCTG 
FANCA2 CCGGAATTCACTCACAAGATCGTGAGG GCGTGTCGACAGAGTTGGGTTCTGCCCT 
FANCA3 CCGGAATTCAAAGTCCCTGACTCCCGT GCGTGTCGACATCTGAAAGAGCATCAGC 
FANCA4 GCTCCATGGTGGACACACAGAACCTTC CCGGAATTCTAGCTCCTCTCTCTCGCA 
FANCA5 CCGGAATTCCAAGAAGGCCGGCAG TTT GCGTGTCGACCCGTCAGAAGAGATG AGG 
FANCC CCGGGGATCCGACATCACCTTTTCGCT CAAGTCTAGAAGGCACGCGTCGACACGC 
FANCC1 CCGGGGATCCGACATCACCTTTTCGCT GCGTGTCGACAGTGGCTATGATTTCCAG 
FANCC2 CCGGGGATCCACCTTCCCAGCCTTGAA CAAGTCTAGAAGGCACGCGTCGACACGC 
FANCD2 CCGGAATTCGTGCACAAGACATTGGTC GCGTGTCGACTGGGGTCTAATCAGAGTC 
FANCD21 CCGGAATTCGTGCACAAGACATTGGTC GCGTGTCGACAATACAGCTCTGACCGCT 
FANCD22 CCGGAATTCGAGCTTCGGGAGAAGTTG GCGTGTCGACAATACAGCTCTGACCGCT 
FANCD23 CCGGAATTCAGTTTGACCCAAGAGAGA GCGTGTCGACGATGAACTTCGTCACAAG 
FANCD24 CCGGAATTCAGAGGCCAGCTAAACAAG GCGTGTCGACTGCTGTGCCAGGCTCAAT 
FANCD25 CCGGAATTCGAGGAGATTGCTGGTGTT GCGTGTCGACTGGGGTCTAATCAGAGTC 
FANCE CCGGAATTCCGGCACCCGTGCCCCGGC GCGTGTCGACGGTGATGGAGCACCAAGA 
FANCE1 CCGGAATTCCGGCACCCGTGCCCCGGC GCGTGTCGACCAAGGTCTTCAGCAGCTG 
FANCE2 CCGGAATTCCCTATTAAGGACCAGCCT GCGTGTCGACGGTGATGGAGCACCAAGA 
FANCF CCGGGGATCCTCATGGAATCCCTTCTG TCTGTATAGGCAATGCTGGTCGACACGC 
FANCG CCGGAATTCGGCCCAGCCTCGGCCACC GCGTGTCGACCTCTTCAAAACGTGGCAG 
FANCG1 CCGGAATTCGGCCCAGCCTCGGCCACC GCGTGTCGACAGTGCCACAATGAAGGGG 
FANCG2 CCGGAATTCTCTAGGCTCTATCAGCAA GCGTGTCGACCTCTTCAAAACGTGGCAG 
FANCL CCGGAATTCAGAGCTTTTCTGTGTTTCTC GCGTGTCGACCTTATTTCAGTGTTTCCTTCC 
Ube2u CTACAGATGTTGCTTTCTTAC CATGAAATGTGGATCTCCAACGTG 
 
GTAGCAACCTCAGTATGTAC GCCAGGTCCTGAGCATCTCCCGG 
UBE2U ATGCACGGCA GAGCTTACCG TTACCTGTCGTATGTAGTAAATCC 
 
ACAGAATTCA GTTTGGCAGGT CATTGAGCAG CATCTTACTT GCC 
Table 4: Primers used in this study 
 
Isolation of plasmid DNA from E. coli. 
Large-scale (midi-prep) and mini-prep plasmid DNA preparations were carried out 
using the QIAGEN MIDI and MINI prep kits, respectively. Both procedures are based on the 
alkaline lysis method, but use a support column to purify isolated plasmid DNA. The lysis is 
obtained with a 1% SDS, 0.2 N NaOH solution; the alkaline mixture ruptures the cells and 
the detergent breaks apart the lipid membranes and solubilizes the cellular proteins. The 
NaOH also denatures the DNA, providing single strands. The lysate is supplemented with 
acetic acid and potassium acetate (3 M K+ and 5 M acetate). The acetic acid neutralizes the 
pH, allowing the DNA strands to renature. The potassium acetate also precipitates the SDS 
from solution, along with the cellular debris. The E. coli chromosomal DNA, a partially 
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renatured tangle at this step, is also trapped in the precipitate. The plasmid DNA remains in 
solution. The centrifuged samples are then applied to kit spin columns, the plasmidic DNA 
binds to the silica matrix of the columns allowing repeated washes with an ethanol-based 
buffer. The purified DNA was eluted with dH2O or Tris-HCl 10 mM, EDTA 1 mM pH 7.5 
(TE) and was always checked by enzymatic digestion with the appropriate enzymes.  
Quantification of plasmid DNA  
DNA concentrations were determined for 1:10 to 1:100 dilutions of stocks, according 
to the following formula: absorbance of one A260 unit indicates a DNA concentration of 
approximately 50 µg/ml. Plasmid DNA concentration was determined by measuring the 
absorbance at 260 nm (A260) in a spectrophotometer using a quartz cuvette. For DNA 
quantification, A260 readings should lie between 0.1 and 1.0. An absorbance of 1 unit at 260 
nm corresponds to 50 µg plasmid DNA per ml, considering the standard path length of 1 cm. 
This relationship is only valid for measurements made at neutral pH, therefore, samples were 
diluted in a low-salt buffer with neutral pH (e.g. Tris·Cl, pH 7.0). 
 
Ligation reaction 
The ligation reactions were generally carried out as follows: 
X ng vector DNA : Y ng insert DNA = 1: 2-5 
1 µl 10× ligation buffer (New England Biolabs) 
0.5 µl T4 DNA Ligase (400 U/µl) (New England Biolabs) 
dH20 to 10 µl 
Ligation was carried out for 1 h at room temperature; 1/10 to whole reaction volume was 
used for transformation of chemical competent E.coli cells.  
 
Yeast two hybrid system 
Yeast two-hybrid analyses were performed according to the manufacturer’s 
instructions for MATCHMAKER 2 Hybrid System (Clontech). 
 
Host strains 
System 2 features the yeast strain AH109 (MATa, trp1-901, leu2-3, 112, ura3-52, his3-200, gal4∆, gal80∆, 
LYS2 : : GAL1UAS-GAL1TATA-HIS3, GAL2UAS-GAL2TATA-ADE2, URA3 : : MEL1UAS-MEL1 TATA-lacZ ) using three reporter 
genes (ADE2, HIS3, and MEL1) under the control of distinct GAL4 upstream activating 
sequences (UASs) and TATA boxes. Strain Y187 (MATα, ura3-52, his3-200, ade2-101, 
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trp1-901, leu2-3, 112, gal4∆, met–, gal80∆, URA3 : : GAL1UAS-GAL1TATA-lacZ) 
contains the lacZ reporter gene under control of the GAL1 UAS. Unless stated otherwise, 
AH109 was used as the host strain for pGBKT7 (Clontech) constructs (baits) whereas Y187 
was used as the host strain for pGAD (Clontech) constructs (preys). 
 
Vectors  
pGBKT7 vector (Clontech) encodes for the DNA Binding Domain (BD) of yeast 
transcriptional factor GAL4 and carries yeast nutritional marker for media lacking of 
tryptophan (i.e. SD-W). pGBKT7 confers bacteria resistance to kanamycin. pGADT7 vector 
(Clontech) encodes for the Activating Domain (AD) of yeast transcriptional factor GAL4 
and carries yeast nutritional marker for media lacking of leucine (i.e. SD-L). pGADT7 
confers bacteria resistance to ampicillin. pGBKT7-53 (Clontech) encodes for murine p53 
fused with GAL4 DNA-BD while pGADT7-T (Clontech) encodes for large T-antigen of 
SV40 fused with GAL4 AD: p53 and large T-antigen interact in a yeast two-hybrid assay (Li 
& Fields, 1993; Iwabuchi et al., 1993) and they were used as positive control in interaction 
matings. pGBKT7-Lam (Clontech) encodes a fusion of the DNA-BD with human lamin C 
and provided a control for a fortuitous interaction between an unrelated protein and either the 
pGADT7-T control or AD/library plasmid. 
 
Yeast strain maintenance, recovery from frozen stocks, and routine culturing 
Yeast strains were stored in YPD medium (20 g/L Difco peptone, 10 g/L Yeast 
extract, Clontech) with 25% glycerol at –70°C. Transformed yeast strains were stored in the 
appropriate SD dropout medium (Clontech) to keep selective pressure on the plasmid. To 
prepare glycerol stock cultures of yeast, a sterile inoculation loop was used to scrape an 
isolated colony from the agar plate. Cells were resuspended in 200–500 µl of YPD medium 
(or the appropriate SD medium) in a 1.5-ml microcentrifuge tube and vortexed vigorously to 
thoroughly disperse the cells. Sterile 50% glycerol was added to a final concentration of 25% 
and the vial was shaken before freezing at –70°C.A small portion of the frozen glycerol 
stock streaked onto a YPD (or appropriate SD) agar plate (YPD or SD, 20g/L Agar) and 
incubated at 30°C until yeast colonies reach ~2 mm in diameter ( 3–5 days), was used as 
working stock. Fresh working plates were streaked from the frozen stock at 1–2-month 
intervals. To prepare liquid overnight cultures, fresh (<1-month old) colonies were used from 
the working stock plate. One large colony was used (2–3-mm diameter) per 5 ml of medium. 
If colonies were small, or if it was necessary to inoculate a larger volume, several colonies 
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were used. Cells in the medium were dispersed by vigorously vortexing for ~1 min the 
suspension and subsequently incubated at 30°C for 16–18 hr with shaking at 230–270 rpm 
(OD600 > 1.5). For mid-log phase culture, the overnight culture was transferred into fresh 
medium so as to produce an OD600 = 0.2–0.3 and incubate at 30°C for 3–5 hr with shaking 
(230–250 rpm). This produced a culture with an OD600 ~0.4–0.6. 
 
PEG/LiAc yeast transformation procedure 
One-two weeks old colonies were inoculated into 1 ml of YPDA (YPD, adenine 
hemisulfate 0,003%) or proper SD and vortexed vigorously to break up any clumps. Cells 
were transferred to a flask containing 50 ml of YPDA or suitable SD and incubated at 30°C for 
16–18 hr with shaking (250 rpm) to stationary phase (OD600>1.5). The overnight culture was 
then transferred into 300 ml of YPDA (enough to produce an OD600 = 0.2–0.3) and incubated 
at 30°C for 3 hr with shaking (230–270 rpm) as the OD600 was 0.5 ± 0.1. Cells were then 
placed in 50-ml tubes and centrifuged at 1,000 x g for 5 min at room temperature. 
Supernatant was discarded and cell pellets were resuspended by vortexing in 25-50 ml of 
sterile TE (Tris-base 10 mM, EDTA 1 mM, pH 7.5) or H2O. Pooled cells were centrifuged at 
1,000 x g for 5 min at room temperature. Decanted the supernatant, cell pellets were re-
suspended in 1.5 ml of freshly prepared, sterile TE/LiAc 100mM pH 7.5. For each 
transformation, 0,1 mg of herring testes carrier DNA (Clontech), DNA-BD/bait 0.1 mg 
and/or AD/library 0.1 mg were mixed to 0,1 ml of yeast competent cells by vortexing. Next, 
0,6 ml of sterile PEG/TE-LiAc solution (PEG 4000 40%, Sigma) was added and the solution 
was mixed by vortexing at high speed. The mix was incubated at 30°C for 30 min with 
shaking (200 rpm). Seventy ul of DMSO (Sigma) were added and mixed well to each 
transformation solution. Cells were incubated for 15 min at 42°C in a water bath and then 
chilled on ice for 1–2 min. After centrifugation for 5 sec at room temperature at 13000 rpm, 
the supernatant was removed and cells were re-suspended in 0,5 ml of TE and plated on 
proper SD agar plates. To obtain a plate with well separated colonies, 100 µl of a 1:1000, 
1:100, and 1:10 dilution were spread on 100-mm SD agar plates. These also provided 
controls for (co)transformation efficiency. Plates were incubated up-side-down at 30°C until 
colonies appeared (generally, 2–4 days). The largest colonies were picked and re-streaked on 
the same selection medium for master plates. 
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Autoactivation tests 
In tests for auto-activation of reporter genes, all the DNA-BD and AD fusion 
constructs were independently transformed into strain AH109. The transformants were 
assayed for MEL1 activation by plating on SD/–Trp/X-α-Gal and SD/–Leu/X-α-Gal 
respectively and subsequently checked for coloration. Positive and negative controls were 
carried out in parallel. Transformants giving white colonies were selected while the ones 
giving blue colonies were discarded. 
 
Plating and screening transformation mixtures  
Transformations of library screenings were plated on SD/–Ade/–His/–Leu/–Trp/X-α-
Gal medium to screen for ADE2, HIS3, and MEL1 expression. Library transformations were 
plated also on SD/–Leu/–Trp medium to select the DNA-BD and AD vectors. Small-scale 
transformations were plated on 100-mm plates while large- and library-scale transformations 
were plated on 150-mm plates and incubated at 30°C until colonies appeared. When 
screening an AD/library, the transformation efficiency and the number of clones screened 
were estimated as follows. Colonies (cfu) growing on the dilution plate that has 30–300 cfu 
were counted and : 
cfu * total suspension vol. (µl)/ Vol.plated (µl)*dilution factor*DNA used (µg)= cfu/µg DNA 
represented the transformation efficiency, while 
cfu/µg * µg of library plasmid used = No. of clones screened  
 
Colony-lift filter assay 
For each plate of transformants to be assayed, a sterile Whatman #5 filter was pre-
soaked by placing it in 5 ml of Z buffer/X-gal solution (Na2HPO4*7H2O 16.1 g/L 
NaH2PO4*H2O 5.50 g/L KCl 0.75 g/LMgSO4*7H2O 0.246 g/L, 0.27 ml β-mercaptoethanol 
(Sigma), 0.33 mg/ml X-gal) in a clean 100- or 150-mm plate. A clean, dry filter was placed 
over the surface of the plate of colonies to be assayed and it was gently rubbed to help 
colonies cling to the filter. In order to orient the filter to the agar, holes were poked through 
the filter into the agar in three or more asymmetric locations. Once the filter was evenly 
wetted, it was carefully lifted off the agar plate with forceps and transferred into a pool of 
liquid nitrogen (colonies facing up). The filter was completely submerged until completely 
frozen (~10 sec). It was then removed from the liquid nitrogen and allowed to thaw at room 
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temperature. This freeze/thaw treatment was to permeabilize the cells. The filter, colony side 
up, was thus placed on the pre-soaked filter avoiding trapping air bubbles and incubated at 
30°C (or room temperature). It was checked periodically for the appearance of blue colonies 
(30 min - 6 hours). The β-galactosidase-producing colonies were identified by aligning the 
filter to the agar plate using the orienting marks. The corresponding positive colonies were 
picked from the original plates to fresh medium.  
 
Plasmid isolation from yeast 
For each plasmid purification, a large (2–4-mm) and fresh (2–4-day-old) yeast colony 
was inoculated into 0.5 ml of the appropriate SD liquid medium and vortexed vigorously to 
completely break up the colony and resuspend the cells. Cells were incubated at 30ºC 
overnight with shaking at 230–250 rpm. The day after, cells were spin down by centrifuging 
at 14,000 rpm for 5 min. The supernatant was poured off and the pellet was resuspended in 
the residual liquid (total volume ~50 µl).Ten µl of lyticase (Sigma) solution (5 units/µl in TE 
buffer) was added to each tube and the cells were thoroughly resuspended by vortexing or by 
repeatedly pipetting up and down. Tubes were incubated at 37ºC for 30–60 min with shaking 
at 200-250 rpm. Ten µl of 20% SDS was added to each tube and the mixture was vortexed 
vigorously for 1 min. To ensure the complete lysis of the cells, one cycle of freezing and 
thawing at –20ºC followed by mixing was carried out. The volume of the sample was 
brought up to 200 µl in TE buffer (pH 7.0) and 200 µl of phenol:chloroform:isoamyl alcohol 
(25:24:1) (JT Baker) was added to the sample. The mixture was vortexed at the highest speed 
for 5 min and subsequently centrifuged at 14,000 rpm for 10 min. The aqueous phase was 
transferred to a fresh tube. Eight µl of 10 M ammonium acetate and 500 µl of 100% ethanol 
(JT Baker) were added. DNA precipitation was enhanced by placing the solution at -70ºC for 
1 hour. The suspension was centrifuged at 14,000 rpm for 10 min, the supernatant was 
discarded and the pellet was air-dried and next resuspended in 20 µl of H2O. 
 
Rescue AD/Library plasmids via transformation of E. coli.  
Yeast-purified plasmids DNA were transformed into E. coli as described and to select 
for transformants containing only the AD/library plasmid, bacteria were plated on LB 
medium containing ampicillin 100µg/ml. 
 
Re-testing protein interactions in yeast  
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Protein interactions in yeast were confirmed by both co-transformation and yeast 
interaction mating.  
1. Cotransformation  
The DNA-BD/bait and AD/library plasmid were transformed together into AH109 using the 
small scale PEG/LiAc transformation procedure. Transformants were plated on SD/–Ade/–
His/–Leu/–Trp and incubated at 30ºC for 3-5 days. Colonies were subjected to colony-lift 
filter assay. 
2. Yeast Mating (direct interaction mating) 
AH109 was transformed with the AD/library plasmid (prey) and selected on SD/–Leu while 
Y187 was transformed with the BD/bait plasmid and selected on SD/–Trp plates. For each 
candidate AD/library plasmid to be tested, several yeast matings were set up as control. For 
each mating experiment, one large and fresh colony of each type has been picked from the 
working stock plates and placed in one 1.5-ml microcentrifuge tube containing 0.5 ml of 
YPD medium. Cells have been completely resuspended by vortexing and then incubated at 
30°C overnight (20–24 hr) with shaking at 200 rpm. Aliquots of 100-ml of the mating 
culture have been spread on the SD minimal media using double dropout (SD/–Leu/–Trp ) to 
select for diploids and both plasmids and quadruple dropout (SD/–Ade/–His/–Leu/–Trp/X-α-
gal) to select for diploids in which a positive two-hybrid interaction occurred.  
 
Preparation of yeast cultures for protein extraction 
For each transformed yeast strain assayed in a western blot, a 5-ml overnight culture 
in the appropriate SD selection medium was prepared as described previously, except single 
isolated colony was used. As a negative control, a 10-ml culture of an untransformed yeast 
colony in YPD medium was prepared. For each clone to be assayed (and the negative 
control), aliquots of 50 ml of YPD medium were separately inoculated with the entire 
overnight culture at 30°C with shaking (220–250 rpm) until the OD600 reached 0.4–0.6. The 
OD600 (of a 1-ml sample) was multiplied by the culture volume to obtain the total number of 
OD600 units. The culture was quickly chilled by pouring it into a prechilled 100-ml centrifuge 
tube halfway filled with ice and the tube was immediately placed in a prechilled rotor and 
centrifuged at 1000 x g for 5 min at 4°C. Supernatant was poured off and the cell pellet was 
resuspended in 50 ml of ice-cold H2O. The pellet was recovered by centrifugation at 1,000 x 
g for 5 min at 4°C and immediately frozen by placing the tube in liquid nitrogen. Cells were 
stored at -80ºC. 
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Yeast protein extraction (Urea/SDS method) 
Complete cracking buffer (Urea 8 M, SDS 5% w/v, Tris-HCl [pH6.8] 40 mM, EDTA 
0.1 mM, Bromophenol blue 0.4 mg/ml, β-mercaptoethanol 10%, protease inhibitor solution 
(Sigma))was pre-warmed at 60°C and 100 µl of cracking buffer per 7.5 OD600 units of cells 
was used. Cell pellets were quickly thawed by separately resuspending each one in the 
prewarmed cracking buffer and putting them for 1 min at 60°C. Because the initial excess 
PMSF in the cracking buffer degrades quickly, additional aliquots of the PMSF stock 
solution to the samples were added after every 7 min, approximately, until they are placed on 
dry ice or stored at –80°C. Each cell suspension was transferred to a 1.5-ml screw-cap 
microcentrifuge tube containing 80 µl of glass beads (Sigma) per 7.5 OD600 units of cells. 
Samples were heated at 70°C for 10 min and then mixed vigorously by vortexing for 1 min. 
Debris and unbroken cells were pelleted in a microcentrifuge at 14,000 rpm for 5 min at 4°C 
and supernatants were transferred to fresh 1.5-ml tubes and placed on ice (first supernatants). 
Pellets were treated as follows: tubes were placed in a 100°C water bath for 3–5 min and 
subsequently vortexed vigorously for 1 min. Debris and unbroken cells were pelleted in a 
microcentrifuge at 14,000 rpm for 5 min at 4°C and each supernatant (second supernatant) 
was combined with the corresponding first supernatant. Samples were boiled briefly and 
immediately loaded onto a gel or stored in a –70°C freezer until ready for the western 
blotting analysis. 
 
Proteins expression in yeast 
Western blots of transformants were performed as described below and the blots were 
probed with antibodies directed against the c-Myc and HA epitope tags. Untransformed yeast 
were used as a control. 
 
Sequence AD/Library inserts  
DNA isolated from E.coli was used and inserts in the positive AD/library plasmids 
were sequenced using the 3' AD Sequencing Primer and T7 Sequencing Primer provided 
with the system. The presence of an open reading frame (ORF) fused to the GAL4 AD 
sequence was verified and the sequence was compared to those in GenBank, EMBL, or other 
databases.  
 
Additional two-hybrid tests  
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For each interaction confirmed in the yeast direct interaction mating, the library insert 
was transferred from the AD to the DNA-BD vector and vice versa subcloning with suited 
enzymatic digestions and ligation. If restriction sites were not compatible between the prey 
and the vector, cDNA library fragments were first amplified by PCR and then subcloned by 
enzymatic digestion and ligation. Next, the two-hybrid assay was repeated. 
 
Cell cultures, treatment and isolation 
Human embryonic kidney (HEK293) and cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (Gibco, Invitrogen), supplemented with 10% foetal bovine serum 
(FBS) (Euroclone, Celbio), 100 U/ml penicillin (Celbio), and 100 µg/ml streptomycin 
(Celbio), at 37 °C in 5% CO2. Cells were routinely maintained in T-75 cell culture flasks 
(Corning, Costar) or 100 mm tissue culture dishes (Corning, Costar).Treatment with N-
acetyl-L-leucyl-L-leucyl-L-norleucinal, (LLnL), was done by adding the proteasome 
inhibitor at a final concentration of 10 µM in the culture medium 8-16 h prior harvesting. 
HEK293 cells were transfected with LipofectAMINE2000 (Invitrogen) while HeLa cells 
were transfected with PolyFect transfection reagent (Qiagen), accordingly to the 
manufacturers instructions. Testes from 18-20 days old CD1 (Charles River) mice were used 
to obtain pachytene spermatocytes by elutriation technique. Spermatogonia were obtained 
from mice 8-9 days old and round spermatids from 30 days old testes. Spermatozoa were 
obtained from the cauda epididymidis of adult (4-12 months old) mice. 
 
Immunofluorescence 
Cells were grown on four well chamber slides (Becton Dickson) and transiently 
transfected as described. After 24-72 hours, cells were washed with phosphate buffered 
saline (PBS, Gibco, Invitrogen) and fixed with 4% paraformaldehyde (PFA, Sigma) in PBS 
for 20 min. Next, cells were permeabilized with 2% Triton X-100 (Roche) in PBS for 10 min 
and treated with blocking buffer (5% FCS, 0.2% Tween-20 (Sigma) in PBS for 30 min. Cells 
were subsequently incubated with anti-FLAG (Sigma) at 1/500 dilution or anti-HA (Santa 
Cruz) at 1/100 dilution in blocking buffer for 2 h at room temperature. After washing five 
times with 0.2% Tween-20 in PBS, cells were incubated in blocking buffer with either FITC- 
or TRITC- conjugated anti-mouse or anti-rabbit antibody (Alexa Fluor, Molecular Probes), 
1/250 dilution, at room temperature for 1h. After five more washes of 0.2% Tween-20 in 
PBS, chamber walls were removed and slides were mounted in vectashield with 4',6-
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diamidino-2-phenylindole (DAPI) (Vector laboratories). The cells were examined under a 
fluorescence microscope (Zeiss, Axiosckop 2).  
 
 
Preparation of whole-cell and nuclear/cytoplasmic lysates. 
Total cell extracts from 1 to 2 X 107 were prepared by lysis in 1 ml of ice-cold RIPA 
buffer (20-50 mM Tris-HCL, pH 7.5-8.0, 150 mM NaCl, 1% Igepal CA-630, 0.5-1% sodium 
dodecylsulfate (SDS) with complete protease inhibitor cocktail (Sigma) and PMSF). The cell 
suspensions were disrupted with a sonicator for 10 sec (twice, with a 30 sec interval) and 
subsequently incubated in ice for 20 min mixing occasionally. Lysates were cleared by 
centrifugation at 15000 X g for 15 min at 4ºC and supernatants were recovered and 
transferred into a new tube. For extraction of proteins from mouse testis, the tissue has been 
homogenized into a ice-cold pestle with ice-cold RIPA buffer and complete protease 
inhibitors cocktail. After incubation of 30 min in ice, mixing occasionally, lysates were 
cleared by centrifugation at 15000 X g for 15 min at 4ºC. Supernatants were recovered and 
transferred into a new tube. For nuclear and cytoplasmic extracts, NE-PER extraction 
reagents kit (Pierce) was used, following the manufacturer’s instructions.  
 
Immunoprecipitation. 
Protein samples of 0.750-1.500 mg were immunoprecipitated by overnight incubation 
at 4ºC with 1-2 µg of the designed antibody on a rotating wheel. Protein A or protein G 
(Sigma Aldrich) resin was blocked for 1 hour with BSA 1mg/ml in RIPA buffer prior 
incubation with the immunoprecipitation solution for 1 hour. Next, the resin was washed 
four times with RIPA buffer and protein samples were eluted with loading sample buffer 
(LSB, 50 mM Tris-HCl, pH 6.8, 2% sodium dodecylsulfate [SDS], 5% β-mercaptoethanol, 
2.5% glycerol and 0.5% bromophenol blue) and denatured at 100 °C for 5 min. 
Immunoprecipitations with with untransfected cells, pre-immune anti-sera and non-related 
antibodies were carried out as controls. 
 
 
In vitro transcription and translation. 
Transcription and translation in vitro were carried out by using TNT® T7 Quick 
Coupled Transcription/Translation System (Promega) following manufacturer’s instructions. 
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Briefly, 40µl of TNT® Quick Master Mix, 1ul of Methionine, 1mM, 2µl of plasmid DNA 
template(s) 
(0.5µg/µl) and 7 µl of nuclease-free were mixed and incubated at 30ºC for 60-90 min. Empty 
vectors or plasmid vectors containing unrelated cDNA were used as negative controls. The 
results of translation were analysed by western blotting. 
 
Protein quantification. 
Protein concentrations were determined using the Bradford assay (Bradford 1976). 
Protein samples were mixed with Bradford reagent (Bio-Rad) and the absorbance at 595 nm 
was measured in a spectrophotometer (Varian). Protein absorbances were converted to 
mg/ml concentrations using a standard curve constructed by measuring the absorbance of a 
range of bovine serum albumin (BSA) concentrations.  
 
SDS/PAGE and Western blotting.  
 Protein samples were resuspended in loading sample buffer (20 mM Tris-HCl, pH 
6.8, 2% sodium dodecylsulfate [SDS], 5% β-mercaptoethanol, 2.5% glycerol and 2.5% 
bromophenol blue) and denatured at 100 °C for 5 min. Thirty to seventy-five µg protein was 
analyzed by SDS polyacrylamide gel electrophoresis (SDS-PAGE) on 10, 12.5 or 15% (w/v) 
polyacrilamide gels, using the Bio-Rad maxi and mini gel equipment, as detailed in the 
manufacturer instructions. Protein molecular weight markers used to establish the apparent 
molecular weights of proteins resolved on the SDS polyacrilamide gels were: New England 
Biolabs (175-6.5 kDa range), Benchmark Protein ladder (Invitrogen, 220-10 kDa range) and 
See blue Plus 2 pre-stained (Invitrogen, 198-3 kDa range). All of the mini gels were run at 
100 V while all of the maxi-gels were run at 120 V with samples in the stacking gel and 200 
V with samples in the resolving gel for an appropriate length of time, using SDS running 
buffer (25 mM Tris, 192 mM glycine, 0.1% SDS). Proteins were electroblotted onto 
polyvinylidene difluoride (PVDF) membranes (Immobilon-P, Millipore) or Nitrocellulose 
membrane (Millipore) using a wet blotter (Bio-Rad) at 100 V for 1 h or at 40 V over night in 
blotting buffer (25 mM Tris, 192 mM glycine, 20% methanol). Membranes were blocked 
with 5% non-fat milk (BioRad) in TBS, pH 7.6, 0.5-1.0% Tween-20 (TBS-T) for 1 h. The 
membranes were then incubated with polyclonal rabbit antibodies or monoclonal mouse 
antibodies for 1 h, using the recommended dilution for each antibody as described in the 
antibody section. After 4 washes in TBS-T for 5-10 minutes, the membranes were incubated 
with a horseradish peroxidase (HRP)-conjugated anti-mouse or anti-rabbit antibody 
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(1:10,000) (Santa Cruz Biotechnology), and the immunoblots were visualised using ECL 
detection kits, with enhanced chemiluminescence (Pierce).  
 
 
 
Antibodies 
Antibodies used include the following: rabbit anti-FANCA (Covance) ; monoclonal 
and polyclonal anti-FANCD2 (FI-17; Santa Cruz Biotechnology and Novus Biotechnology 
respectively); rabbit polyclonal anti-fancd2 (kind gift of dr.Alan D’Andrea), rabbit 
polyclonal anti-FANCG (Fanconi Anemia Research Fund); monoclonal anti-FLAG (M2; 
Sigma- Aldrich), monoclonal anti-cMyc (9E10; Santa Cruz Biotechnology), and monoclonal 
anti-HA (12CA5; Roche Diagnostics). A mouse ERK antibody (1:500) (Santacruz 
Biotechnology) was used as the control for equal loading of total extracts. Mouse anti-
HDAC (Santacruz Biotechnology) or anti-Sp1 antibody (Santa Cruz Biotechnology) for 
equal loading of nuclear lysates. Rabbit antibodies against clone 54 murine and against 
ISG20L2 human were generated by PRIMM, after immunization with peptides specifically 
designed by the company. 
 
 
RNA isolation and cDNA preparation. 
Total RNA was extracted from cell lines by the guanidinium isothiocyanate method, 
using Trizol reagent (Invitrogen). The RNA concentrations were determined by absorbency 
at 260 nm, and their quality was verified by the integrity of the 18S and 28S rRNAs after 
ethidium bromide staining of the total RNA samples subjected to 1% agarose gel 
electrophoresis. Synthesis of cDNA from total RNA (4 µg) was performed using the Super 
Script II First Strand Kit (Invitrogen), with random hexamers, according to the manufacturer 
instructions. 
 
Bioinformatic analysis. 
 The human sequence database (http://genome.ucsc.edu/cgi-bin/hgGateway) was 
screened by using as initial query the sequence the human proteins and the BLAT program. 
The Genscan and Gene Predictions were corrected by searching the nonredundant sequence 
database and the human EST database (http://www.ncbi.nlm.nih.gov/) using BLAST 
program. The mouse sequence database were screened by using the human cDNAs and the 
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BLAT program. The retrieved putative sequences were then ascertained by searching the 
nonredundant sequence and the human EST database. To characterize the genomic structure, 
both human and mouse cDNAs were used to screen the respective genomic DNAs at the 
Human Genome Browser Gateway and in the High Troughput Sequences Database. 
 
Northen blot analysis. 
A membrane carrying a panel of human polyA+ RNA was hybridized with 32P-
labeled clone 54 and ISG20L2 human probes according to the manufacturers instructions 
(Clontech). 
 
RNA in situ hybridization. 
The clone 54 antisense probe was obtained by linearization of cDNA in pCRII-TOPO 
vector (TOPO TA cloning, Invitrogen) with EcoRV (New England Biolabs) and 
transcription with SP6 RNA polymerase, while digestion of the same plasmid with BamHI 
(New England Biolabs) and transcription with T7 RNA polymerase generated the sense 
control probe. The ISG20L2 antisense probe was obtained by linearization of the cDNA 
pCRII-TOPO vector with XhoI and transcription with T3 RNA polymerase, and the sense 
control probe was transcribed with T7 RNA polymerase after digestion of the plasmid with 
NotI. Embryos, at different developmental stages, were harvested from CD1 pregnant female 
mice and fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS) overnight at 
4ºC.Whole-mount in situ hybridization analysis was performed on embryos at E9.5 and 
E10.5. Embryos were treated with proteinase K (10 Ag/ ml) for either 7 (E9.5) or 10 min 
(E10.5). Hybridization with the digoxigenin-labeled probes (as reported below) was 
performed overnight at 68ºC in 50% formamide, 5_ standard saline citrate buffer (SSC; pH 
4.5), 1% sodium dodecyl sulfate (SDS), 50 Ag/ml yeast RNA, and 50 Ag/ml heparin and the 
digoxigenin-labeled probes (1 Ag/ml). The following day, after two washes in a solution 
containing 50% formamide, 4_ SSC, and 1% SDS at 68ºC, embryos were washed twice in 
the solution containing 50% formamide and 2_ SSC at 65ºC and five times in 100 mM 
maleic acid, 150 mM NaCl, 0.1% Tween 20, pH 7.5 (MABT) and finally treated for 2 h in 
1% blocking reagent (Roche) in MABT with 2% sheep serum. Embryos were incubated 
overnight with alkaline phosphatase (AP)-labeled anti-digoxigenin antibody (1:2000; Roche) 
in 1% blocking reagent in MABT at 4ºC. After extensive washes in Tris buffer saline with 
0.1% Tween 20 (TBST) embryos were exposed to the substrate for AP, nitroblue 
tetrazolium–5-bromo-4-chloro-3-inodoyl phosphate (NBT-BCIP; Sigma). Staining was 
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blocked by washes with PBS, pH 5.5, followed by postfixation in 4% paraformaldehyde for 
1 h. Hybridized embryos were photographed at the stereoscope using a digital camera (Leica 
DC500). Embryos at E14.5, neonatal mice, and adult tissues were analyzed by in situ 
hybridization of sectioned tissue. To this purpose, embryos and dissected organs were 
cryoprotected by treatment with 30% sucrose in PBS and embedded in 7.5% gelatin. 
Twenty-micrometer cryosections were collected on Superfrost Plus slides and postfixed with 
4% paraformaldehyde in PBS for 15 min. After being bleached with 6% H2O2 in PBS with 
0.1% Tween 20, sections were treated with either 1 (embryonic tissues) or 5 Ag/ml (neonatal 
and adult tissue) proteinase K for 15 min. After washes with 2 mg/ml glycine and 
postfixation with 4% paraformaldehyde and 0.2% glutaraldehyde sections were 
prehybridized with 50% formamide, 5_ SSC (pH 4.5), 1% SDS, 50 Ag/ml yeast RNA, and 
50 Ag/ml heparin. Hybridization was performed overnight at 65jC. Hybridized sections were 
washed with 50% formamide, 4_ SSC, and 1% SDS at 65ºC and with 50% formamide and 
2_ SSC at 60ºC. Sections were blocked for 1 h with 1% Blocking Reagent (Roche) in MABT 
containing 10% sheep serum and incubated with AP-labeled anti-digoxigenin 
antibody(1:2000; Roche) in 1% Blocking Reagent in MABT overnight at 4ºC. After 
extensive washing with TBST, sections were exposed to NBT-BCIP (Sigma). Reaction was 
blocked by washes with PBS, pH 5.5, followed by postfixation in 4% paraformaldehyde for 
20 min. Slides were coverslipped with 70% glycerol in PBS and photographed (AxioCam 
digital camera; Carl Zeiss, Gottingen, Germany) using a microscope with Nomarski optics 
(Axioplan; Zeiss). 
 
Tissue preparation.  
Freshly frozen, postfixed sections were used for all of the experiments. At least one 
litter was used for each age group from which data are reported, with at least two embryos 
examined at each age. Pregnant CD1 mice were decapitated. For embryos at E14.5 and the 
entire uterus were freshly frozen and embedded in Optimal Cutting Temperature (OCT) 
compound (Roche Products, UK) for cryostat sectioning. Mouse embryos older than E14.5 
were dissected out quickly and staged according to their limb bud morphology, before being 
frozen and embedded in OCT. Embryonic trunk sagittal and transverse sections (14 µm) 
were prepared to detail the expression patterns. Sections were mounted onto 3-
aminopropyltriethoxy-silane-coated microscope slides and stored at -80 °C until use in the 
hybridization procedure. 
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Polymerase chain reaction (PCR) 
The general PCR conditions were as follow: (Pfu polymerase)  
1 µl cDNA template 
5 µl Pfu buffer 
20 pmol forward primer 
20 pmol reverse primer 
1 µl Pfu polymerase (3 U/µl) 
0.2 mM of each dNTP 
dH20 to 50 µl 
The PCR reaction was performed with the following cycling parameters: 
 
 
1 cycle 1 min at 95 °C 
30 cycles 30 sec at 95 °C 
 30 sec at the annealing temperature 
 2 min at 72 °C (1min per each kb of DNA to amplify) 
1 cycle 10 min at 72 °C 
 
 
Restriction enzyme digestion of DNA  
The analytical DNA digestions were performed in a final volume of 20-50 µl, at 37 
°C for 1-2 h. All of the restriction enzymes were from New England Biolabs, and the 
digestions were performed in the appropriate buffers, supplied by the manufacturer with the 
enzyme. All of the digestions were analysed by agarose gel electrophoresis. Each analytical 
digestion used 500 ng plasmid DNA, with 3 units of enzyme per µg plasmid DNA. 
 
Agarose gel electrophoresis 
Agarose gels (1% w/v in TAE, 40 mM Tris-acetate, pH 7.5, 2 mM EDTA) were 
prepared and supplemented with ethidium bromide (1 µg/ml). The percentage of the agarose 
in gels was determined depending on the size of the DNA fragments to be resolved. Gels 
were generally run at 120 V in 1× TAE buffer, and DNA was visualized on a UV 
transilluminator. 
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Isolation of DNA from agarose gels 
Following agarose gel electrophoresis, the DNA-containing gel slices were excised 
under UV light. The DNA was extracted from these gel slices using QiaexII Gel Extraction 
Kit (QIAGEN), following the protocol supplied by the manufacturer. Briefly, the gel slices 
containing the DNA were dissolved in sodium perchlorate, with the buffer composition 
adjusted to allow binding of the released DNA on to a silica support. The bound DNA was 
then washed from the agarose and the electrophoresis buffer with alcohol-containing buffer. 
Purified DNA was eluted from the resin using 20 µl dH20.  
 
DNA sequence analysis 
For DNA sequence analysis, plasmids or PCR were processed by the DNA 
sequencing core at TIGEM. Sequencing reactions were carried out using Taq DNA 
polymerase and fluorescently labelled dideoxy terminators, and then run on our automated 
sequencers. Control reactions are carried out to insure high quality control. Single run 
sequencing reactions can yield 600 to 700 bases routinely, depending on the type of template 
and primer used. Sequences obtained with an automated sequencer begin roughly 15 to 20 
bases after the primer sequence. 
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Chapter 3 
RESULTS 
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3.1 Identification of putative FA interactors using a yeast two-hybrid 
system approach. 
 
3.1.1: Library screening. 
 
The first part of this PhD project was aimed at the identification of new interactors of 
FA proteins by using the systematic approach of the yeast two-hybrid screening. At this 
purpose were generated 23 bait constructs of 7 FA genes (partial and full length), fused with 
the GAL4 DNA binding domain (BD) in pGBKT7 vector (table 5). Since functional domains 
of the FA proteins employed were not known, the length of each partial cDNA fragment was 
arbitrarily chosen to be approximately 1000 bp, so as to maximize the chances of expression 
in yeast. Fragments of cDNA were designed to partially overlap each other, amplified by 
PCR and subcloned into the bait vector. Once transformed in AH109, each construct was 
tested for: 
- Toxicity effects in yeast (by monitoring the culture growth rate) 
- Self-activation of reporter genes (by plating them on selective media: SD-WH, SD-
WA, SD-WHA in presence of X-α-Gal) 
- Protein production and stability (by western blotting analysis) 
No baits were discarded for toxicity effects. FANCG, FANCG1 FANCA1 and FANCA2 were 
rejected for auto-activation of reporter genes. FANCA and FANCC2 were discarded as no 
protein was detected while FANCD2 was expressed in low amount. Of the 16 baits suited for 
yeast two-hybrid assay, we used 8 constructs, FANCA3, FANCA5, FANCD21, FANCD22, 
FANCD23, FANCD24, FANCD25 and FANCG2 to screen a commercial cDNA library. They 
included all the FANCD2 baits, since FANCD2 is considered a fundamental ‘crossroad’ for 
FA-BRCA pathway (in review (Wang 2007)), the only suitable fragment of FANCG since it 
is crucial for the FA complex assembly (Garcia-Higuera, Kuang et al. 1999; Medhurst, 
Huber et al. 2001) as well as two of the three suited FANCA baits because FANCA (as well 
as FANCD2 (Garcia-Higuera, Taniguchi et al. 2001)) binds directly BRCA1, connecting FA 
pathway with DNA-repair (Folias, Matkovic et al. 2002). A human testis library fused with 
the GAL4 activation domain (AD) into the pACT2 vector was used for the screening. The 
rationale behind this choice is that FA genes are expressed in testis at high levels (Chen, 
Tomkins et al. 1996; Lo Ten Foe JR 1996; Whitney, Royle et al. 1996) and testis manifests 
pathological phenotypes in both patients and animal models (Chen, Tomkins et al. 1996; 
Whitney, Royle et al. 1996; Cheng, van de Vrugt et al. 2000; Yang, Kuang et al. 2001; 
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Koomen, Cheng et al. 2002; Houghtaling, Timmers et al. 2003; Wong, Alon et al. 2003). 
Moreover, FA-BRCA pathway in this tissue was still uncharacterized. 
We selected and analysed 167 clones by direct sequencing (table 6). Databases 
queries allowed the identification of 60 putative interactors, as they belong to known or 
predicted proteins, and exclusion of 107 clones as genomic, Alu or out of frame sequences, 
5’ and 3’ untranslated regions. 
 
 
Construct FA protein Insert (protein amminoacids) 
pGBKT7-FANCA FULL LENGTH (1-1456) 
pGBKT7- FANCA1 1-355 
pGBKT7- FANCA2 291-647 
pGBKT7- FANCA3 594-948 
pGBKT7- FANCA4 910-1256 
pGBKT7- FANCA5 
FANCA 
 
1210-1456 
pGBKT7- FANCC FULL LENGTH (1-558) 
pGBKT7- FANCC1 1-325 
pGBKT7- FANCC2 
FANCC 
 
246-558 
pGBKT7-FANCD2 FULL LENGTH (1-1468) 
pGBKT7-FANCD21 1-359 
pGBKT7-FANCD22 321-671 
pGBKT7- FANC D23 615-961 
pGBKT7- FANC D24 927-1270 
pGBKT7- FANC D25 
FANCD2 
 
1233-1468 
pGBKT7- FANC E FULL LENGTH (1-537) 
pGBKT7- FANCE1 1-308 
pGBKT7- FANCE2 
FANC E 
 
249-537 
pGBKT7- FANCF FANCF FULL LENGTH (1-374) 
pGBKT7- FANCG FULL LENGTH (1-622) 
pGBKT7- FANCG1 1-351 
pGBKT7- FANCG2 
FANCG 
 
287-622 
pGBKT7- FANCL FANCL FULL LENGTH 
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Table 5: FA bait plasmids generated for this work and their length (in aa). In red, baits giving auto-
activation. In brown, baits producing low or no amount of protein. In black, baits suited but not used for yeast 
two-hybrid screening. In green, baits used to screen a cDNA testis library.  
 
 
 
No of clones after 
 
BAITS Library 
screening 
Sequencing 
analysis 
Direct mating 
BD-bait/AD-prey 
Direct mating 
AD-bait/BD-prey 
pGBKT7-FANCA3 1 1   
pGBKT7-FANCA5 2 2   
pGBKT7-FANCG2 134 44  7 clone 4 (ISG20L2) 
pGBKT7-FANCD21 0 0   
pGBKT7-FANCD22 0 0   
pGBKT7-FANCD23 29 12 3 
clone 54 (UBE2U) 
clone 62 (CRIPS1) 
pGBKT7-FANCD24 1 1   
pGBKT7-FANCD25 0 0   
 
Table 6: Library screening and yeast interaction mating results. 
 
 
3.1.2: Direct interaction matings by co-transformations. 
 
In order to investigate the interactions found, the 60 preys were tested in a direct 
interaction assay with their respective baits, allowing us to confirm 10 bindings (table 6). 
Next, preys and baits were switched into the vectors and tested by direct interaction matings 
in this new combination. All of them gave no auto-activation of reporter genes and each 
interaction was tested in three independent analyses. Three clones resulted positive, as 
confirmed also by X-α-Gal tests. Specifically, the clone 4 was found to interact with 
FANCG2, while clones 54 and 62 bound FANCD23 (table 6). To validate these interactions 
in yeast, full length cDNA of clones 4, 54 and 62 were obtained by RT-PCR and cloned into 
pGBKT7 and pGADT7 vectors, in frame with BD and AD, respectively. After auto-
activation tests and protein production detection, they were used for yeast direct interaction 
mating as described previously. All interactions, between full length FANCD2 and clones 54 
and 62 and between FANCG2 (the only FANCG portion without auto-activaction) and clone 
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4, were confirmed. Since clone 62 represented the CRISP2 (cysteine-rich secretory protein 2) 
gene, known to be specifically expressed in testis without any evident association with FA 
pathway, we decided to focus our attention on the other two clones, because potentially 
connected to the FA-BRCA pathway. In fact, accordingly to databases analysis and 
bioinformatic tools, clone 4 represented a novel ISG20L2 gene encoding for a protein with a 
putative conserved domain of ‘EXOIII’ family, which includes a variety of exonuclease 
proteins, therefore possibly linked to DNA-repair. Clone 54 was a novel gene as well 
(UBE2U), for the synthesis of a predicted ubiquitin-conjugating enzyme E2 and as 
mentioned, monoubiquitination of FANCD2 is a crucial step in the FA-BRCA pathway. 
While the putative E3 in the pathway was known as the FANCL product, the E2 enzyme 
involved in the ubiquitination modification was unknown at the time of this study. Then, the 
work of this thesis focused on the characterization of these two novel genes, including 
expression studies and validation of the interactions with the respective proteins. 
 
 
 
3.2 UBE2U: a novel putative Ubiquitin-conjugating enzyme E2. 
 
 
3.2.1: Cloning of human and murine clone 54: UBE2U. 
 
Clone 54 had a putative open reading frame of 226 amino acids. The predicted 
protein showed high homology to the members of the ubiquitin-conjugating enzyme family 
E2 and it is reported with the provisional name of UBE2U in database. The human sequence 
databases were screened using as initial query the sequence of clone 54 and BLAST and 
BLAT programs. The screening identified ESTs that allowed the extension of the transcript 
at both ends and the identification of putative alternative forms. Combining results from EST 
database and exon-intron genomic structure, at least three transcripts of approximately 1.6, 
3.3 and 3.8 kb were expected, all resulting in alternative splicing (Fig. 10). Both transcripts 
of 3.3 and 3.8, share the same open reading frame for 226 residues (isoform A, GenBank 
Accesion number NP_689702). They differ at the 3’ UTR in that a splicing event between 
exons 8a and 8b removes intronic bp in transcript of 3.3 kb (Fig.10). The transcript of 1.6 kb 
derives from the assembly of another two exons: the 9 and 10. It encodes for a 317 amino 
acids protein (isoform B), consisting of 91 additional amino at the COOH-terminus of 
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isoform A (Fig. 8). The murine putative Ube2u gene was also cloned by bioinformatic tools, 
using the human cDNA and protein sequences, as queries. The BLAST and BLAT programs 
allowed us to retrieve predicted genes (chr4_19.128 and chr4_19.129) on syntenic regions of 
chromosome 4, the cDNA of which was blasted against the non redundant sequence and the 
human EST databases to reassure the sequence. The mouse transcript was of 1552 bp, 
resulting in a protein of 352 amino acids (Fig. 8), consistent with a predicted sequence also 
obtained by automated computational analysis (GenBank Accession Number XP_355502). 
Contrarily to what observed in the human UBE2U gene, there was no evidence for 
alternatively spliced forms. 
 
 
3.2.2: Homology, genomic organization and alternative splicing of the UBE2U gene. 
 
 The alignment between the human and the mouse proteins is shown in Fig. 8, where 
we also included the Macaca (GenBank Accession Number BAB69736) and rat (as 
determined by bioinformatic analysis) genes. The alignment shows that the homology 
between the orthologs is conserved in correspondence of human isoform A, while it is almost 
absent in the COOH-terminal region, containing the 91 human additional residues that 
characterize isoform B. In this work we refer to UBE2U as isoform A unless stated 
otherwise. The human and mouse genomic structures were determined by searching the 
respective genome database using as a template the cDNAs in a BLAT analysis. Positive 
match were obtained in the syntenic region of human 1 and mouse 4 chromosomes. Ten 
exons with the appropriate consensus sequences from intronic splicing were identified in 
both species. The size of all exons perfectly matched, suggesting that the genomic structures 
between the two genes are well conserved. Comparison of the genomic sequence of the 
human and mouse genes in a mVista search allowed the identification of conserved regions 
only corresponding to exons 1 to 8. 
 
 
3.2.3: Interaction of clone 54 (UBE2U) and other FA proteins in yeast. 
 
 In order to determine whether UBE2U is part of the FA-BRCA pathway, we analyzed 
interactions between UBE2U and other FA proteins by direct yeast interaction matings. In 
these experiments, cDNA full length of human UBE2U was used as bait and FA proteins (or 
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partial proteins) as preys and vice-versa (table 7). In these studies, not only we did confirm 
the interaction of UBE2U with FANCD23, but we also found that UBE2U interacts with 
FANCC, FANCF and FANCL. 
 
MOU        ----------MYSKAYILLEREFRELKRDTRKDITAYPVSDDMMNWKAEIEGLRNSVCEG 50 
RAT        MSYKTDSKLAGYSKAYSLLEREFKELQNSRSKGINAYPVSSDLMSWKAEIEGLKYSVCEG 60 
HUM        ----------MHGRAYLLLHRDFCDLKENNYKGITAKPVSEDMMEWEVEIEGLQNSVWQG 50 
MAC        ----------MHGRAYLLLQRDFYDLKENNYKGITARPVSEDMMEWEVEIEGLQNSVWQG 50 
                         :.:** **.*:* :*:..  *.*.* ***.*:*.*:.*****: ** :* 
 
MOU        LVFYLTLEFSQEYNSVPPNVKFTTIPFHPNVDPYTGKPSIDFLDKPGKWNTNYTVLSILL 110 
RAT        LVFHLTIDFSQDYNLVPPVVKFVTIPFHPNVHPYTGQPSLGILDKPDMWDTSYTILRILF 120 
HUM        LVFQLTIHFTSEYNYAPPVVKFITIPFHPNVDPHTGQPCIDFLDNPEKWNTNYTLSSILL 110 
MAC        LVFQLTIHFTSEYNYAPPVVKFVTIPFHPNVDPHTGQPCIDFLDNPKKWNTNYTLSSILL 110 
           *** **:.*:.:** .** *** ********.*:**:*.:.:**:*  *:*.**:  **: 
 
MOU        DLQMLLSYPVLKNPVNLEAAQLLIRNASTYKMVIQELLPPALPKRESSLVIPEKPQDRVR 170 
RAT        DLQMLLSYPMVKNPLNLEAAELLVKDESLYRTVIRELLQSEPPKTEGSLVLAEKPQEHIR 180 
HUM        ALQVMLSNPVLENPVNLEAARILVKDESLYRTILRLFNRP-LQMKDDSQELPKDPRKCIR 169 
MAC        ALQVMLSNPVLENPVNLEAARILTKDESLYRTILKLFNRP-LQMKDDSQELPKDPHKCIG 169 
           **::** *:::**:*****.:* :: * *: ::: :  .     :.*  :.:.*:. :  
 
MOU        VIKTISFNDYYKTWSQIATTKVAEHSRNPFVGDPHFMGQYYKWKQQDRQNQVQWESKFAL 230 
RAT        IIKTISFNDYYKTWSQIATTKVAEHSKNQFVGDPHFMAQYYKWKEQDRQYQRQWESKFVL 240 
HUM        PIKTTSFSDYYQTWSRIATSKATEYYRTPLLKVPNFIGQYYKWKKMDLQHQKEWNLKYSV 229 
MAC        PTKTTSFSDYYQAWSRIATSKATEYYRTALLKDPNFIGQYYKWKKMDLQHHKEWNLKYSV 229 
             ** **.***::**:***:*.:*: :. ::  *:*:.******: * * : :*: *: : 
 
MOU        SKWQTARKKIMAQEKSNHYNQVIGIYPSPSELSFEYEIEEEEEEEEEEEEEEEEEEEEEE 290 
RAT        SKWQNIRKKMTQESKEPSDKEEV-LYPSPTELSSEPNVEDESGFYNVPQEWSEES----- 294 
HUM        IKCWLARK-RMPHEVTHS-MEEIKLCP----TLNEIFLESPTAINSITDIYETEEEG--- 280 
MAC        IKCWLARKNRMPDEVRHS-MEGIKLCPTQIPTTDEIFLESPTAINSVTNIYETEEEG--- 285 
            *    **    ..      : : : *       *  :*.     .  :  . *.      
 
MOU        KEEEEEEPRIYQIPQEWPEEHDSKESWEEEADHLVSWTNGLDEESLNYEYFDNVKNYENL 350 
RAT        ----------------FSEEHDSEESWEEEVDNLVAWTDGLDEESLNYENYENFENIDN- 337 
HUM        -----------WKSDTSLYENDTDEPREEEVEDLISWTN-----TLNTNTSED------- 317 
MAC        -----------WKSDTSLYENNTDEPWEEEVEDLISWIN-----TLNTNTLED------- 322 
                              *:::.*. ***.:.*::* :     :** :  ::        
 
MOU             GN 352 
RAT             -- 
HUM             -- 
MAC             -- 
 
Figure 8. Alignment of human UBE2U with UBE2U of mouse, rat and macaca origin. In yellow is highlighted the 
ubiquitin-conjugating domain (UBC) while with the square is reported the cysteine active residue of the catalytic site. 
The isoform A of the human protein is highlighted in green. 
 
 
Additionally, UBE2U appeared to interact with itself as well, giving self-dimerization. These 
interactions were found using both, UBE2U fused to BD with FA cDNAs fused to AD and 
vice versa (using UBE2U fused to AD with FA cDNAs fused to BD). Particularly worth of 
note is the interaction of UBE2U with FANCL, since FANCL is considered the putative 
ubiquitin-ligase E3 of the FA-BRCA pathway in vivo (Meetei, de Winter et al. 2003). We 
also detected interactions between BD-UBE2U and AD-FANCD2, as well as between AD-
UBE2U and BD-FANCE. Interestingly, we found AD-FANCL interacting with BD-
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FANCD21 and BD-FANCD23, as well as with BD-FANCE. Finally, BD-FANCL interacted 
with AD-FANCF and with itself (Table 7 and Fig.9). 
 
 
pGADT7 (AD) pGBKT7 
(BD) FANCD2 FANCD21 FANCD22 FANCD23 FANCC FANCE FANCF FANCL UBE2U 
FANCD2 - - 
FANCD21 + - 
FANCD22 - - 
FANCD23 + + 
FANCC - + 
FANCE + +  
FANCF 
nd 
- + 
FANCL - - - - - - + + + 
UBE2U + - - + + - + + + 
 
Table 7: Direct interaction matings of UBE2U and FA proteins. Direct interaction mating assays carried out 
between UBE2U and FA proteins. BD: proteins fused with the GAL4 binding domain; AD: proteins fused with 
GAL4 activation domain. Interactions (+) found in both two-hybrid protein combinations are in green, whereas 
those found in only one combination are in yellow. (-): no interaction; nd: interactions not checked. FANCD24 
and FANCD25 were not used since as preys (with AD) they auto-activated reporter genes 
 
 
 
 
 
 
 
 
 
 
 
 Figure 9: Interaction between UBE2U and FA proteins in yeast. Schematic representation of interactions 
found between UBE2U and FA proteins investigated in yeast direct interaction mating assays 
 
 
3.2.4: Northern blot and alternative splicing of UBE2U. 
D2 
L
F 
E 
 
UBE2U 
C 
 84 
 
As a first step toward the characterization of UBE2U, Northern blot analysis of 
human tissues was performed using a specific probe (Fig. 10). Consistent with 
bioinformatics data, a highly expressed transcript of 1.6 kb, as well as transcripts of major 
sizes, were detected in human testis. The gene was not expressed in thymus, spleen, small 
intestine, colon, prostate, uterus, and peripheral blood leukocytes. In order to confirm the 
presence of the three 1.6, 3.3, and 3.8 kb transcripts, we amplified the putative cDNAs using 
specific oligonucleotides (1F/10R, 1F/8aR and 1F/8bR). No product was obtained from 
different cell lines, suggesting that the gene is not widely expressed (data not shown). 
 
 
Figure 10: Transcripts analysis for UBE2U. A: Northern blot analysis of UBE2U on human different tissues. 
B: Schematic representation of genomic structure of human UBE2U from exon 8a to exon 10. C: Alternative 
splicing of human UBE2U leading to three different transcript.  
 
 
 
3.2.5: Ube2u is expressed in testis. 
 
To understand at which developmental stages and in which tissues the gene could be 
active, expression studies by RT-PCR and in situ hybridization (ISH) were carried out in 
mouse. RT-PCR analysis revealed that the expression of this gene was restricted to testis, as 
reported in figure 11. During mouse embryonic development, in fact, the Ube2u gene is not 
expressed in eyes (E14.5), mesencephalon (E14.5), telencephalon (E14.5, E16.5), kidney 
(E16.5), heart (E14.5) and lung (E14.5, E16.5). In adult mouse, the gene is not transcribed in 
8a 8b 9 10
gt gtag ag ag
1.6 kb
8a 9 10
8a 8b
8a 8b 3.3 kb
3.8 kb
A B
C
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peripheral blood, bone marrow, fibroblasts and cochlea. Moreover, no expression was found 
in mouse melanoma cell lines B16 or in embryonic stem (ES) cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Ube2u is expressed in testis. RT-PCR analysis of Ube2u in cell lines, embryonic and adult tissues 
from mouse. Actin (200bp) has been used as internal control of RT-PCR. (-), –RT. Marker: 2-Log DNA 
Ladder. 
 
 
 
3.2.6: Ube2u is expressed in meiotic cells and its expression overlaps with Fancd2 
expression.  
 
In order to further characterize the expression of the Ube2u gene in mouse testis, we 
studied adult sections using RNA in situ hybridization. The expression of the Ube2u mRNA 
varied with the seminiferous cycle in different developmental stages of mouse testis. 
Whereas no hybridization could be seen in seminiferous tubules in 2 weeks mouse testis, 
strong signals were detected in seminiferous tubules of 3, 5 and 12 weeks mice (Fig.12). The 
presence of Ube2u mRNA, as indicated by brown staining, was limited to central layers of 
epithelium cross section of seminiferous tubule, where spermatocytes (meiotic cells) and 
round spermatides are located. A weak or no signal was instead found in correspondence of 
spermatogonia (outer layer) or elongated spermatides (inner, lumen layer). Interestingly, 
even the Fancd2 gene resulted expressed mainly in round and elongated spermatides (Fig. 
12), supporting thus the hypothesis of interaction between the two products 
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Figure 12: RNA in situ hybridization analysis of Ube2u and Fancd2. RNA in situ hybridization on adult testis 
(A,B,C,D,E and F)sections. Epithelium of seminiferous tubules shows various stages of male germ cells 
development: from the outer layers to the inner layers we progressively find more differentiated and mature 
cells (from spermatogonia to spermatides). Antisense probes of Ube2u detected transcript in correspondence of 
spermatocytes and spermatides (B, as well as C and D at higher magnifications). Antisense probes of Fancd2 
(E and F higher magnification) detected transcripts in spermatides but at low levels also in spermatocytes, 
showing with Ube2u. Sense probes used as controls do not show any hybridization signals (A). 
  
 
In order to confirm this expression pattern, we decided to carry out RT-PCR analysis on 
mRNA samples of cells at different stages during the spermatogenesis, from spermatogonia 
to mature spermatozoa. As shown in figure13, a PCR product of the expected size was found 
in whole testis extracts and interstitial cells. It was also detected in spermatocytes, secondary 
spermatocytes and spermatides but not in spermatogonia or in spermatozoa.  
A B
C D
E F
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Figure 13: RT-PCR analysis on cells during spermatogenesis. A RT-PCR product of 318 bp indicated the 
Ube2u gene. RT-PCR of actin (200bp) has been used as loading control. M, 2-Log DNA ladder, E12.5 and 
E14.5; Int, interstitial cells; WT, whole testis, SPG, spermatogonia, SC, spermatocytes, SPD, spermatides, 
SCII, secondary spermatocytes, SPZ, spermatozoa; (-), -RT. 
 
 
3.2.7: Western blotting analysis of Ube2u in mouse testis. 
 
Western blotting analysis was carried out on protein samples from cells of mouse 
spermatogenesis. These experiments exploited two antibodies (YFE05-1 and YFE05-2) 
directed against the murine Ube2u protein produced in our laboratory (M&M next section) 
(Fig. 14). Samples analyzed included whole testis and interstitial cells protein extracts of 4-
12 months old mice, together with spermatogones, spermatocytes spermatides and 
spermatozoa. In agreement with RT-PCR data, the protein was identified in whole testis and 
in interstitial cells. Among cells of the different stages of spermatogenesis the protein was 
detected in spermatocytes, spermatides and spermatozoa but not in spermatogonia. 
Accordingly to the amount of ERK1/2 used as samples loading control, the highest 
expression level was detected in spermatocytes. These data are consistent with those 
obtained by RT-PCR except for the presence of a low amount of protein in spermatozoa, 
where the Ube2u transcript was not detected.  
 
 
 
M
 
E 
12
.
5 
E 
14
.
5 
In
t 
W
T 
SP
G
 
SC
 
SP
D
/S
CI
I 
SP
D
 
SP
Z 
-
 
Actin 
Ube2u 
 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Western blotting analysis on mouse protein extracts of cells during spermatogenesis. YFE05-1 
has been used as specific anti-Ube2u antibody while anti-ERK1/2 has been used to detect ERK1 and ERK2 as 
loading control. Protein is detected at high levels in interstitial cells and in spermatocytes. 
 
 
3.2.8: No UBE2U expression in transient transfections. 
 
In order to further characterize the novel putative gene at the protein level and to 
validate the interaction between human UBE2U and FANCD2 found in yeast, we performed 
experiments of protein cellular localization and co-immunoprecipitation in mammalian cells. 
However, due to the limitations of expression pattern of UBE2U, no cellular models were 
available for these studies (we did not detect expression in any cell line investigated). 
Additionally, a specific antibody directed against the human protein was not available; 
therefore analyses could not be performed at endogenous level. For these reasons, we carried 
out transient transfections in mammalian cell lines. The human cDNA of UBE2U was 
subcloned into expression vectors pcDNA3.1 fused in frame with either N-ter FLAG- or 
myc- or HA- tags and transiently transfected in HeLa, Cos-7 and HEK293 cell lines. Even 
using different protocols to increase efficiency of transfection, we were not able to detect the 
protein at any level in any of the cell lines used by both immunofluorescence and western 
blotting techniques. In order to verify whether the proteasome mediated the degradation of 
UBE2U, we treated HEK293 cells with N-acetyl-L-leucinyl-L-leucinal-L-norleucinal (LLnL) 
and again we detected no expressed protein, as showed in fig. 15A, whereas a signal is 
detected loading HA-UBE2U transcribed and translated (tnt) in vitro. Since butyrate is also a 
molecule able to induce the transcription, we treated cells with this compound alone and in 
Ube2u 
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combination with LLnL as well. Again, no fused HA protein was detected (Fig. 15B). Next, 
in order to exploit the transcription and translation (tnt) in vitro to validate the interaction 
between UBE2U and FANCD2, we tested whether antibodies against HA were able to 
immunoprecipitate HA-UBE2U produced in rabbit reticulocytes (Fig. 15C). Although the 
assays were repeated several times, no immunoprecipates were detected, suggesting that the 
antibody anti-HA was not able to immunoprecipitate the protein from rabbit retyculocites. 
Moreover, we could not exclude that, despite using protease inhibitors, the protein was not 
stable and thus degraded in vitro. 
 
 
Figure15 Western blotting analyses of HEK293 cells transiently transfected with pcDNA3.1HA-UBE2U 
and treated with LLnL and/or butyrate. A: HEK293 cells were transfected with pcDNA3.1HA-UBE2U and 
treated with LLnL 50 µM for 10 hours. Cells were harvested 24 or 48 hours (hs) after transfection.. HA-
UBE2U tnt has been obtained by transcription and translation (tnt) of pcDNA3.1HA-UBE2U in rabbit 
reticulocytes (1/10 of reaction loaded). B: HEK293 cells transiently transfected with pcDNA3.1HA-UBE2U 
and treated with LLnL 50 uM (for 10 hours) and/or butyrate 2mM (for 24 hours). Cells were harvested 48 hours 
after transfection. C: Immunoprecipitation of HA-UBE2U tnt using anti-HA antibodies. No immunoprecipitates 
are detected. Tnt, transcripted and translated. 
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3.2.9: No interaction between Ueb2u and Fancd2 in mouse testis protein extracts. 
 
In order to investigate whether UEB2U is able to bind FANCD2, we took advantage 
of the high level of both proteins in mouse testis and tried to confirm their interaction by 
using mouse testis extracts. Thus, we produced two rabbit polyclonal antibodies (two 
different sera) directed against the same amminoterminal portion of the murine protein. 
Immune antisera were purified with protein A beads and tested against whole testis protein 
extracts. In experiments of western blotting, an expected band of 42 kDa was specifically 
detected (theoretical molecular weight of UBE2U = 41.9 kDa) by the two antibodies used 
(YFE05-1 and YFE05-2) as shown in fig. 16. In filters incubated with corresponding pre-
immune antisera the bands were not detected, supporting the specificity of the antibodies 
generated. Thanks to the availability of an antibobody against mouse Fancd2 (kindly donated 
by dr Alan D’Andrea), we set up experiments of immunoprecipitation using antibodies 
against both Ube2u and Fancd2. As shown in fig. 17 Fancd2 was clearly immunoprecipitated 
by its relative antisera. However, no specific band of Ube2u was detected in the 
immuniprecipitates at least under our experimental conditions. On the other hand, the 
immunoprecipitation experiments performed with our anti-Ube2U antibodies suggest that the 
antisera are not able to specifically precipitate the antigen (data not shown). Future 
immunochemical experiments and the development of additional reagents are needed to 
further investigate the putative interaction between the two proteins 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Western blot using the two specific antibodies YFE05-1 and YFE05-2, generated against 
murine Ube2u. Protein extracts from mouse testis were probed with immune and pre-immune (PI) antisera. 
Protein extracts from NIH3T3 cells were used as negative control.  
.  
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Figure 17: Coimmunoprecipitation of Fancd2 and Ube2u. Protein extracts from mouse testis were 
immunoprecipitated with anti Fancd2 and immunoblotted for Fancd2 and Ube2u (YFE05-1). 
 
 
 
 
3.3 ISG20L2: a novel putative exonuclease. 
 
3.3.1: Cloning of human and murine clone 4. 
 
The potential interactor of FANCG (clone 4) had a partial open reading frame that 
resulted to belong to the ISG20L2 (interferon stimulated exonuclease gene 20-like 2) gene 
localized on chromosome 1q23.1. Two chromosomal regions on 6p22.3 and within intron 12 
of the USP28 gene on chromosome 11q23.2 also share a collinear high homology to the 
ISG20L2 cDNA, suggesting that two pseudogenes are also present in the genome. The 
human transcript of 2,0 kb encoded for a predicted protein of 353 amino acids characterized 
by aputative conserved domain of the EXOIII family (Fig. 18), which includes a variety of 
exonuclease proteins, such as ribonuclease T and the alpha and epsilon subunits of DNA 
polymerase III. The murine ortholog gene Isg20l2 is localized on the syntenic region of 
chromosome 3, whereas its pseudogene is on chromosome 6. The mouse transcript of 2,0 kb 
encodes for a protein of 368 amino acids sharing a 72% of residues identity with the human 
product. Alignment of different species shows that the gene is conserved throughout 
evolution (Fig. 18). 
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Mouse           MSTILLNLDFG-QPS-KKAFGGNAKHQRFVKKRRFLEQKGFLNKKNQPPNKVSKLNSEPP 58 
Rat             MSTILLNLDFG-EPS-KKAFGGNAKHQRFVKKRRFLEQKGFLSKKNQPPSKVSKLNSEPP 58 
Canis           MSTLLLNLDFG-EPPPKKALEGNAKHRKFVKKRRLLERRGFLNKKNQPPSKTPKQHSEPM 59 
Taurus          MSTLLLNLDFG-EPPPKKALEGNAKHRKFVKKRRLLERKGFLNKKKQPPSKVPKLHSEPS 59 
Human           MSTLLLNLDFG-EPPPKKALEGNAKHRNFVKKRRLLERRGFLSKKNQPPSKAPKLHSEPS 59 
XenTrop         MSDLLLNLNVGASQPSGKAEYTNKKHERFNKRRKYLERKGLLKQKQCPPRPNRPMPNSAP 60 
XenLaevis       MSDLLLNLGVDSSPPSGRAGHTNKKHERFIKRRKYLERRGLLKQKQCPPRPNRPVPANNP 60 
                ** :****... . .. :*   * **..* *:*: **::*:*.:*: **        .   
 
Mouse           KKGETSRVDGILKILPCPKKK-EAAASKRDSEQSKDKKAPLSWLTPAPSKKTASVVSKID 117 
Rat             KKGETSRVDSISKILSCLKKKKEAAASKRDSEQSKDKKASLSWLTPAPSKKTDSVVAKID 118 
Canis           KKGETPKVDGTWKVSPLPKKK-AVASSS-GPEQSLDKKTAVPWLTPAPSQKAGSALAKVD 117 
Taurus          QKGETPRVDGTWKATPLPKKKTTAASSS-GSEQSLDKKAAVPWLTPAPSQKAGSVVAKVD 118 
Human           KKGETPTVDGTWKTPSFPKKK-TAASSN-GSGQPLDKKAAVSWLTPAPSKKADSVAAKVD 117 
XenTrop         GHQAKSWAQGKKEGEQGGTWNQFNRSNATKSSTVFNG----FHQQGAPVKHQGKPVQSNT 116 
XenLaevis       GQQVNSWAQGKKQEQQGNTRNQFNRTNTTKSSTNFNG----FHQQKAPVKQQGQPIQFNT 116 
                 :  .. .:.  :     . :    :.   .    : .:.      ** ::  .       
 
Mouse           LLGEFQSALPKTKS-TQKKGSKKKSLKKKIATENSTQAQSKDKGSKK-----KPLKKNAV 171 
Rat             LLGEFQSALPKPKRRTQKKGSKK-PLKKKIATENSTQTQSKDKGSNK-----KPLKKNAV 172 
Canis           LLGEFQSALPKIRS---------------------HPTRPHKKGPQK-----NPTQKNAP 151 
Taurus          LLGEFQSALPKIKS---------------------HPTRPQKKGSQK-----NPPPKNGP 152 
Human           LLGEFQSALPKINS---------------------HPTRSQKKSSQKKSSKKNHPQKNAP 156 
XenTrop         LINHFSSGPHHSRSATFMPKETT-----KAGFKGPGSSEPARVNGHTLN-TKVPIFPGQP 170 
XenLaevis       RTVQFNSGPHNFRLATFTPKETS-----KASYNGPSSSEPARVNGQTFN-TKVQIFPGQT 170 
                   .*.*.  : .                        :..   . :. .:..     .   
 
Mouse           PNSTQARSEDKCPT--VPQNLPGKMVAIDCEMVGTGPKGRVSSLARCSIVNYNGDVLYDE 229 
Rat             QNSTQAQPEDKCPK--VPQSLPRKMVAIDCEMVGTGPKGRVSSLARCSIVNYNGDVLYDE 230 
Canis           QNSIQSHSDNKCSG--TTQKTPKKMVAIDCEMVGTGPKGHVSSLARCSIVNYHGDVLYDE 209 
Taurus          QNSTHTHSENKYSG--VSQKIPGKMVAIDCEMVGTGPKGHVSSLARCSIVNYDGDVLYDE 210 
Human           QNSTQAHSENKCSG--ASQKLPRKMVAIDCEMVGTGPKGHVSSLARCSIVNYNGDVLYDE 214 
XenTrop         QDSVLNEFDSGLP---SSAVPSRKAVAIDCEMVGTGPNGRVSNLARCSIVNWFGDVMYDK 227 
XenLaevis       HNSILSEFDSGLPSLPSTTGPSHKAVAIDCEMVGTGPNGRNSDLARCSIVNWFGDVMYDK 230 
                 :*   . :.  .    .   . * ************:*: *.********: ***:**: 
 
Mouse           YVLPPCYIVNYRTRWSGIRKCHMVNATPFKTARSQILKILSGKVVIGHAIHNDYKALQYF 289 
Rat             YIRPPCYIVDYRTRWSGIRKCHMVNATPFKTARSQILKILSGKVVVGHAIHNDYKALQYF 290 
Canis           YILPPCHIVDYRTRWSGIRKQHMVNATPFKVARGQILKILTGKIVVGHAIHNDFKALQYF 269 
Taurus          YILPPCHIVDYRTRWSGIRKQHMVNATPFKIARNQILKILAGKIVVGHAIHNDFKALQYI 270 
Human           YILPPCHIVDYRTRWSGIRKQHMVNATPFKIARGQILKILTGKIVVGHAIHNDFKALQYF 274 
XenTrop         YIKPKSPVTDYRTRWSGIRREHLRNATPFDVAQKEILKILNGKVVVGHAIHNDYKALNYF 287 
XenLaevis       YIKPKSPVTDYRTRWSGIRREHLVNAIPFVVAQKEILKILNGKVVVGHAIHNDYKALNYF 290 
                *: * . :.:*********: *: ** **  *: :***** **:*:*******:***:*: 
 
Mouse           HPKSLTRDTSRIPLLNRKADCPENVTLSLKHLTKKLLSRDIQVGNTGHSSVEDAQATMEL 349 
Rat             HPKSLTRDTSQIPLLNRKADCPENVTLSLKHLTKKLLSRDIQTGLSGHSSVEDAQATLEL 350 
Canis           HPKSLTRDTSHIPPLNRKADCPENATMSLKSLTKKLLNRDIQVGKSGHSSVEDAQATMEL 329 
Taurus          HPKSLTRDTSHIPLLNRKADCPENATMSLKSLTKKLLNRDIQAGKSGHSSVEDAQATMEL 330 
Human           HPKSLTRDTSHIPPLNRKADCPENATMSLKHLTKKLLNRDIQVGKSGHSSVEDAQATMEL 334 
XenTrop         HPQEMTRDTSKIPLLNRKAGLPEKEVASLKRLSKLLLHKDIQTGSHGHSSVEDAKTTMEL 347 
XenLaevis       HPKEMTRDTSKIPLLNHKAGFPEKEAASLKRLAKQLLHKDIQTGRQGHSSVEDAKTTMEL 350 
                **:.:*****:** **:**. **: . *** *:* ** :***.*  ********::*:** 
 
Mouse           YKLVEVEWEQHLAQNPPEN 368 
Rat             YKLVEVEWEQHLAQNPPEN 369 
Canis           YKLVEVEWEQHLAQNPPKD 348 
Taurus          YKLVEVEWEQHLAQNPPKD 349 
Human           YKLVEVEWEEHLARNPPTD 353 
XenTrop         YRVIEVEWERELAAGHVQQ 366 
XenLaevis       YRVIEVEWERKLAAGHVQQ 369 
 
Figure 18: Alignment of ISG20L2 human protein with orthologs of other species. The conserved EXOIII 
domain is highlighted in yellow.  
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3.3.2: High expression of ISG20L2 in testis. 
 
The full length mouse transcript was consistent with Northern blot analysis on mouse tissues, 
showing a single transcript of 2,0 kb expressed in testis but not in heart, brain, spleen, lung, 
liver, skeletal muscle, and kidney (data not shown). Northern blot analysis carried out on 
human tissues showed a single transcript of 2,0 kb in testis, while no bands were detected in 
spleen, thymus, prostate, uterus, small intestine colon and leukocyte (Fig. 19A). RT-PCR 
performed on human cell lines revealed a band of 1263 bp, proving expression of the gene in 
lymphoblasts, HeLa, HEK293, CaCo2 and fibroblasts, as showed in fig. 19B. On the basis of 
northern blot data from mouse tissues, we investigated the expression of Isg20l2 in testis by 
RNA in situ hybridization and high levels of expression were detected in spermatides (data 
not shown). 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 19: Expression analysis of human ISG20L2. A) Northern blot analysis of ISG20L2 in several human 
tissues. B) RT-PCR analysis of ISG20L2 in several human cell lines.  
 
 
3.3.3: Biochemical analysis of ISG20L2. 
 
With the aim of characterizing this novel gene, immunofluorescence, western blotting 
and co-immunoprecipitation analysis were set up. The coding region of human ISG20L2 was 
subcloned into pcDNA3.1 in frame with FLAG or HA tags and transiently transfected in 
HeLa and HEK293 cell lines. The cellular localization of the recombinant protein was 
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studied by immunofluorescence and western blot analysis of both cytoplasmic and nuclear 
extracts. The interaction between FANCG and IGS20L2 was investigated by co-
immunoprecipitation studies. In addition, we exploited also a specific antibody generated 
against the human protein ISG20L2 as we report below. 
HeLa cells transfected with pcDNA3.1FLAG-ISG20L2 were analysed by 
immunofluorescence 48 hours after transfection and the signal of the exogenous protein was 
detected mainly in the nucleolus (Fig. 20). 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Immunofluorescence analysis of HeLa cells transfected with pcDNA3.1FLAG-ISG20L2. The 
recombinant protein localizes in nucleoli (darker zones of DAPI staining) in three different imagines chosen as 
examples from indipendent transfections.  
 
 
 
Expression of the ISG20L2 protein was investigated by mainly using antibodies 
generated against the human protein. We tested 4 different anti-sera produced against the C- 
and N- termini of the human protein (‘PEA05-1’ and ‘PEA05-2’ against N-terminus, 
‘QEA05-1’ and ‘QEA05-2’ against C-terminus) initially by western blotting analysis of 
FLAG-ISG20L2. First, rabbit reticulocytes were exploited for the transcription and 
translation in vitro of ISG20L2 subcloned into pcDNA3.1FLAG. As showed in fig. 21(A), 
QEA05-1 was able to detect a faint band at the expected molecular weight of 43 kDa, while 
the other anti-sera tested, PEA05-1, PEA05-2 and QEA05-2 did not recognize any specific 
band (data not shown). Next, transient transfections of HEK 293 cells were carried out with 
pcDNA3.1FLAG-ISG20L2. Nuclear and cytoplasmic protein extracts were probed using an 
anti-FLAG and the specific anti-ISG20L2 antibodies. As shown in fig. 21(B) QEA05-1 was 
able to detect a specific band, while the other anti-sera tested gave not clear outcomes (data 
not shown). Bands of the expected molecular size were identified in the nuclear as well as in 
the cytoplasmic fraction by using QEA05-1. Signals were detected in both non-transfected 
and transiently transfected cells. Then, the signals were compared to those obtained with 
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anti-FLAG antibody showing a perfect match. As a result, QEA05-1 seemed able to detect 
the over-expressed, but also the endogenous protein in HEK293 cells and it was chosen for 
the following experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Testing QEA05-1. A: Anti-ISG20L2 antibody QEA05-1 was tested on transcripted and translated 
in vitro (tnt) FLAG-ISG20L2. Anti-FLAG was used to check for protein expression, while we used a plasmid 
containing an unrelated cDNA (pcDNA3.1HA-EpoR) as negative control. B: Western blot analysis of nuclear 
and cytoplasmic extracts of HEK293 cells transfected with pcDNA3.1FLAG-ISG20L2. Cytoplasmic and 
nuclear extracts of HEK293 cells untransfected and transfected with pcDNA3.1 FLAG-ISG20L2 are shown. 
Anti-Histone deacetylase (HDAC) antibody has been used as nuclear marker. Additionally, in these 
experiments, filters hybridized with anti-ISG20L2 (QEA05-1) were re-probed with anti-FLAG antibody and 
vice-versa (filters hybridized with anti-FLAG antibody were re-probed, after stripping, with anti-ISGL20L2). 
 
 
 
To further assess the specificity of this antibody, proteins from nuclei and cytoplasms 
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Panc-1, HepG2 and EPN cells were separated by electrophoresis and analysed by western 
blot. QEA05-1 and its pre-immune antiserum were used to hybridize two filters. Specific 
ISG20L2 bands of the expected molecular weight were detected on the filter probed with 
antibody QEA05-1 whereas the same bands were absent in the filter hybridized with pre-
immune antiserum. The specificity of this antibody was further confirmed by stripping the 
filters and re-probing them with anti-FLAG antibody, which detected bands of the same size 
of those obtained with QEA05-1 antibody in transfected cells. The expression study of of the 
endogenous protein was further extended to nuclear and cytoplasmic fractions from other 
cell lines. Protein extracts from lymphoblast, EPN (epithelial prostatic, human), HeLa, 
HepG2 (Human hepatocellular liver carcinoma), HEK293, K562 (erythroleukaemia, human) 
LAN-5 (neuroblastoma) and Panc1 (human pancreatic carcinoma, epithelial-like) cell lines 
were analysed. As showed in fig. 22, the ISG20L2 was expressed in both compartments of 
all the cell lines investigated. 
 In order to confirm the interactions observed in yeast two-hybrid screening studies, 
we performed also a series of coimmunoprecipitation experiments. In these investigations, 
we co-transfected pcDNA3.1FLAG-FANCG and pcDNA3.1HA-ISG20L2 in HEK293 cells. 
When we immunoprecipited both the proteins by the specific anti-tag antibodies, we were 
unable to demonstrate in the immunoprecipitate material the presence of the other protein, 
thus suggesting the absence of interaction between ISG20L2 and FANCG (data not 
reported). However, due to the intrinsic constraints of the approach (i.e. the binding between 
the two proteins might mask the epitopes recognized by the antibodies), we believe that it is 
important to repeat the experiments employing additional antisera directed towards further 
protein epitopes. 
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Figure 22 A: Western blot analysis of nuclear (n) and cytoplasmic (c) compartment of several cell lines. 
Filters were first separately probed with anti-ISG20L2 specific antibody (QEAO5-1) and its pre-immune 
antiserum (QEA05-1 PI). Next, filters were reprobed with anti-FLAG antibody. Only HEK293 cells transiently 
transfected with pcDNA3.1FLAG-ISG20L2 showed the signals. B: Western blot analysis of nuclear (n) and 
cytoplasmic (c) compartment of several human cell lines. Specific bands of ISG20L2 are present in both the 
compartments analyzed in all the cell lines investigated. Sp1 has been used as nuclear marker 
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Chapter 4 
DISCUSSION 
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4.1 Screening a cDNA library of human testis. 
 
The discovery and characterization of the thirteen FA genes have revealed the 
connection between FA, the DNA-damage response and cancer. Especially in the last 
decade, studies in the FA research field disclosed a crowded network of interacting proteins, 
but hinted also that other players of this network are still missing. In addition, the 
pathogenetic mechanism underlying the disease is still unclear. As described in the 
introduction of this PhD thesis work, understanding the molecular biology of FA is 
nowadays crucial not only for haematologists and oncologists, who manage patients with FA 
or with bone marrow failure syndromes or with cancers, but also for scientists interested in 
DNA-repair, ubiquitin biology, fertility, drugs sensitivity and resistance.  
The principal aim of the present work was to identify novel interactors of FA proteins 
so as to contribute to unravelling the FA-BRCA pathway. Starting point of this project was 
the large-scale approach of the yeast two-hybrid system, a powerful methodology to detect 
protein-protein interactions. When we started our studies, only nine of the thirteen FA genes 
were cloned. We chose as baits the most characterized genes not only as full length cDNAs, 
but also as partially overlapping cDNA fragments mainly for two reasons. First, one 
limitation of protein expression in yeast two-hybrid systems is that the yeast translational 
machinery is not always able to biosynthesize large proteins. Second, in case of interactions, 
we would also have had insights into functional domains which were and still are largely 
unknown for FA proteins. For these reasons, we arbitrarily chose to clone cDNA fragments 
of average size of approximately 1000 bp. As reported, we chose to screen a human testis 
library because the only phenotype shared between FA patients and knocked out mice was 
hypogonadism and reduced fertility (Chen, Tomkins et al. 1996; Whitney, Royle et al. 1996; 
Cheng, van de Vrugt et al. 2000; Yang, Kuang et al. 2001; Koomen, Cheng et al. 2002; 
Houghtaling, Timmers et al. 2003; Wong, Alon et al. 2003), suggesting a crucial role of the 
FA-BRCA pathway in gametogenesis. Moreover, consistently with these data, FA genes are 
expressed at high levels in testis (Chen, Tomkins et al. 1996; Lo Ten Foe JR 1996; Whitney, 
Royle et al. 1996). Finally, the FA-BRCA pathway was completely uncharacterized in that 
tissue and the hypothesis of a role in crossing-over events was particularly suggestive. 
Among 23 bait-constructs generated, a few of them were excluded because of their auto-
activation of reporter genes or of their inefficiency in synthesizing proteins in yeast. Then we 
selected 8 baits. Five including all fragments of FANCD2, because the monoubiquitination 
of this protein is a crucial step in the FA-BRCA pathway (in review (Wang 2007)) and 
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because it directly binds BRCA1 (Taniguchi, Garcia-Higuera et al. 2002) connecting FA-
BRCA pathways with DNA-repair. Two baits were selected for two portions of FANCA 
because binding to several proteins of the FA-core complex and directly interacting with 
BRCA1 as well (Folias, Matkovic et al. 2002), and one bait for the only suitable fragment of 
FANCG, being this protein a scaffold for the FA-core complex, not dispensable for its 
assembly (Garcia-Higuera, Kuang et al. 1999; Medhurst, Huber et al. 2001). After eight 
independent library screenings, 167 clones were obtained and further investigated to confirm 
interaction in a tiered approach. Disappointedly, 107 of them (64%) resulted to be frame 
shifted sequences and 5’ and 3’ untranslated regions (UTR) or even genomic sequences and 
ALU sequences, representing artefact protein products. Of the 60 clones selected, 44 
interacted with the N-terminal part of FANCG whereas 12 interacted with FANCD23 and 1 
with FANCD24. Just one clone was found to interact with FANCA3 while another two were 
bound to FANCA5. The relatively high number of clones rescued using FANCG2 as bait 
could be explained considering the four tetratricopeptide repeat (TPR) domains present in the 
partial protein (of the seven contained in the full length). The tetratricopeptide repeat (TPR) 
is a degenerate 34 amino acid sequence identified in a wide variety of proteins, present in 
tandem arrays of 3–16 motifs. It forms scaffolds to mediate protein–protein interactions and 
the assembly of multiprotein complexes (Das, Cohen et al. 1998). In FANCG2 these repeats 
probably facilitated the interaction with numerous preys. Notably, all clones rescued from 
the screenings were found only once and none of them bound to any known interaction. 
Although these observations should have alerted us on the limitations of our analyses, we 
justified the results taking into consideration three aspects. First, using partial length cDNAs 
as baits we could have destroyed potential binding domains, which had not been well defined 
even for known FA proteins. Second, we were dealing with a tissue, as the testis, where the 
FA-BRCA pathway was never investigated. Finally, the FA-core complex assembly is 
dynamic and it could involve several determinant missing players. Further investigations 
were carried out to verify interactions with yeast direct interaction matings, leading us to 
assess that 50 clones resulted false positives. The high number of false positives detected 
was probably due to different cellular environments present in strains used for the large-scale 
screening (AH109 mated with Y187, diploid) and the direct interaction mating (AH109 
alone), as well as to different culture conditions between the two procedures. The remaining 
10 clones were tested after switching vectors, confirming the interactions of clone 4 with 
FANCG2, as well as clones 54 and 62 with FANCD23. Although again this outcome is of 
difficult interpretation, we can consider that in this system, baits are hybrid proteins fused 
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with the AD or the BD domains of GAL4 (accordingly to the vector in which they are cloned 
in). Large-scale screening was performed using BD-baits interacting with an AD-prey 
library. The interactions found were afterwards examined for the opposite combination: AD-
bait with BD-prey. Therefore, accordingly to the domain (AD or BD) a protein is fused with, 
the conformation can vary, leading to formation or disruption of different functional 
interacting domains.  
The last tiered step towards the selection of potential interactors of the FA proteins 
allowed us to thus isolate 3 novel candidates that were first characterized using 
bioinformatics tools. Clone 4 encoded for ISG20L2, a protein with a predicted exonuclease 
domain ‘EXOIII’, clone 54 encoded for a predicted ubiquitin-conjugating enzyme E2 
(UBE2U), while clone 62 corresponded to CRISP2 (cysteine-rich secretory protein 2). These 
findings provided the basis for the second part of this PhD project, aimed at further 
characterizing two novel interactors, UBE2U and ISG20L2, potentially associated with the 
FA-BRCA pathway. The first, because the ubiquitin-conjugating enzyme E2 of the FA-
BRCA pathway was unknown and the second, because an exonuclease could have been 
implicated in DNA-damage repair. CRISP2, a testis specific protein of the sperm acrosome 
(Busso, Cohen et al. 2005), was not investigated because unlikely associated with FA.  
 
 
 
4.2 Two-hybrid system in FA: data from literature. 
 
An extensive literature search for applications of yeast two-hybrid system in FA 
allowed us to find that, until 2002, four of sixteen proteins described to interact with FA 
proteins had been identified using this technique. Through several library screenings, GRP94 
and FAZF were found to bind FANCC (Hoshino, Wang et al. 1998; Hoatlin, Zhi et al. 1999) 
while SNX5 and CYP2E1 where found to interact with FANCA and FANCG, respectively 
(Otsuki, Kajigaya et al. 1999; Futaki, Igarashi et al. 2002). However, after these first reports, 
the interactions have not been further confirmed or investigated. The largest-scale screening 
was next reported by Reuter and colleagues (2003), who described 69 novel potential 
FANCA, FANCC and FANCG interacting proteins. These proteins were collected from 
experiments performed in four different laboratories, using five libraries derived from 
various tissues. All candidates were tested in the yeast two-hybrid system, and many were 
additionally evaluated by in vitro and in vivo co-immunoprecipitation and co-localization 
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experiments. Their studies provided new evidences for a connection of the FA-BRCA 
pathway with a range of cellular functions linked to haematopoiesis, cancer, and 
detoxification (Reuter, Medhurst et al. 2003). Authors indicated new possible pathways to 
look at, together with new proteins putatively involved in the FA-BRCA pathway, but again 
there are no new relevant updates or reports regarding these candidates. Consistently with 
also our outcomes, the yeast two-hybrid system therefore appears to be not the most suitable 
strategy to isolate new FA proteins interactors from large-scale library screenings. More 
successful was instead the application of direct interaction mating assays to detect 
interactions between candidates or to map binding domains. In 2002, Folias and colleagues 
reported the interaction between the N-terminal portion of FANCA and BRCA1, 
hypothesizing, for the first time in FA research, a link to DNA-repair process (Folias, 
Matkovic et al. 2002). This connection was later confirmed also in the work reported by Zhu 
and Dutta (Zhu and Dutta 2006), in which they showed that rereplication activated the FA-
BRCA pathway, both for the activation of a G2/M checkpoint and for DNA-repair processes, 
involving FANCA, BRCA1 and ATR. Also in 2003, Gordon and Buchwald investigated the 
architecture of the FA proteins complex by studying direct interaction mating in yeast two-
hybrid system (Gordon and Buchwald 2003). They identified binding domains between 
FANCA/FANCG, FANCC/FANCE and FANCF/FANCG. Additionally, they detected a 
direct interaction between FANCE and FANCD2, providing a direct link between the FA 
protein core complex and its downstream target. Again in 2003, Hussain and colleagues 
tested the interactions between BRCA2 (FANCD1) or its effector RAD51 and the proteins 
FANCA, FANCC and FANCG. They found that FANCG co-localized in nuclear foci with 
both BRCA2 (FANCD1) and RAD51 after DNA damage, binding to two separate sites 
flanking the BRC repeats of BRCA2 (FANCD1) (Hussain, Witt et al. 2003). Later, the same 
group showed that FANCD2 bound a highly conserved C-terminal site of BRCA2 that also 
bound FANCG/XRCC9 (Hussain, Wilson et al. 2004). Since 2004, there have been no new 
significant data regarding FA proteins studied with the yeast two-hybrid system, until the last 
year, when a novel interactor of FANCD2, Tip60, was identified screening a human foetal 
library from brain (Hejna, Holtorf et al. 2008). Tip60 is a histone acetyltransferase, member 
of a conserved chromatin remodelling complex (Doyon and Cote 2004; Doyon, Selleck et al. 
2004). It is able to acetylate not only histones, but also several target proteins involved in 
DNA-repair or checkpoint response to DNA-damage, including p53 (Kusch, Florens et al. 
2004) and ATM (Sun, Jiang et al. 2005). Tip 60 also co-localizes with γH2AX in DNA 
damage-induced foci (Sun, Jiang et al. 2005) and acetylates H2AX thereby regulating its 
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ubiquitination by UBC13 during double strand breakage repair (Ikura, Tashiro et al. 2007). 
Again in 2008, Tremblay and colleagues reported the use of the yeast direct two-hybrid 
assay to check for connections between FA and HSC self-renewal pathways (Tremblay et al 
2008). HES1 was found to be a novel interactor of the FA-core complex, and, analogously to 
other subunits of the complex, it is required for cellular resistance to MMC, FANCD2 
monoubiquitination and proper stability of several FA-core complex components (Tremblay, 
Huang et al. 2008). HES1 is a downstream effector of Notch1, involved in increasing HSC 
self-renewal, reducing HSC cycling and preserving the long-term reconstitution ability of 
primitive haematopoietic cells (Varnum-Finney, Xu et al. 2000; Stier, Cheng et al. 2002; 
Kunisato, Chiba et al. 2003; Yu, Alder et al. 2006).  
As a result, after almost ten years of work done by several groups, the search for new 
interactors of the FA proteins by screening libraries with the yeast two-hybrid approach has 
not provided us with many functional insights, in spite of all the efforts carried out to achieve 
this aim. This is likely due to different aspects related to both the yeast model and partly the 
characteristics of the FA proteins. In fact, proteins produced in the yeast two-hybrid system 
are fused with BD or AD and could not localize in the yeast nucleus, or could not fold 
properly, or could not be functional when expressed as a fusion protein, or could be toxic to 
the host, or, sometimes, the appropriate post-translational modification could not take place, 
or the potential interacting protein could not be sufficiently represented in the library. On the 
other hand, aside from FANCJ and FANCM, there are no orthologues of FA proteins in 
yeast and the lacking of a complete FA machinery, together with the dynamic assembly of 
the core complex, could influence outcomes from this system. At this purpose, the most 
relevant biochemical discoveries in FA have been achieved investigating direct interactions 
between candidate proteins, as previously enlisted, or using immunochemical analysis 
coupled with mass spectrometry (Meetei, de Winter et al. 2003; Meetei, Sechi et al. 2003), as 
described in the introduction section of this thesis.  
Nevertheless, since the three clones (4, 54 and 62) we identified were confirmed by 
direct interaction mating in both combinations of the bait/prey constructs, they have been 
regarded as good candidates for further studies. 
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4.3 Characterization of UBE2U as a potential new interactor of FANCD2. 
 
UBE2U was considered the most promising interactor found, because it bound to 
FANCD2 and showed high homology to the members of the ubiquitin-conjugating enzyme 
family E2. FANCD2, together with FANCI, is the monoubiquitinated protein of the FA-
BRCA pathway. Ubiquitination is a post-translational modification that consists in a covalent 
binding of a molecule of ubiquitin to the ε-amine of lysine residues of target proteins. It 
requires a series of ATP-dependent sequential steps, catalyzed by E1 (ubiquitin-activating), 
E2 (ubiquitin-conjugating) and E3 (ubiquitin-ligating) enzymes (reviewed here (Hochstrasser 
2006)). Notably, while the putative E3 ligase in vivo of the FA-BRCA pathway was known 
(FANCL), the ubiquitin-conjugating enzyme E2 was still unknown when we isolated this 
clone. The identifying characteristic of an E2 is a 14-16 kDa core (UBC domain) that is 35% 
conserved among family members. This portion of the enzyme contains an active site 
cysteine and substitution of this residue abolishes E2 activity (reviewed here (Passmore and 
Barford 2004)). E2 proteins have various individual and redundant roles within the cell and 
have important functions in target degradation (proteasomal pathway), and target 
modification for regulatory purposes (non-proteasomal pathways) such as in FA-BRCA 
pathway. There are several different E2 enzymes (over 30 in humans), which are broadly 
grouped into four classes: class I consists of only the UBC domain, whereas classes II, III, 
and IV have a C-terminal, N-terminal and both N- and C-terminals extensions, respectively, 
in addition to the UBC domain. These extensions appear to be important for some subfamily 
function, including E2 localization and protein-protein interaction (reviewed here (Glickman 
and Ciechanover 2002)). 
  Human UBE2U belongs to the class II and has the catalytic cysteine (Cys89) while 
mouse isoform does not. Murine Ube2u could represent an E2 variant (UEV), that lacking 
the catalytic cysteine, forms heterodimers with E2s containing functional active sites (in 
review here (Hochstrasser 2006)). As a consequence of alternative splicing, two isoforms are 
expressed in human: isoform A, (227 aa residues long) and isoform B (321 aa residues long). 
In mouse, instead, there is only the longest isoform of the transcript of Ube2u. Isoform A 
results more conserved among orthologues than the carboxyterminal extension 
characterizing isoform B, suggesting that probably isoform A is the functionally active one 
in human. In particular, within this extension of the mouse Ube2u protein, there is a poly-Glu 
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stretch (residues 268 to 297) interrupted by a Lys at residue 291. The functional significance 
of this motif is unknown but there is no conservation among the species for this zone of the 
protein. Northern blotting analysis on human and mouse tissues detected a high level of 
expression only in testis. This expression pattern was confirmed by RT-PCR on different 
mouse embryonic and adult tissues and cell lines. Moreover, RNA in situ hybridization 
revealed that spermatocytes and spermatides were the cells with the highest levels of 
expression and this pattern was confirmed during spermatogenesis at the RNA and protein 
levels. Spermatogenesis is a process in which spermatogonia differentiate into mature 
spermatozoa and consists of different phases, including the two meiotic divisions that take 
place in primary and secondary spermatocytes. Ube2u resulted expressed during these phases 
and its expression pattern overlapped with that of Fancd2, which during meiosis, is known to 
localize in synaptonemal complexes of meiotic chromosomes together with BRCA1 (Garcia-
Higuera, Taniguchi et al. 2001). At this stage of characterization, we hypothesized that 
Ube2u could have been involved in the regulation of Fancd2 during meiosis, therefore we 
moved further to confirm the connection with the FA-BRCA pathway. First, we determined 
whether UBE2U bound with other FA proteins and whether FA proteins bound each other in 
yeast. In addition to the previous with FANCD2, interactions between UBE2U and FANCC, 
FANCF and FANCL were detected. Being FANCL the E3 enzyme, it was tested against 
FANCD2 finding no interaction. However, FANCL was found to interact with BD-
FANCD21 and BD-FANCD23. We detected also an interaction between BD-UBE2U and 
AD-FANCD2. The interaction between FANCE and FANCD2 was instead not confirmed 
(Pace P 2002; Gordon, Alon et al. 2005). However, we could not exclude that, despite the 
high sensitivity of the direct interaction mating, the low level of expression of FANCD2 full 
length has influenced this outcome. Once ascertained the interactions of UBE2U with 
FANCD2 and other FA proteins in yeast, we investigated these interactions in mammalian 
cells. Transient transfections of several cell lines were carried out with several constructs. 
Expression of the protein was investigated by immunofluorescence and western blotting 
analysis without, however, detecting the protein, even after inhibition of the proteasome. 
Now, since UBE2U has a restricted pattern of expression, we can hypothesize that it might 
be toxic to the cells not constitutively expressing it and that the control might be at level of 
mRNA (also by 5’ and 3’ UTRs). Only using translation and transcription in vitro we were 
able to produce small amounts of the tagged protein, the immunprecipitation of which, 
however, failed.  
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The inability to express UBE2U had a relevant impact on this PhD project, since it 
prevented us from studying the human protein. Moreover, since it is not endogenously 
expressed in all mammalian cell lines tested, alternative approaches like RNA interference 
were unfeasible. However, murine Fancd2 and Ube2u showed an overlapping expression 
pattern in testis, therefore we exploited the mouse as a model to verify the interactions 
between the two proteins, after production of antibodies directed against the murine Ube2u. 
As described, they allowed us to detect the protein in spermatocytes, spermatides, and 
spermatozoa, but not to immunoprecipitate Ube2u. In the final part of this work, thanks to a 
suited antibody anti-Fancd2 (kindly donated by Dr Alan D’Andrea), we checked for 
interactions between Fancd2 and Ube2u, however again without success. Remarkably, 
although during our studies the ubiquitin-conjugating enzyme E2 of FANCD2 and FANCI 
was recognized as UBE2T (Machida, Machida et al. 2006), UBE2U should be further 
investigated to rule out any potential implication with the FA-BRCA network, which could 
enrol different players when meiosis occurs in testis, especially since UBE2T has not been 
studied yet in this tissue. 
 
 
 
4.4 ISG20L2: another potential player of the FA pathway. 
 
ISG20L2 was another gene studied in this project because it was found to interact 
with the C-terminal end of FANCG. The protein had a predicted conserved exonuclease 
domain EXOIII, a characteristic of a variety of exonuclease proteins (ribonuclease T, alpha 
and epsilon subunits of DNA polymerase III). Ribonuclease T is responsible for the end-
turnover of tRNA, and removes the terminal AMP residue from uncharged tRNA. DNA 
polymerase III is a complex, multichain enzyme responsible for most of the replicative 
synthesis in bacteria, and exhibits 3' to 5' exonuclease activity. This clone was selected 
because its potential exonuclease activity could have linked it to the DNA-repair. We found 
ISG20L2 to be expressed in human testis, mainly in spermatides, but not in other tissues. 
However, its expression was detected in all cell lines tested. Moreover, immunofluorescence 
analysis localized the exogenous protein in nucleoli, in agreement with a proteomic study 
published in 2002 (Andersen, Lyon et al. 2002), but at the present there are no evidences for 
connections between the FA-BRCA pathway and the nucleolus compartment. The nucleolus 
is an organelle fundamental for ribosome biogenesis, even if several studies suggest that it 
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may also play a role in other mechanisms such as RNA transport, RNA modification, and 
cell cycle regulation (Schneiter, Kadowaki et al. 1995; Pederson 1998; Olson, Dundr et al. 
2000; Ideue, Azad et al. 2004). In this regard, Gleizes and co-workers (2007) reported that 
ribosome biogenesis and in particular rRNA processing was altered in Diamond-Blackfan 
anemia, an inherited bone marrow failure syndrome due to mutations in at least 7 genes 
encoding for ribosomal proteins (Choesmel, Bacqueville et al. 2007). Moreover, there is 
evidence for a role of ribosome biogenesis in cancer (Amsterdam, Sadler et al. 2004; 
Pandolfi 2004). Therefore, we tested the interaction of ISG20L2 with FANCG using 
ectopically expressed proteins (FLAG-FANCG and HA-ISG20L2), but as mentioned, we 
were not able to confirm the direct binding, suggesting we should try further to define the 
best procedures changing experimental conditions or reagents such as epitope tags, 
incubation conditions and antibodies. In this regard, since there were no available antibodies 
against ISG20L2, we produced antibodies directed against both the C- and the N- termini of 
the human protein. Using different controls, such as FLAG-ISG20L2 over-expressed in 
HEK293 cells or transcripted and translated in vitro, we defined the conditions to detect the 
endogenous protein. ISG20L2 was expressed in all cell lines tested. Moreover, in addition to 
an expected nuclear localization, both endogenous and overexpressed proteins were also 
found in the cytoplasm. Previous immunofluorescence studies did not reveal any sign of the 
protein in that compartment, likely because its concentration is below the threshold level of 
detection for the technique.  
 During the last year, a work was published by Diaz and co-workers (Coute, 
Kindbeiter et al. 2008) showing that the recombinant tagged ISG20L2 protein is a 
component of nucleoli with a 3’ to 5’ exoribonuclease activity. Whereas its N-terminus binds 
to several ribosomal proteins, the C-terminal end is crucial for the localization in the 
nucleolus. When ISG20L2 is overexpressed, the 12S precursor of 5.8S rRNA decreases; 
conversely, it increases when ISG20L2 is silenced. All together these data indicated that 
ISG20L2 is involved in the biogenesis of the large ribosomal subunit and in the processing 
of 12S pre-rRNA to the mature 5.8S rRNA. In this context, although our results do not 
provide new insights into the functional role of ISG20L2, we extended our knowledge 
towards the characterization of the new gene. We produced and validate the first antibody, 
allowing us to reveal that the endogenous protein is not restricted to the nucleolus but it also 
localizes in the cytoplasm, rising new questions about its putative role in this cellular 
compartment. ISG20L2 contains an exonuclease domain conserved among members of the 
DEDDh group of the DEDD superfamily of exonuclease plethora. This group contains 
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several RNases, as well DNases, which are involved in various biological functions. More 
specifically, ISG20L2 is a member of the REX4 subgroup, which is composed of other three 
members in vertebrate (REX4, ISG20, and IS20L1). They all accumulate within nucleolus 
but their specific role in this nuclear compartment remains to be determined. As our 
knowledge on the REX4 family is very limited, any conclusions on the potential role of 
ISG20L2 within cytoplasm would be very speculative. However, since exonucleases are 
often multifunctional factors, we cannot exclude it might be involved in processing of 
cytoplasmic RNAs. Among the many different proteins identified as associated with the N-
terminal half of ISG20L2, whereas 18 are ribosomal components, another 5 are involved in 
mRNA splicing and trafficking. (Counté et al, 2008). Therefore, it is plausible that ISG20L2, 
apart from an involvement in ribosome biogenesis and RNA metabolism within nucleoli, 
may play an additional role in the turn-over of mRNAs in the cytoplasm.  
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Despite the identification of many genes involved in FA-BRCA pathway, a clear picture of 
how this pathway could explain the major phenotypic features of FA remains elusive. Their 
functional characterization has been leading to connect the FA proteins to the complex 
network responsible for DNA-damage response, even if many aspects remain to be 
elucidated. This PhD thesis project started and developed from this background with the aim 
to find new genes involved in the FA-BRCA pathway. By using the systematic approach of 
the yeast two-hybrid system, we identified two novel genes potentially involved in the FA-
BRCA pathway.  
 The first encoded for a putative ubiquitin-conjugating enzyme UBE2U and interacted 
with one of the two monoubiquitinated members of the pathway, FANCD2. The other one, 
ISG20L2, encoded for a putative exonuclease and interacted with FANCG. Both were 
regarded as good candidates of the pathway and further investigated. The interactions 
between these proteins were at first validated in yeast, but afterwards they were not 
confirmed in mammalian cells. We concluded that the yeast two-hybrid system is not the 
most suitable tool for a large-scale screening of interactors in FA. Indeed, a careful 
examination of literature highlighted that this strategy was not particularly successful, 
especially when using a protein of the FA-core complex as bait. On the other hand, studies 
on FA protein associations based on characterization of immunocomplexes are being proved 
to be effective and will represent the most suitable technique in this field for the near future. 
 The highest expression of UBE2U and ISG20L2 in testis, resulted at first to be 
promising because it would lead us to provide insights into the role of the FA-BRCA 
pathway in testis. Indeed the FA pathway was never investigated during spermatogenesis, 
even though FA genes show the highest expression during this process and the only 
phenotype FA knock-out mice share with patients is infertility. However, a series of 
impediments (lack of over-expression, quality of antibodies produced) prevented us from 
gaining information into the field. For this reason, we cannot exclude that UBE2U and 
ISG20L2 might be functionally related to the FA-BRCA pathway at least in testis and further 
investigations are needed to definitively exclude these interactions. Moreover, the enzymatic 
characterizations of UBE2U as ubiquitin-conjugating enzyme E2 and ISG20L2 as a potential 
cytoplasmic ribonuclease should be determinant to shed light upon the functional role of 
these two genes.  
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